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Abstract 
The demand for faster, greener, more cost effective processes is of great important 
across all industries including chemical pharmaceutical and petrochemical sectors.  
As a result the key driver of chromatographic research is addressing these demands. 
The ultimate goal in liquid chromatography is “The best separation in the shortest 
time”. While sub 2µm fully porous particle stationary phases have addressing this 
demand for faster more efficiency separations, a research focus which has recently 
seen a resurgence has been core-shell particle technologies which offer similar 
performance to sub 2 µm particles without the added back pressure requirements of 
sub 2 µm fully porous particles.  
The aim of this study was the development of an ultrafast impurity assay using core-
shell stationary phase technology. This involved the transfer of an existing 
pharmaceutical impurity assay currently using a 5 µm fully porous stationary phase 
to core-shell stationary phase technologies of particle sizes 2.6 µm and 1.7 µm and 
subsequent method optimisation. Optimisation of isocratic method parameters such 
as mobile phase composition, temperature and development of a gradient method led 
to a reduction in run of 57% for both assays with resolution between critical peak 
pairs maintained above 2.  
Another industrial focus is the development of greener, more environmentally 
friendly  This has led in recent years to research into alternative techniques to HPLC, 
one such technique is Supercritical Fluid Chromatography (SFC) The use of non-
toxic carbon dioxide as its primary mobile phase means that SFC has the potential to 
meet this requirement of greener chromatography. SFC lies intermediate of HPLC 
and GC and possess qualities of both, including gas like viscosity and density whilst 
maintaining liquid like solvation power. As a result of these increased diffusion and 
low viscosity of supercritical fluid compared to solvents used in HPLC, much higher 
flow rates can be utilised allowing for faster separations and higher throughput, thus 
addressing both the desire for faster and greener chromatographic processes. SFC 
has also the distinct advantage of providing orthogonal selectivity to HPLC and thus 
is an attractive complementary technique. 
The second aim of this study was the evaluation of stationary phase and mobile 
phase combinations for the development of ultrafast SFC pharmaceutical impurity 
method. Four stationary phases were chosen; bare silica, cyano, diol and 2-ethyl 
pyridine along mobile phase containing a methanol modifier and additives such as 
TFA, TEA and AA. All four stationary phases were found to provide orthogonal 
selectivity to the existing reversed phase HPLC method. Run times were in the 
region of 30% to 75% faster than the original HPLC method up to 50% faster than 
the newly developed core-shell stationary phase HPLC methods in some cases.
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1 Chapter 1: Literature Survey 
1.1 Introduction 
High performance liquid chromatography (HPLC) is a well-established analytical 
technique. It has formed the basis of many analytical methods in laboratories around 
the world for more than 20 years. While it is one of several techniques used in the 
separation and analysis of chemical mixtures, HPLC for many reasons, has seen its 
popularity soar above other techniques; reasons include, its wide applicability as a 
separation technique, its excellent assay precision and the wide variety of equipment 
and related products which are commercially available[1]. HPLC in the 
pharmaceutical industry  is used in variety of assays including; the determination of 
chemical substance and purity determination of possible degradation products to 
determine possible shelf lives of drugs[2] 
The goal in chromatography can be loosely defined as the best separation achievable 
in the shortest amount of time. This has become increasingly important in recent 
years as fast analysis time is a key driver of chromatographic research.[3]  Guillarme 
et al.[4] noted that the increasing demand for high-throughput separations in fields 
such as toxicology forensics and clinical chemistry as a driving force while Wren 
and Tchrlitcheff [2] state that in the pharmaceutical industry, while there is a need 
for reduced run times there is also a need for similar or improved efficiencies to 
those that are achieved currently being achieved by conventional LC. 
One of the best ways of increasing efficiency while also deceasing analysis time is 
by decreasing particle size of columns used. Van Deemter plate theory states that 
decreasing particle size leads to a decrease in height equivalent of theoretical plates 
(H), thus an increase in efficiency[5]. The Van Deemter equation (Eqn. (i)) was one 
of the earliest applications of rate theory and its relationship to column efficiency. 
ܪ ൌ        ܣ       ൅         ஻௨         ൅       ܥݑ   Eq. (i) 
 
A=   
Eddy 
Diffusion 
B = Longitudinal 
Diffusion 
C =  
Mass 
Transfer 
u = Linear 
Velocity 
(mm/sec) 
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Taking into account, the physical, kinetic and thermodynamic properties of a 
separation, the van Deemter equation relates variance per unit length H (plate height) 
to linear mobile phase velocity (u) (measured in mm/sec). The A, B and C terms of 
the equation are defined as follows; A = eddy diffusion, B = longitudinal mass 
transfer and C = resistance to mass transfer. Together these terms are the 
contributing factors of band broadening – a key source of efficiency loss in 
chromatography [6]  The Van Deemter equation  is used to predict the optimum 
linear velocity of mobile phase at which the lowest plate height (H) can be 
achieved[5].  Van Deemter theory suggests that smaller particle sizes leads to 
increased efficiencies and thus smaller plate heights due to a reduced C term as a 
result of better mass transfer properties, due to shorter diffusion path lengths of 
smaller particles and also a reduction in the A term.  This is shown below in Fig. 
1.1.1 where the Van Deemter curves of particle sizes ranging from 10 µm down to 
1.7 µm are compared. The plots show that as particle size (dp) decreases, the H’s are 
significantly reduced. According to van Deemter theory, the A term of the Van 
Deemter equation (Eq.(i)), often referred to as the “packing term”, is a function of 
particle size so as particle size decreases so does the overall plate height. Also shown 
in this plot, at smaller particle sizes, increasing the linear mobile phase velocities do 
not have not have the significant negative impact on efficiency that plagues larger 
particle sizes like 5 and 10 µm, demonstrated by the much flatter Van Deemter 
curves of decreasing particle size. The “flatness” of the Van Deemter curve is a 
function of the C term (the resistance to mass transfer)   
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Fig. 1.1.1: Van Deemter curves for different particles sizes (10, 5, 3, 1.7 µm) illustrating 
reduction in HETP with decreasing particle size.  Reproduced from Ref [7] 
 
As smaller particles mean faster and more efficient separations, a key focus point of 
chromatographic research has been developing increasingly smaller particles to fulfil 
the need for faster, more efficient separations. A bi-annual survey carried out by 
Ronald E. Mayors for the chromatography magazine LC-GC examined the trends in 
liquid chromatography (LC) usage by their readers, but more specifically the current 
trends in the LC column usage, which documents the trend in reducing particle 
sizes[8]. 324 readers were surveyed for this study. The data collected included 
particle sizes used at the time of each survey, and showed a clear trend of decreasing 
particles size usage over the past 20 years for which surveys have been carried out. 
The statistics are given in Table 1.1.1. 
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Table 1.1.1: Results of survey carried out to determine column particle size usage across 
LC-GC readers. Sample size: 324. Table reproduced from Ref [8] 
Analytical HPLC particle size trend 1985 – 2011*. 
 Percentage of respondents using these particle sizes 
Year <2 µm 2- 2.9 µm 3-4 µm 5-7 µm 10 µm > 10 µm 
1985 nq** nq 6.1 53 38 2.7 
1989 nq nq 6.3 54 36 3.9 
1994 nq nq 20 56 21 3.7 
1997 nq nq 18 59 20 2.7 
2007 7.1 nq 38 48 6 0.7 
2009 14 nq 39 42 4.3 0 
2011 12 25 24 38 1.7 0 
* normalised data 
 ** “nq”: not queried 
 
During the late eighties particle sizes in categories  “10 µm” and “5-7 µm” were the 
most popular, while in the nineties 5-7 µm still remained the most popular, however 
popularity of 10 µm columns has seen a significant decrease with a surge in the 
popularity of the smaller 3-4 µm particles. This preference of decreasing particle size 
continued into the 2000s where particles of 4 µm in diameter or less held the 
majority share of columns used. Majors[8] attributes the persistence with 5-7 µm 
particles to users having validated methods which were developed on 5 µm columns 
who did not want to have to re-validate a method for smaller particles unless it was 
absolutely necessary. 
While smaller particles produce higher efficiencies than larger particles, there is a 
trade-off in that the back pressure associated with these columns significantly 
increases. A consequence of this increased back pressure is friction heating across 
the column leading to the formation of temperature gradients. According to Gritti et 
al.[9] the amount of heat produced is the combined result of the pressure gradient 
and the linear velocity and while this is not significant for columns packed with 
larger particles with column length of 15-20 cm whose operational pressure is in the 
region of 200-400 bar, it becomes increasingly significant for particle sizes of sub 
3µm which are run at a pressure of 400 – 1000 bar. Temperature gradients across the 
column were shown to affect the efficiency of the column. Gritti et al. [9] report a 6 
fold increase in the C term of the Van Deemter equation of a 1.7 µm column, run at 
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above 400 bar determined experimentally when compared to predicted values due to 
transcolumn thermal heterogeneity. As well as affecting the efficiency of a column, 
increased back pressure and frictional heating also affect retention factors.  In an 
effort to estimate the effect of frictional heating, Novàková et al. [10] carried out two 
concurrent experiments on an Acquity BEH C18 column (50 x 2.1 mm, 1.7 µm) 
whereby for experiment 1, a low flow rate was applied and temperature was 
systematically increased from 30 to 60°C in approximately 4°C increments,  and for 
the second experiment a constant temperature of 30°C was applied while the flow 
rate was increased to induce pressures of 100, 300, 600 and 1000 bar on temperature 
in the column.  The retention factors of a range of compounds were compared for 
both experiments. The authors found that when chromatograms run at 300, 600 and 
1000 bar and a constant temperature of 30°C, were compared to the those run at 100 
bar and varying temperatures, perfect overlays of chromatograms were achieved 
when those carried out at 300 bar were compared to those carried out at 100 bar and 
34°C. Chromatogram overlays are given in Fig. 1.1.2. This was also true for the 600 
and 1000 bar chromatograms were separations equates to temperatures of 38 and 
46°C respectively, indicating that the increased pressure has a significant effect on 
the temperature with in the column due to frictional heating. This reduction in 
retention factor due to frictional heating is also noted by de Villiers et al. [11] where 
a 10% decrease in retention factor is noted when pressure is increased from 212 to 
718 bar.  It is clear that this significant increase in back pressure and associated 
frictional heating has a major effect on the chromatography obtained. 
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Fig 1.1.2. Estimation of frictional heating using overlay chromatograms obtained at 300, 
600 and 1000 bar and its corresponding temperatures. Data obtained on an Aquity BEH C18 
column (50 x 2.1 mm, 1.7 µm) at 34, 38  and 46°C. Reproduced from Ref. [10] 
Additionally, this increase in back pressure means that conventional HPLC 
instruments with a pressure maximum of 400 bar can no longer be used.  Therefore it 
is necessary to use specialised ultra-high pressure instruments which are capable of 
reaching 1000 bar. The need for specialised instruments make moving to smaller 
particle sizes unattractive due to the cost associated with replacing existing 
conventional LC instruments.  
An alternative to sub 2 µm stationary phases which have been re-developed in recent 
years is core-shell stationary phases. Core shell particles offer sub 2 µm column 
performances without the added back pressure constraints and have become a very 
attractive alternative. These stationary phase technologies with be discussed in more 
detail below.  
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1.2 Core shell stationary phases and their place in high performance liquid 
chromatography (HPLC) 
 
A huge area of interest in the last 7 years in chromatographic research has been the 
use of core-shell particles as stationary phase materials. “Core shell” or 
“superficially porous” particles, as their names suggests, are particles which involve 
a solid silica core around which there is a porous shell. For the purposes of this 
review, these particles shall be referred to as core-shell particles throughout, unless 
otherwise stated. 
Core shell particles are by no means a new stationary phase technology.  These 
particles have been in existence for nearly 50 years since the early days of modern 
LC [12].  However, despite their inception in the 1960’s, core-shell stationary phases 
were slow to evolve [13-15]. It has only been in recent years that the focus of 
chromatographic research has reverted back to these particles types, primarily since 
they became commercially available in 2006 [16]. 
1.2.1 Coreshell stationary phases from a historical perspective. 
1.2.1.1 First generation core-shell particles 
 
The primary driver for the development of early core-shell particles was to increase 
efficiency, as diffusion through a thin porous shell, rather than through a fully porous 
particle, (which at the time were in the region of 80 µm) would be faster and thus 
more efficient[17].  Kirkland first mentioned the use of modified glass bead supports 
modified with a porous thin layer for use in gas liquid chromatography in 1965[13]. 
These glass particles ranging in size from 60-80 µm and were modified in one of two 
ways; 1) coating with a 0.1- 1 µm layer of diatomaceous earth or 2) coated with a 
silica sol of the same dimensions. These particles were packed into columns and 
coated with a liquid phase and used as stationary phases for gas chromatography 
(GC). Kirkland[13] reported that beads modified with  thin porous films significantly 
improved the performance of glass beads as a support for GC. He also reported 
reduced HETPs for modified beads when compared to unmodified beads at higher 
linear velocities both for the diatomaceous earth coated beads and those coated with 
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silica sol as shown in Fig. 1.2.1 below illustrates HETP plots for naphthalene both on 
unmodified silica supports and those modified with silica sol or a layer of 
diatomaceous earth. When compared with unmodified glass beads at higher linear 
velocities, those modified with a silica sol or diatomaceous earth layer have 
significantly shallower Van Deemter curves, indicating greater efficiency at higher 
linear velocities. 
 
Fig. 1.2.1: HETP vs. flow rate plots for Naphthalene. Columns are modified and unmodified 
glass spheres of 60-80 µm in diameter for gas chromatography. Reproduced from ref [13] 
 
Around this time Horvath and Lipsky[15] also suggested the use of pellicular 
particles instead of fully porous particles as stationary phases.  These particles 
consisted of a “thin skin” coating on the surface of a glass support.  The authors 
coated an ion – exchange resin on the surface of glass spheres and used these for the 
rapid separation of nucleoside phosphoric acids. These pellicular particles were 
produced by coating 50 µm glass spheres with a solution of styrene, divinylbenzene 
and benzyl peroxide in ether. The solvent was then evaporated and the resulting 
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coating polymerised and cross-linked at 90°C and further converted into an anion 
exchange resin with benzyl – dimethylammonium. They were then packed into a 19 
cm, 1 mm i.d. column and used for the separation of a variety of nucleotides 
including adenylic acid (AMP), urydylic acid (UMP) and guanylic acid (GMP). The 
results showed a significant decrease in analysis time (of ~ 90 mins) compared to 
more commonly used column chromatography using a strong anion exchange resin 
which required more than 20 hours to separate the same components[15].  
Again in 1969 Kirkland[14] reported the use of “controlled surface porosity” (CSP) 
supports for LC and GC, similar to what he reported previously. However the core of 
these materials was silica based rather than glass based. These CSP supports differed 
from Horvath’s pellicular particle as they had a thicker layer or “shell” of a 
controlled thickness and pore size. Kirkland reported better performance of these 
new CSP’s when compared to both GC and LC. In GC, the occurrence of pools of 
liquid at contact points in glass beads in traditional stationary phases was eliminated 
with CSP’s which lead to increased efficiency. It was also found that an increase in 
linear velocity could be achieved, without a significant decrease in efficiency. At a 
linear velocity of 0.4 cm/sec, plate height of 0.4 mm were achieved, for benzyl 
alcohol, while at a higher velocity 4 times that at 1.6cm/sec, plate heights of ~0.6 
mm were achievable. This is in comparison to plate height for the same compound 
using a diatomaceous support of 1.0 mm at 0.4 cm/sec, increasing to 2.0 mm at 1.2 
cm/sec, at which point no further data is recorded, this is illustrated below in Fig. 
1.2.2.  In liquid – liquid chromatography (LLC), when compared with columns 
packed with diatomaceous earth, there was a significant decrease in HETP. This 
decrease was attributed to the contributions to resistance to mass transfer of the two 
particle types with CSP’s being significantly better. Their mechanical strength and 
spherical shape resulted in higher column stability and better column reproducibility 
and were designed to be suitable for use with LLC[17]  
 
10 
 
 
Fig. 1.2.2: Comparison of diatomaceous earth vs. controlled porosity for LC showing 
reduction in H for controlled porosity particles. Reproduced from ref [14] 
While these particles showed potential and some particles were eventually 
commercialised under the trade name Zipax amongst others, for these types of 
separations they quickly fell out of favour due to their inherent 
irreproducibilities.[17]  Guiochon and Gritti [17] also attributed Van Deemter plate 
theory[5], which approximated that column efficiency was inversely proportional to 
the particle size, for the demise of pellicular and core-shell particles during this time 
as much work was being carried out on reducing the particle size of fully porous 
particles in order to increase efficiencies[5]. Comparing the scales used for the 
HETP vs. linear velocity plots shown in Fig. 1.2.2 with those which will be shown 
later in Fig. 1.2.6, there is a 3-order of magnitude decrease in both the scale used for 
linear velocity (going from cm/sec to mm/sec) and HETP (mm to µm) in modern day 
Van Deemter plots. It is clear that these pellicular and CSP particles were vastly 
inferior to what was to come later, as illustrated in sections 1.2.1.2 to 1.2.1.3. 
1.2.1.2 Second generation core-shell particles 
 
While smaller fully porous particles were preferred over larger core-shell particles 
due to their much smaller diffusion path lengths and higher sample load capacity, 
Kirkland[18] observed that core-shell particles still had an advantage over fully 
porous particles for some applications, for example, the separation of 
macromolecules favoured core-shell columns due to their size and poor diffusional 
properties.  This then lead to the development in the early 90’s of a second 
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generation of core-shell particles which were especially designed for the separation 
of macromolecules[18]. The particles developed were 5 µm core-shell with a ~1 µm 
porous shell, resulting in ~ 7 µm particles, significantly smaller than the ~50 µm 
particles which were reported in the past [13-15]. These particles were produced by 
co-spray drying an aqueous silica sol mixture and dense silica beads in order to 
produce a uniform porous shell around the solid core and subsequently sintering 
them to induce strength. The particles were then rehydroxlated for subsequent 
modification. These particles were used for size exclusion chromatography without 
further modification, while particles were modified with C8 groups for reversed 
phase chromatography. The particles were compared with fully porous particles of 
approximately 8.7 µm in diameter. The authors found that for reversed phase 
chromatography, macromolecules could be separated in a fast time using flow rates 
higher than is possible for fully porous particles. Fig. 1.2.3 below shows the 
separation of 5 macromolecules in less than 90 sec with a flow rate of 5 ml/min and 
a back pressure of 150 bar. The flow rate used in this study for the fully porous 
particles in this study was 2.0 mL/min. 
 
Fig. 1.2.3: Separation of proteins using “poroshell” column, 15x0.46cm, Conditions: 
Gradient mobile phase 25% ACN/0.1% TFA to 75% ACN/0.1% TFA in 4 mins, flow rate 5.0 
mL/min, column temp: 80°C. Reproduced from reference [18] 
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Kirkland suggested that these superficially porous particles were better suited to the 
separation of macromolecules rather than small molecules as diffusion of large 
molecules in and out of pores was significantly slower than small molecules,  
resulting in enhanced kinetic properties of thin porous shell which proved more 
useful for large molecules rather than small [18]. Around the year 2000, this 
stationary phase was marketed commercially as “Poroshell” by Agilent[19] for the 
separation of macromolecules and while they proved superior for the separation of 
proteins and peptides[20, 21] with authors quoting an increase of 50% in peak 
capacity obtained compared to their fully porous counterparts [21], they met with 
limited success, most likely due to their niche market applicability. 
 
1.2.1.3 Third generation core-shell particles 
 
The drive towards ever decreasing particle sizes resulted in the development of 
particles with diameters less than 2 µm. While these columns delivered increased 
efficiencies, the resultant back pressures meant they were no longer compatible with 
conventional standard HPLC systems. This lead to a renewed interest in core-shell 
particles with the launch of the 2.7 µm Halo core-shell particle from Advanced 
Material Technologies in the mid 2000’s. This product then re-ignited the interest in 
core-shell technologies and a number of other companies followed suit such as 
Phenomenex with the launch of it’s Kinetex 2.6 µm column[22] and more recently 
its 1.7 µm column. The 2.7 µm Halo core-shell particle consisted of a 1.7 µm non 
porous silica core with a 0.5 µm thick shell[23]. These particles produced 
efficiencies which rivalled and even surpassed the efficiencies which could be 
obtained on sub 2 µm fully porous columns at the time. Typical reduced plate height 
which would be obtained on a fully porous particle was approximately 2 mm; 
however Halo core-shell particles were capable of obtaining reduced plate height of 
as small of 1.5mm for small molecules. Such efficiencies had never been seen 
before[23]. Additionally these particles demonstrated significantly lower back 
pressure than comparable sub 2 µm columns. Fig. 1.2.4 below shows a plot of back 
pressures obtained on Halo 2.7 µm columns versus, their fully porous 1.7, 1.8 and 
1.9 µm counterparts. The plots showed a 3-4 fold decrease in the back pressures 
generated for Halo columns at 0.5 ml/min when compared to a 1.7 µm fully porous 
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column. Also noteworthy is that even at twice the speed (1.1 mL/min) the Halo 
column was still capable of producing a 35% decrease in back pressure when 
compared to the 1.7 µm fully porous particle. The comparable efficiencies paired 
with the drop in back pressure meant that core-shell particles became quite 
favourable.  
 
 
Fig 1.2.4: Column pressure plots for columns of sub 2 µm fully porous and core-shell 
particles and 2.7 µm core-shell particles illustrating lower back pressures for core-shell 
particles. Reproduced from Ref [23] 
 
1.2.2 Properties of core-shell stationary phases 
Core shell stationary phases are widely quoted as being of superior performance 
when compared to their fully porous counter parts. Intensive studies have been 
carried out to investigate the causes. Coreshell thickness and particle size distribution 
are hypothesised to influence performance most; these are discussed below. 
 
1.2.2.1 Shell Thickness 
 
Studies by Omamogho and Glennon [24], Gritti et al. [25, 26] and Kirkland [27] 
have found shell thickness is an important parameter in controlling the performance 
of columns packed with shell particles. A study by Omamogho and Glennon  of an 
1.7 µm core-shell column (EiS-150-C18) which was packed in house, with a shell 
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radius of 0.15 µm versus a commercially available 1.7 µm core-shell column 
(Phenomenex Kinetex) with a shell size of 0.23 µm and two commercially available 
fully porous columns (Agilent Zorbax XDB 1.8 and Water Acquity BEH 1.7 µm) 
showed a significant decrease in the HETP obtained for Eis-150-C18 of 24% when 
compared to both the fully porous Zorbax column and the other 1.7 µm core-shell 
columns. Kirkland et al. [28] (see Fig. 1.2.5 below) found that at lower linear 
velocities, differences in the shell thickness do not show any significant difference in 
the reduced plate heights which are observed. However , at higher mobile phase 
velocity a thinner shell offers reduced plate height when a 4 µm fused core column 
with a 0.2 µm shell was compared to the same size particle with a 0.6 µm shell. This 
trend is in line with the expected improved mass transfer for the thinner shell, this is 
especially apparent for the higher molecular weight analyte verapamil. 
 
Fig. 1.2.5: Effect of porous shell thickness and solute molecular weight on column 
efficiency. Columns 4 µm fused core with 0.2 µm /0.6 µm shell. Mobile phase: Analytes 1-
Cl-4-nitrobenzene and Verapamil Mobile Phase. 30% acetonitrile/70% 0.1% aqueous 
trifluoroacetic acid, Temperature: 40°C  Reproduced from ref[28] 
 
Omamogho et al. [29] also reported better efficiencies with thinner shell sizes. For 
three 1.7 µm Eiroshell™ C18 (EiS-C18) with shell sizes of 150, 250 and 350 nm 
resulted in, reduced plate heights (hmin) of 1.9, 2.2 and 2.5 respectively. The 
contributions of the B-term to hmin were 0.43, 0.66 and 0.79 for the three respective 
shell size. This decrease with decreasing shell size was attributed to a number of 
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factors including: 1) reduced porosity with decreasing shell size – porosity is 
governed by shell size so solutes spend less time in the column and band broadening 
is reduced and 2) the ratio of solid core to shell size – a larger shell size and smaller 
core provide more column area for solute to interact with. 
 
A concern with core-shell particles is their volume fraction will be substantially 
lower due to their partially porous nature and thus their loading capacity will be 
much lower than that of fully porous particles. For some core-shell particles this has 
proved somewhat unfounded with studies showing that core-shell particles such as 
Halo 2.7 µm core-shell particles, with a shell diameter of 0.5 µm, retained  a volume 
fraction of 80%, however other similar sized core-shell particles, such as Kinetex 
2.6µm core-shell particles only maintained a volume fraction of 58% when 
compared to their fully porous counterparts [30]. This is the only study which has 
been carried out and there is a lack of other substantial evidence to validate or nullify 
these concerns. Therefore no definitive conclusion can be drawn on whether core-
shell particles can maintain the same sample loading capacity as their fully porous 
counterparts without significantly more research. 
 
1.2.2.2 Particle size distribution 
 
A parameter which sets core-shell particles apart from their fully porous counter 
parts is their particle size distribution.  A narrow particle size distribution is 
important as it leads to greater packing efficiency and in turn leads to a reduced A 
term in the Van Deemter equation – a major source of band broadening and loss in 
efficiency. Because core-shell particles consist of a solid core, the size of this core is 
better predicted leading to a narrower size distribution of particle sizes[31]. Gritti et 
al.[32] report a standard deviation of 5% in particle size distribution for Halo 2.7 µm 
core-shell particles while a much larger standard deviation of 13% is seen for a 
column packed with porous 3 µm type B silica. Type B silica is a newer generation 
silica which is synthesised from an organic sol starting material, as opposed to 
inorganic sol (type A)[33]. The primary advantage of this type of silica is its trace 
levels of metal impurities compared to type A silica resulting in the lack of need to 
base deactivate the silica support for analysis of more basic compounds required 
when higher levels of metal impurities are present. The difference in particle size 
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distribution between porous particles and their fully porous counterparts is also 
shown by DeStefano et al. [23] who report a standard deviation of 5-6% for core-
shell particles and 19% for fully porous particles. Omamagho and Glennon[24] 
report a massive 33% and 27% standard deviation for zorbax XDB 1.8 µm and 
Acquity – BEH 1.7µm fully porous particles respectively. This is compared to a 
standard deviation of just 6.1% and 5.2% in the case of Kinetex 1.7 µm and Eiroshell 
Eis-150 core-shell particles respectively.  As previously noted, a narrow particle size 
distribution leads to a reduction in the packing term (A) of the Van Deemter equation 
leading to higher efficiencies. For this reason, core-shell particles packed columns 
are a very attractive alternative to fully porous particle packed columns. 
1.2.3 Comparison of the efficiencies of fully porous stationary phases to core-
shell stationary phases 
1.2.3.1 Van Deemter plots 
 
As mentioned previously, the Van Deemter equation (Eqn (i)) [5] was one of the first 
applications of rate theory and its relationship to column efficiency. This equation is 
used to predict the optimum linear velocity (u) at which the lowest plate height (h) 
can be achieved, taking into account the physical, kinetic and thermodynamic 
properties of separation. 
ܪ ൌ        ܣ       ൅         ஻௨         ൅       ܥݑ    Eqn (i) 
Van Deemter theory[5] suggests that smaller particle sizes leads to increased 
efficiencies and thus smaller plate heights due to a reduced C term as a result of 
better mass transfer properties, due to shorter diffusion path lengths of smaller 
particles and also a reduction in the A term . This theory can also be applied to core-
shell particles where a key advantage of core-shell columns is their lower H value 
when compared with fully porous columns of the same particle size and dimensions.  
DeStefano et al.[28] showed that when a 5 µm core-shell column was compared with 
a 5 µm fully porous column, core-shell plate heights (HETP) were significantly 
reduced both for small molecules and larger molecule. Fig 1.2.6. below shows a 
representative Van Deemter plot, where for the larger verapamil solute, a minimum 
HETP of ~6.1 mm for the core-shell particle column and ~10.8 mm fully porous 
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particle column respectively were obtained and a minimum HETP of ~5.4 mm and 
~10.7 mm for the core-shell and fully porous particle columns respectively were 
obtained for the smaller 1-Cl-4-nitrobenzene solute. 
 
Fig 1.2.6: Comparison of Fused-Core and totally porous particles. Columns: 4.6 mm×150 
mm; 5 µm Halo fused core with 0.6 µm shell and 5 µm totally porous particles. Analytes 1-
Cl-4-nitrobenzene and Verapamil – Mobile phase: 35% acetonitrile/65% aqueous 0.1% 
trifluoroacetic acid; temperature 40°C. Reproduced from Ref [28] 
 
 
As seen, core-shell columns are capable of producing higher efficiencies when 
compared to fully porous columns packed with particles of the same size, as a 
consequence it can be theorised that larger core-shell particles are capable of 
producing efficiencies as good if not better than comparable smaller fully porous 
particles. This theory was proven in the work of Oláh et al.[34], where a 2.6 µm 
Kinetex core-shell column showed similar and often improved minimum plate 
heights when compared its smaller fully porous counterparts. The 1.7 µm Acquity 
and 1.9 µm Hypersil Gold fully porous particles were shown to have a minimum 
plate height of 4.6 µm and 5.4 µm respectively while the Kinetex 2.6 µm core-shell 
particle had a minimum plate height of 5.0 µm when estradiol was analysed. As can 
be seen from the analysis of Van Deemter plots, core-shell particles show increased 
efficiencies when compared to their fully porous counterparts, which further 
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supports the argument that core-shell particles can out-perform their fully porous 
counterparts.  
 
1.2.3.2 Knox plots 
 
However, while the Van Deemter equation is widely used, it still has its limitations, 
with one of the main limitations being that the Van Deemter plot is dependent on 
particle size and is also system specific [35]  This has led to the  equation being  
modified to become the Knox equation [36]  The advantage of the Knox equation for 
comparing core-shell columns is that particle size is independent, as will be 
discussed below, and also takes into account the porosity of the column. The Knox 
equation (Eq.(ii)) is given below. 
݄ ൌ ܣݒ଴.ଷଷ ൅ ஻௩ ൅ ܥݒ   Eq. (ii) 
Similar to the Van Deemter equation A, B and C are constants which define a set of 
constants pertaining to diffusion and mass transfer of the mobile phase. A is eddy 
diffusion combined with mobile phase mass transfer, B is longitudinal mass transfer, 
C is stationary phase mass transfer, h is reduced plate height and v is reduced 
velocity. While the Van Deemter equation treats all contributions to  brand 
broadening as individual contributions, the Knox equation differs here, as mass 
transfer is split into two types, mobile phase mass transfer and stationary phase mass 
transfer. Stationary phase mass transfer becomes term C while eddy diffusion and 
mobile phase transfer become term A[36]. The reason given by Snyder et al.[37] for 
this is due to the fact that where two interparticle flow streams recombine, there is a 
loss in velocity due to remixing, therefore it is necessary to treat these two processes 
as a single band broadening event. Knox [35] also stated that this combined A term 
is by far the most important contribution to dispersion and band broadening. 
It is also necessary to note that the Knox equation is a dimensionless equation[38]. 
This equation is particle size independent, both the HETP (H in Van Deemter 
equation) and mobile phase velocity (u in Van Deemter equation) are calculated to 
be independent of particle size giving rise to reduced plate height (h) and reduced 
velocity (v).  “h”, the reduced plate height is calculated as plate height devisable by 
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the mean particle diameter (dp) (Eq. (iii)) while “v” the reduced velocity is a function 
of particle size, “u”, the linear velocity and also the diffusion coefficient of the 
analyte in the mobile phase (DM). (Eq. (iv)). Knox stated that the advantage of using 
reduced parameter such as “h “ and “u” was that columns of different particle size 
and the use of different eluents could be directly compared as well as comparisons 
between two different chromatographic system such as GC and LC[39].   
݄ ൌ ܪ/݀௣   Eq. (iii) 
ݒ ൌ ݑ݀௣ /ܦெ               Eq. (iv) 
Cunliffe and Maloney used a Knox plot to compare the performance of sub 2 µm 
fully porous particle columns to core-shell columns independent of their particle 
size[16]. Columns chosen for this study included, Supelco Ascentis Express C18 2.7 
µm, Advanced Material Technology Halo C18 2.7 µm along with a range of sub 2 
µm fully porous particles. This study found that the core-shell columns had a 
reduced plate height of approximately 2 in the case of the Ascentis C18 and of less 
than 2 for the Halo C18 column. This is compared to reduced plate heights of ~ 3 for 
Zorbax and Acquity fully porous columns and ~ 4 in the case of the Thermo columns 
tested. Fig 1.2.7 below illustrates representative Knox plot obtained. This study 
showed that despite the larger particle size, core-shell columns were still capable of 
producing efficiencies which were as good if not surpassing that of fully porous 
columns with smaller particle sizes. Another point to note here is that the core-shell 
columns continue to maintain low reduced plate height at higher reduced linear 
velocities when compared to the fully porous columns. As both the Van Deemter and 
Knox plots have demonstrated, efficiency is superior on core-shell columns when 
compared to their fully porous counterparts. The advantage of Knox plots versus 
Van Deemter plots is the fact that Knox is dimensionless. While Van Deemter plots 
are capable of comparing columns of different particle sizes, Knox plots provide 
direct comparison of column efficiencies or plate height, as particle size and linear 
velocity are independent. 
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Fig. 1.2.7: Knox plots for Naphthalene for the five columns analysed. Column dimensions 
2.1 x 100 mm. Particle sizes: Acquity: 1.7 µm, Zorbax: 1.8 µm, Thermo: 1.9 µm, (all fully 
porous particles) Halo: 2.7 µm, Express: 2.7 µm (both core-shell particles) Mobile Phase: 
50:50 ACN:Water. Reproduced from Ref. [16] 
 
1.2.3.3 Kinetic Plots – Poppe plots 
 
In recent years kinetic plots such as Poppe plots, have been developed as another 
tool by which LC columns of different particle types and sizes can be compared 
against each other[40]. Unlike Knox and Van Deemter plots, Poppe plots take into 
account the permeability of columns as well as maximum operating pressure in their 
calculations. They are used to help visualise the compromise between speed and, 
efficiency in isocratic mode, or peak capacity in gradient mode [41]. Poppe plots 
allow optimal conditions such as flow rate and column length to be determined under 
a given set of separation conditions such as a fixed run time and utilising the 
maximum pressure attainable on a column, as a result it is possible to compare 
different column types and length under ideal conditions rather than arbitrary 
conditions[42]. Poppe plots consist of N (number of theoretical plate) plotted against 
plate time (t0/N) which is a measure of void time (t0), divided by plate number in the 
---case of isocratic separations[43]. This was further expanded by Wang et al [44] to 
include gradient separations where plate time is replaced with gradient time (tg) and 
theoretical plates by peak capacity (n). Poppe plots  can either be constructed using 
Van Deemter or Knox values for plate height(H) and linear velocity(u). Using a 
21 
 
range of void volumes (t0) together with linear velocity of an unretained solute(u) 
interstitial linear velocity (ue) and total and interstitial porosity (εtot, εo) column 
lengths (L) are determined by Eq. (v), this in turn is used to calculate the pressure 
drop (ΔP) which is calculated by Eq. (vi) where Φ is the flow resistance, η is mobile 
phase viscosity  and dp is particle size[42]. The optimal plate count (N) and plate 
count production (N/t0) can then be calculated and a Poppe plot constructed as 
shown in Fig. 1.2.8 
ܮ ൌ ݑݐ଴ ൌ ቀ ఌ೚ఌ೟೚೟ቁ ݑ௘ݐ௢              Eq. (v) 
∆ܲ ൌ  ߔߟ ௨೐௅ௗ೛మ       Eq. (vi) 
 
 Zhang et al [42] used these Poppe plots to compare the performance of 2.7 µm 
superficially porous particles with a pressure limit of 600 bar with sub 2 µm fully 
porous particles with a pressure capacity of 1000 bar. A theoretical Poppe plot 
comparing both stationary phases is shown below in Fig. 1.2.8. The plot shows that 
on the left side which equates, both curves converge which indicates that both 
columns produce similar efficiencies  when the analysis is very fast (t0 <10s) while 
on the right hand side of the graph, the curves begin to diverge and the 2.7 µm core-
shell column (B) (backpressure 570 bar) outperformed the 1.7µm fully porous 
column (A) (back pressure 950 bar) at longer analysis times, with a 2 fold increase in 
plate counts even at t0 > 1000 sec. This plot also shows that for a theoretical column 
packed with 2.7 µm fully porous particles (C) run at the same pressure of the core-
shell column (570 bar), the core-shell column would theoretically still outperform its 
fully porous counterpart both on the left at very fast conditions and on the right 
where the dead time is greater than 1000 sec.  
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Fig. 1.2.8: Theoretical isocratic Poppe plots for packed bed columns. Each dotted line 
represents a constant column dead time. Case a: 1.7µm BEH C18 at ΔPmax = 950 bar. 
Case b: 2.7µm Halo C18 at ΔPmax = 570 bar. Case c (hypothetical): 2.7µm BEH C18 at 
ΔP = 570 bar. Reproduced from Ref [42] 
 
This theoretical model was proved to be quite accurate under experimental 
conditions where slightly higher plate counts were observed for the fully porous 
column for very fast separations whereas the total analysis time was 40% shorter for 
the superficially porous column for a 5cm column while at longer column lengths of 
45 cm,  the core-shell column was seen to outperform the fully porous column with 
both higher plate counts and shorter analysis times. Table 1.2.1 below shows a 
comparison of the calculated and experimental data for dead time, plate count and 
back pressure for both the fully porous and core-shell columns. There are no 
significant differences between the experimental and calculated values which 
indicates that the theory is quite accurate and gives a good indication of column 
performance at maximum pressures. 
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Table 1.2.1: Comparison of the calculated and experimental column dead time, plate count 
and backpressure on Halo C18 phase and BEH C18 phase at various column lengths. 
Reproduced from Ref [42] 
 
 
 
Wang et al. [45] also report similar findings to Zhang[42] shown in Table 1.2.2, 
stating that 2.7 µm core-shell columns gave better performance over their smaller 1.8 
µm  fully porous counterparts and  indeed 1.7 µm core-shell stationary phases at 
longer run times when the dead time is in excess of 30 sec. When similar particle 
sizes were compared (2.7 µm core-shell particle and 3.0 µm fully porous) there was 
a 36% increase in efficiency for core-shell particles with efficiency rising from 
140,000 to 191,000.  Also while larger particles are more efficient at longer run 
times, it was also shown in this analysis that the smaller 1.7µm core-shell column 
outperformed the fully porous particle at shorter dead times of >10 sec with an 
increased plate count of approximately 8% from 20,200 to 21,800. This increase was 
not as significant as seen for larger particles, however showed that 1.7 µm core-shell 
particles are capable of equalling and slightly out performing their fully porous 
counterparts. 
Table 1.2.2: Comparison of optimum conditions from the analysis of Poppe plots obtained 
for fully porous 1.8 µm and 3.0 µm particles and 1.7 µm and 2.7 µm superficially porous 
particles. Reproduced from Ref [45] 
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Wang also points out the ability of the 2.7µm core-shell column to be run on a 
conventional HPLC system with pressure capabilities of 600 bar when extra brand 
broadening is minimised. Thus for slightly lower efficiencies, it possible to carry out 
ultrafast separations without the need to purchase expensive high pressure 
instruments.  Another hypothesis which both Wang[45] and Zhang [42] share is that  
should the back pressure capabilities of the 2.7µm core-shell column extend to 1000 
bar, efficiency could be further improved.  
In conclusion, like Van Deemter and Knox plots, Poppe plots have been shown to be 
another useful tool in critically comparing column types. Poppe plots provide a more 
sophisticated method of comparing columns than either Van Deemter or Knox plots. 
Poppe plots allow optimised conditions e.g. linear velocity (µ) and column length 
(L) to be determined whilst keeping separation conditions constant, i.e. maximum 
back pressure and a fixed run time instead of arbitrary values used in Van Deemter 
and Knox plots.[42]  Poppe plots have shown core-shell particles are capable of 
providing better efficiencies than their smaller fully porous counterparts. Theoretical 
Poppe plots have also demonstrated that when back pressure capabilities are 
increased to 1000 bar, 2.7 µm core-shell columns, have the potential to provide even 
greater improvement in efficiencies. 
1.2.4 Application of core-shell particles  
Much of the work carried out on the new generation of core-shell stationary phases 
has been related to investigation of effect of particle size distribution on efficiency of 
core-shell particles[23, 24, 32], determination of an optimum shell thickness and 
their associated mass transfer kinetics [24-26, 29, 32]. Considerable work has also be 
carried out on column efficiencies in terms of Van Deemter plots [28, 34], Knox 
plots [16] and kinetic plots such as Poppe plots[42, 45]. However, there has been 
little work carried out carried out on the evaluation of the core-shell column under 
real chromatographic conditions. Some of the work which has been carried out has 
focused on the area of protein separation and is shown below. 
The analysis of proteins was carried out by Fekete et al. [46] using Phenomenex 
Aeris™ WIDEPORE column with a 3.6 µm particle size with a 0.3 µm diameter. 
Filgrastin related proteins were separated using the Aeris column as well as other 
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fully porous and core-shell columns. The peak capacity (nc) obtained for fully porous 
columns ranged from 50 to 87 for the most part. An Acquity BEH300 fully porous 
particle column performed better with a peak capacity of 103, this was comparable to 
the nc = 114 achieved by the Aeris core-shell column, however this was still a 10% 
decrease in peak capacity. Fig. 1.2.9 below shows chromatograms of filgrastim 
related proteins obtained on both the Aeris WIDEPORE and Acquity BEH300 
columns. A comparison of the chromatograms not only shows an increase in peak 
capacity but also a reduction in retention time of ~ 1 minute of the last eluting peak 
from ~5.2 min to ~4.0 minutes when the Aeris WIDEPORE column is used. 
 
Fig. 1.2.9: Comparative chromatograms of filgrastim related proteins obtained with Aeris 
WIDEPORE (A) and Acquity BEH 300 (B) 150 x 2.1 mm columns. Chromatogram 1: native 
filgrastim, chromatogram 2: oxidised forms, chromatogram 3: reduced form. Conditions: 
Mobile Phase A: 0.1% TFA in water, mobile phase B: 0.1% TFA in acetonitrile, flow rate 
300 µL/min, linear gradient 45-65% in 6.5mins, temp 80°C, detection at 210 nm. 
Reproduced from ref[46] 
 
Schuster et al. [47] carried a similar study where core-shell particle columns were 
used for a proteomic applications. Here, Advanced Material Technology Inc. Halo 
Peptide ES-C18 of particle size 2.7 µm with a shell diameter of 0.5 µm was compared 
to fully porous Waters BEH C18 column of 1.7 µm for proteomic applications. Fig. 
1.2.10 shows chromatograms of the separation of range of peptides on 3 different 
columns used in a peak capacity study, with two columns being core-shell (the only 
difference being the length of the column used) and one being a fully porous particle 
column. When comparing the core-shell particle column and fully porous column of 
the same dimensions, it is shown that the last peptide to elute on the Halo Peptide 
column, which was known to be Hel 11-7 does not elute in the gradient time on the 
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BEH column. It was also found that despite peak capacities being approximately 
15% higher on the BEH column than the HALO peptide column, the back pressure is 
almost double that of the HALO Peptide column. The advantage of the core-shell 
column is shown to be the low back pressure which is associated with it. This is 
demonstrated by increasing the length of the column by 50% which increases the 
peak capacity by 9% from 278 to 303 when compared to the fully porous column, 
while still having a reduction in back pressure of 57% when compared with the 
shorter fully porous columns run at the same conditions. 
 
Fig 1.2.10: Representative chromatograms for peak capacity studies. Columns: 2.1 x100 
mm HALO Peptide ES-C18, 2.1 x 110 mm BEH C18, 2.1 x150 mm HALO Peptide ES-C18. Flow 
rate 0.5mL/min, Temperature 45°C; gradient 5-70% in 60 or 90 minutes, A; water/0.1% 
trifluoroacetic acid; B: 80/20 acetonitrile/water/0.1% trifluoroacetic acid; sample 15 µL of 
11 synthetic peptides (50 ng each). Reproduced from ref [46] 
 
As can be seen core-shell particles have been shown to both match and often rival 
fully porous particles both of similar sizes and also smaller sizes in terms of 
efficiency.  As seen in section 1.2.3.1, Kinetex 2.6 µm core-shell particles provide 
similar and sometimes decreased plate heights (H) when compared to 1.7 µm and 1.8 
µm core-shell particles. Shell size have been found to be an important parameter in 
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controlling efficiency with thinner shells providing better efficiency compared to 
thicker shells as discussed in section 1.2.2.1. Van Deemter, Knox and Poppe plots 
ave provided further evidence of the capabilities of core-shell particles to provide 
efficiencies that rival their fully porous counterparts.  
Much of the applications of core-shell particles have focussed primarily on the 
separation of proteins and peptides as shown above. The lack of publication of a 
significant amount of practical applications of core-shell particles could be linked to 
the trend Majors[8] found during his survey of HPLC column usage across the LC-
GC community. Results of the survey found that at the time over 60% of HPLC 
users still use columns which are between 3 and 7 µm in size. The likely reason for 
this as hypothesised by Majors was the reluctance to replace larger particle columns 
with smaller particle columns due to the need for revalidation of method, unless it 
was absolutely necessary, therefore, industry and LC users in general are slow to 
adopt this new technology across a wider range of applications. 
1.3 Supercritical Fluid Chromatography (SFC) – A greener alternative to 
HPLC 
As mentioned in the introduction a primary driver in chromatographic research at 
present is the desire for faster, more efficient separations. For this reason, much of 
the research in HPLC has focussed on the development of new types of stationary 
phases capable of fulfilling this need. One such way which was discussed in detail in 
section 1.2 is the development of core-shell stationary phases as alternatives to fully 
porous sub 2 µm stationary phases. Another factor which is driving chromatographic 
research today is reduced solvent consumption and the strive for more 
environmentally friendly practices. While core-shell particles and reduction in 
stationary phase particles sizes are currently addressing both of these research 
drivers, there becomes a point at which, decreasing particle size and synthesis of 
novel core-shell stationary phases which continue to improve efficiency reaches its 
limit and further reductions in particle sizes will lead to increasing problems such as 
frictional heating. As a result other chromatographic techniques are being considered 
in the strive for continuous improvement in the field of separations, which as well as 
being equal if not superior to HPLC in terms of efficiency and speed, are also a more 
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environmentally friendly alternative.  One such technique is Supercritical Fluid 
Chromatography (SFC). 
SFC is a chromatographic technique which lies intermediate between LC and GC 
and possesses some of the characteristics of both[48].  The main mobile phase used 
in SFC is supercritical fluid instead of liquid. Supercritical fluids are neither gases 
nor liquids but possess properties which are intermediate of the two.[48] 
Supercritical fluids have a similar density and solvating power to some liquid 
solvents whilst maintaining more gaseous like properties such as low viscosity and 
high diffusivity.[49, 50] As a result of the increased diffusion capabilities and low 
viscosity of supercritical fluids compared to solvents used in HPLC, SFC is an 
attractive alternative as much higher linear velocities can be used which in turn leads 
to faster separations and higher throughputs[51]. According to Berger and Smith, 
packed column SFC when compared to LC is faster, more efficient, has a wider 
range of selectivity and produced less toxic waste[48].  One of the main supercritical 
fluids used in SFC is carbon dioxide (CO2). CO2 is an inexpensive, non-toxic gas 
which is produced as a by-product of natural processes such as fermentation and 
from the chemical industry. This makes it a greener alternative to traditional solvents 
used in HPLC such as methanol and hexane.[51] A brief history, principles and 
applications of SFC will be discussed in more detail in the proceeding sections. 
1.3.1 SFC from an historical perspective 
The inventers of SFC are considered to be Klesper et al. [52] in 1962. They describe 
the separation of porphyrins using supercritical chloroflouromethanes which they 
marketed as high pressure gas chromatography.  Around this time, Giddings et al. 
[53] carried out similar work, however very little further progress was made on this 
front at the time, due in part to the exponential growth of HPLC which was occurring 
around the same time.  
It was not until the 1980’s that SFC saw a major growth, where much of the work 
carried out in the 80’s was using capillary columns which was likened to GC and 
used GC style open tubular columns and GC detectors such as Flame Ionisation 
Detection (FID), electron capture and sulphur chemiluminescence[49]. However, the 
application of open tubular SFC, according to Taylor, was limited to use in the 
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petrochemical industry, as the forerunners in the pharmaceutical industry at the time 
found the technique to be severely lacking due to its poor reproducibility and limited 
application range, in part due to the low solvating power and polarity of carbon 
dioxide alone. Another downfall of open tubular SFC was its inability to 
independently change flow velocity and pressure, the only means of changing 
pressure was by changing the flow velocity[54] 
Around this time, packed column SFC was also being developed. This utilised 
modified HPLC hardware and is nowadays the most widely used form of SFC. The 
inclusion of a back pressure regulator allowed the supercritical fluid to be kept at a 
sufficient pressure to remain under supercritical conditions. The principle advantage 
of packed column SFC was the ability to directly control the flow rate and outlet 
pressure of the supercritical fluid independently, something which was not 
achievable with open tubular SFC.[49] The first commercially available SFC 
instruments were launched in the late 1990’s with several vendors such as Hewlett 
Packard (now Agilent), JASCO and Gilson now manufacturing instruments. Modern 
SFC’s were in essence the same as HPLC instruments, with the addition of a chilled 
CO2 pump, a modifier pump and a back pressure regulator which allowed the 
pressure to be controlled  independently of flow rate.[54] 
1.3.2 SFC Hardware  
Typical SFC instruments today are based primarily on HPLC instrumentation with 
adjustments made to accommodate the need for the supercritical fluid solvent – 
mainly CO2, to be kept under appropriate conditions. In general, an SFC system 
consists of a HPLC and an external CO2 conditioning module[55]. This module is 
used to transform gaseous CO2 into its supercritical state. Without the need for LC 
pump compression requirements, this module cools the CO2 prior to the pump and 
contains a back pressure regulator which controlls the pressure of the system.  
SFC systems are generally binary systems with a CO2 pump and a second pump for 
liquid co solvent[51]. There are a number of types of injection including loop 
injection, in-line injection and in-column injection which allows samples to be 
directly injected onto the column without dilution. As a generally rule, any HPLC 
stationary phase can be used for SFC whether typically used for normal or reversed 
30 
 
phase. SFC is compatible with both HPLC detectors such as UV-Vis, diode array 
and chiral detectors as well as GC detectors such as FID[51]. At all times the 
instrument is a closed system, ensuring that CO2 remains in its supercritical state. 
1.3.3 What are supercritical Fluids? 
A supercritical fluid is defined as a compound, mixture or element above its critical 
pressure and temperature[56]. Above a critical temperature and pressure, known as 
its critical point, a gas cannot be liquefied and exists in a state which is intermittent 
between a liquid and gas. Carbon dioxide is generally the supercritical fluid of 
choice for SFC due to its favourable operating conditions, purity, safety, ease of use 
and low cost[50]. CO2 has a critical temperature of 31.1°C and a critical pressure of 
73.8 bar. It is cheap and readily available, as it is produced as a by-product of 
chemical industry or natural processes such as fermentation[51]. It is non-toxic and 
has modest critical parameters, which are mentioned above. As well as this, CO2 is 
an attractive alternative to liquid mobile phases like methanol and hexane in terms of 
waste generated, CO2 can be de-pressurized post column and CO2 can be vented or 
recycled, leaving samples dissolved in a small volume of organic modifier if present, 
decreasing the total amount of waste generated.[51]  Other supercritical fluids such 
as ammonia have been used, however supercritical ammonia was found to give 
irreproducible results which may be due to the varying water content of ammonia. 
Another reason ammonia was seen to be less favourable is due to face that is too 
aggressive and toxic for use. Ammonia, in the majority of cases, was also found to 
dissolve silica based materials [57] As the majority of stationary phases are made 
from silica based materials, this makes it very unsuitable for packed column SFC. 
Other supercritical fluids used included nitrous oxide which was argued to be a 
stronger solvent than  supercritical Carbon dioxide sCO2 [58].  However it was found 
to be entirely unsuitable due to strong oxidising nature which in the presence of 
organic co-solvents proved hazardous and was not recommended for use in 
supercritical fluid chromatography [59].  
 
31 
 
1.3.4 SFC - a complementary technique to HPLC? 
The power of SFC is linked to its primary mobile phase – supercritical fluid and in 
particular, its liquid like solvating power coupled with reduced diffusivity and 
viscosity when compared to LC. Diffusion coefficients of supercritical fluids are in 
the region of 1 x 10-4 - 10-5 cm2 s-1 while the diffusion coefficient for liquids and 
gases are 1 x 10-5 - 10-6 cm2 s-1 and 0.1-1.0 cm2s-1 [48], so while not nearly as 
diffusive as a gas, supercritical fluids are in the region of 10 to 100 more diffusive 
than liquids. Table 1.3.1 shows the viscosity of sCO2 at a range of temperature 
compared with water and acetonitrile at the same temperature[60], sCO2 at the same 
temperature, has at the very least viscosity approximately 1/5 to that of water and in 
some cases is as much as 20 times less viscous than water. This reduced viscosity 
and increased diffusivity allow higher flow rates to be used, all whilst keeping back 
pressure significantly lower than LC, with SFC having a 2/3 fold decrease in back 
pressure which in turn  leads to the potential for longer columns to be used to 
improve efficiencies. [48, 60] 
Table 1.3.1: Viscosity of sCO2 (100, 200 and 400 bar), H2O and Acetonitrile (CH3CN) at 
different temperatures (20, 40 and 60 °C) 
 
The solvation power of CO2 or any supercritical fluid is linked to its density – above 
a pressure of 32 bar and a temperature of approximately 74°C, sCO2 behaves like a 
liquid. CO2 is very non polar and has a similar polarity to pentane[61] making SFC a 
similar technique to normal phase HPLC. Another reason why SFC is considered 
analogous to normal phase is due to the absorption of CO2 onto the surface of the 
stationary phase, similar to mobile phase absorption in normal phase LC[62]. 
Selectivity can be altered in SFC by the addition of an organic modifier [51] which 
alter the polarity of the mobile phase and also to an extent the polarity of the 
stationary phase through mobile phase absorption[62].  Selectivity can also  be 
changed by altering the temperature and pressure of the mobile phase, however this 
method is not as powerful as the addition of an organic modifier. As mentioned 
32 
 
previously, SFC is generally considered analogous to normal phase for this reason it 
gives orthogonal selectivity to reversed phase HPLC[63, 64]. This orthogonal 
selectivity makes SFC a very attractive complementary technique which can be used 
in conjunction with RP HPLC or as an alternative standalone method. The role of 
modifiers as well as effects of temperature and pressure in separations will be 
discussed in the following sections. 
1.3.4.1 Use of modifiers and additives  
 
1.3.4.1.1 Modifiers 
 
CO2 is similar in nature to pentane and for this reason is more suited to the separation 
of moderately polar to non-polar solutes. In order to increase the solvation capacity 
of CO2 for the separation of more polar solutes, more polar modifiers are added to 
CO2. Some of the modifiers used in SFC are methanol[65-69] and ethanol[70-72] for 
the separation of more polar compounds. and a mixture of modifier solvents such as 
methanol and acetonitrile are also used[73, 74]. The addition of modifiers change the 
density of the mobile phase which has an effect on the elution strength[60], affects 
the polarity of the mobile phase, changes mobile phase/ solute and stationary 
phase/solute interactions decreasing retention and improves efficiency and peak 
shape [60, 69, 75]. Hoffman et al.[69] found that the addition of a methanol modifier 
was more advantageous than acetonitrile in the separation of ethoxylated and 
propoxylated surfactants on a C18 stationary phase. Methanol as a modifier produced 
better peak shape with peak asymmetry values of 1.09, 1.10 and 1.14 recorded for 
methanol modified CO2 and values of 1.15, 1.21 and 1.44 recorded for an acetonitrile 
modifier. The improved peak asymmetry values for a methanol modifier were likely 
due to the greater hydrogen bonding capacity of the methanol compared to 
acetonitrile and coverage of excess silanols on the surface of the stationary phase by 
methanol. West et al. [76] investigated the effect of a range of alcoholic modifier as 
well as concentration of modifier on the separation of enantiomeric amino acid 
derivatives on polysaccharide based chiral stationary phases. The authors found that 
there was a slight increase in retention when methanol was changed to ethanol and 
then subsequently to isopropanol as shown in Fig. 1.3.1.  
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Fig. 1.3.1: Effect of the nature of alcohol modifier in a CO2 mobile phase on the separation 
of amino acid derivative PP on a Lux chiral column. Conditions: Modifier percentage: 3%, 
back pressure 150 bar. flow rate: 3mL/min. Reproduced from Ref. [76] 
The increase in the retention between the 3 similar alcoholic modifiers is due to their 
decreasing polarity, methanol being the most polar and isopropanol, the least. The 
authors choose ethanol as the modifier of choice for further analysis, as despite 
having a longer analysis time than methanol, ethanol is a more environmentally 
friendly and non-toxic option. Isopropanol provided a higher resolution between the 
enantiomers than either methanol or ethanol however this increase in resolution was 
offset by the increase in run time of the analysis. A study of effect of modifier 
concentration on separation, showed as expected retention is decreased with 
increasing modifier concentration; results showed that a modifier concentration of 
just 5% was capable of providing adequate resolution between peaks with a 
reasonable run time. In the majority of cases however, methanol is the modifier of 
choice for most applications as it produces very efficient separations while also 
having the advantage of low viscosity, high polarity and a low boiling point [77]. 
Wenda et al.[68] tested the effect of modifier concentration as well as changing 
density on resolution and selectivity of flurbiprofen enantiomers. Analysis of 
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flurbiprofen was carried out on an amylose derived, Chirapak AD-H chiral column,  
using different concentrations of methanol from 13% to 23% while incrementally 
changing the back pressure – this change in back pressure changed the density of the 
mobile phase. Decreased resolution between the enantiomers is shown in Fig. 1.3.2 
with increasing density. There is also an overall trend of decreased resolution with 
increasing methanol concentration. A decrease in retention factor resolution was also 
noted by Li et al.[78] with increasing modifier concentration and also with 
increasing density.  
 
 
Fig. 1.3.2: Dependence on resolution (right) and selectivity (left) on modifier (methanol) 
concentration and density of the mobile phase. Analyte:  Flurbiprofen enantiomers. Column: 
Chiralpak AD-H Reproduced from Ref. [68] 
 
Also shown in Fig. 1.3.2 is the effect of methanol concentration on the selectivity of 
the mobile phase, and thus density was found to have a moderate effect on overall 
selectivity, while at 18% and 23% methanol concentration and density do not appear 
to have an effect on the selectivity. More profound effects on selectivity are noted 
when a lower methanol concentration is used. Wang et al.[79] found that for a range 
of 48 enantiomers, a change in density had little or no effect on selectivity, however 
the author noted that the effect of density on selectivity is quite a controversial topic 
with varying opinions on the topic, it is clear that is an area that further research is 
required. 
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1.3.4.1.2 Additives  
 
Additives in SFC play a similar role to those used in HPLC such as coverage of 
stationary phase active sites and suppression of ionisation or ion pairing by 
solutes[62]. Additives to  modifiers are also capable of extending solute polarity and 
changing the polarity of the mobile phase as well as the stationary phase [62]. Some 
additives which have been used include water [80] [81] salts such as ammonium 
acetate [82], basic additives like ammonia [83] and isopropylamine (IPA) [84] and 
strong acids like triflouroacetic acid (TFA) [84]. De Klerck et al.[84] found that for 
the separation of a range of enantiomers of basic, neutral and acidic nature, on 
polysaccharide based stationary phases there was a decrease in retention when 
applied to the separation of enantiomers with increasing methanol concentration. In 
this study IPA and TFA were used as additives. The authors found that with the 
addition of the both additives simultaneously, there was decrease in retention factor 
of the first peak (k1) and greater number analytes fully eluted within 30 minutes. 
TFA and IPA were found to have different effects on the separation; TFA was 
believed to deactivate free silanol groups by forming hydrogen bonds, as well as 
lowering the pH of the mobile phase, partially protonating and charging basic 
functional groups and reducing retention time. IPA was believed to suppress non 
stereospecific interactions between analytes and the silica matrix of the stationary 
phase, enhancing enantioselectivity and reducing retention. Patel et al.[85] found 
that for the separation of peptides a methanol:sCO2 mobile phase gradient containing 
0.2% TFA achieved the best separation on an amino column. It was theorised that 
TFA would fully protonate the peptides in the mobile phase forming a dication while 
triflouroacetates present due to the nature of the peptide analytes (which were salts 
of trifluoroacetate) would be act as a dianion, which lead to ion pairing.  
The advantage of using volatile salts like ammonium acetate (AA) as an additive 
over acid or bases is due to their better compatibility with mass spectrometric 
detection, as unlike acid and base additives, volatile salts do not cause ion 
suppression[82]. Gassiot et al. [82] demonstrated that the addition of ammonium 
acetate in increasing concentrations to a methanol mobile phase, both decreased 
retention and improved peak shape of sulphonamide compounds analysed on a 2-
ethylpyridine (2-EP) stationary phase as shown in Fig 1.3.3.  
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Fig. 1.3.3: Evolution of peak retention time and peak shape with increasing amounts of AA 
in the modifier. Column: 2-EP, mobile phase 10% methanol in CO2, 100bar, 35°C, 4 
mL/min. Compound on left: sulphonamide 3, right: naproxen. (a) 0.3 mM AA in MeOH (b) 5 
mM AA in MeOH (c) 30 mM AA in MeOH. Reproduced from Ref. [82] 
Asymmetry of compound 3 (shown on the left side of Fig. 1.3.3) showed a reduction 
from 4.18 when 0.3 mM AA was added to the methanol modifier to 1.26 when 30 
mM AA was added to the methanol modifier, this is coupled with a reduction in the 
run time for compound 3 of approximately 50%. Also shown in Fig 1.3.3. is the 
effect of increasing AA concentration on naproxen, whose retention behaviour was 
not affected by the addition of AA to the mobile phase. The addition of AA was 
hypothesised to interact with free silanols in the stationary phase and thus decrease 
retention and improving peak shape of the basic sulphonamide compounds. The non-
effect of AA concentration on naproxen is thought to be due to its acidic nature, 
which in an acidic mobile phase like methanol/CO2 is uncharged. The retention 
mechanism for this compound is thought to be predominately due to π-π interactions 
with the ethylpyridine stationary phase. Zheng et al. [86] report similar findings to 
Gassiot[82] for the separation of sodium sulphonates on silica and cyanopropyl 
columns. Retention decreased with increasing concentration of AA on a cyanopropyl 
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column, this was hypothesised to be due to the interaction with available silanol 
groups at lower concentrations of AA while as AA concentration increases, after all 
available silanol groups have been masked by ammonium salts, the dominant 
interaction becomes ion pairing between the ammonium and sulphonate groups, 
which at increasing concentration, also increase, thus reducing retention. The same 
group[87] also report similar behaviour with various other ammonium salts such as 
tetrabutylammonium acetate and ammonium chloride. Examples of salt additives in 
the literature appear to be confined to the use of ammonium salts and do not extend 
to other salts which are commonly used in HPLC such as phosphate and formate 
buffers. This is most likely due to issues with solubility in the CO2 and organic 
modifier mobile phases.  
In the early years of SFC development, water was used as a modifier – water was 
added to CO2 by means of saturation however this proved to be unreliable as the 
amount of water which was dissolved in the CO2 varied and so was difficult to 
control[88]. Water as an additive has proved more successful in recent years with 
Liu et al.[81] reporting a dramatic improvement in peak shape when 5% water was 
added to methanol modifier when compared to a methanol only modifier when 
hydrophilic compounds were analysed as shown in Fig. 1.3.4. 
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Fig. 1.3.4: Comparison of peak shape of five hydrophilic compounds using methanol 
(CH3OH) and methanol + water (CH3OH + H2O) modifiers. All columns: 4.6 × 250 mm and 
5 μm. CO2 back pressure and temperature were 100 bar and 40 °C. Detection: UV 210 or 
254 nm. Sample: 1 mg mL−1 concentration and 15 μL injection volume. Flow rate: 2.1 mL 
min−1. 1: neohesperidin dihydrochalcone hydrate; column: CN; 30% modifier, 210 nm. 2: 
glycyrrhizin; column: Synergi; 30% modifier, 254 nm. 3: naringin; column: DEAP; 60% 
modifier, 210 nm. 4: compound 4; column: Diol; 30% modifier, 210 nm. 5: 4-nitrophenyl β-
D-cellobioside; column: BASIC; 60% modifier, 210 nm. Reproduced from Ref. [81] 
 
The improvement is peak shape was thought to be due to the increased polarity of 
the mobile phase due to the addition of a water additive. This increase in polarity in 
turn increased the solubility for hydrophilic compounds resulting in the suppression 
of peak tailing for all 5 highly hydrophilic compounds. It is clear that the use of 
additives in the mobile phase in SFC are of huge importance and can be used, similar 
to HPLC to  change retention, and perhaps more importantly to improve peak shape 
of compounds with poor peak shape with a CO2/modifier only mobile phase by 
interaction with surface silanols which reduces peak tailing.  
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1.3.4.2 Temperature and pressure of the supercritical fluid 
 
Another way to control retention and solvation in SFC is by adjusting the 
temperature and pressure of the supercritical fluid. While the effects are not as 
profound as adding a modifier or additive, it is none the less an important method of 
affecting retention.[60, 62]. The density of the mobile phase is responsible for its 
solvation capability. In an investigation into the influence of temperature on 
retention of a range of enantiomeric pairs, West et al.[76] showed that by increasing 
temperature increments from 10 to 40°C, there was an increase in retention due to 
increased density of the mobile phase which causes a decrease in elution strength. Of 
the 6 enantiomeric pairs, 5% ethanol in CO2 was capable of separating all but 1 
enantiomer pair on a Lux cellulose 1 column. Lou et al.[89] found that while the 
effect of pressure (at constant temperature) on retention in SFC is quite straight 
forward with a steady increase in solubility and decrease in retention factor recorded 
with higher pressures. However the influence of temperature (at constant pressure) is 
more complicated with a number of factors influencing the retention. The authors 
found that temperature affects the vapour pressure and density of the supercritical 
fluid, changing its retentive properties as a result of solute affinity for the stationary 
phase, for example, as shown in Table 1.3.2, with increasing temperature, anthracene 
and chrysene’s affinity for the  C18 (ODS) stationary phase was considerable 
increased, thus increasing retention.   
Table 1.3.2: Relative affinities of anthracene and chrysene for an ODS stationary phase at 
different temperatures. Reproduced from Ref. [89] 
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As well as affecting the solute affinity for the stationary phase, increasing 
temperature at constant pressure also affects the solubility of the solute. However 
this is not as straight forward as was the case for increasing pressure at constant 
temperature. The authors found at a constant pressure of 100 bar, there was first a 
decrease in solubility, then a subsequent increase in solubility by increasing 
temperature from 40 to 150 °C incrementally, however at constant pressure of 200 
bar a steady increase in the solubility was recorded across the range of temperatures. 
Toribio et al.[90] found that with the separation of range of enantiomers, temperature 
had varying effects on their retention behaviour citing increasing, decreasing and no 
effect on retention when temperature was changed. This phenomenon was also noted 
by Berger et al. [91] who also cites varying effects on retention behaviour when 
temperature is varied and describes the effect of temperature as unpredictable. It is 
clear that the effect of temperature is not well understood and needs to be 
investigated further to determine its precise effects on parameters such as retention, 
solubility and selectivity. 
 
1.3.5 Applications of SFC 
As SFC is considered to be analogous to normal phase HPLC it is perhaps 
unsurprising that SFC has found much of its applicability in the area of preparative 
chromatography and more specifically in area of chiral chromatography [76, 77, 84, 
92-97]. In a recent review Miller[98] cites many advantages of preparative SFC over 
preparative HPLC which included;  more rapid preparative separations, increased 
throughputs and decreased solvent consumption. Another reason why SFC is 
preferred over HPLC on a preparative scale was as a result of decreased solvent 
consumption, less waste was generated making it a greener technique. However, 
possibly the most important advantage of lower solvent consumption is the higher 
product concentration which can be obtained as a result of evaporation of the sCO2 
mobile phase, leaving pure product in higher concentrations in less organic 
solvent[98, 99].  Wang et al.[96] report the enantioseparation of 14 different 
thiazide, flavonone and amino acid derivatives on a novel β-cyclodextrin 
phenylcarbamate derivative column which were cationic in nature. In the case of the 
separation of flavonone racemates it was found that position of the phenolic group 
41 
 
on the flavonone was important and that when the phenolic group was in the 4’ –
position, the cationic stationary phases shows a heightened enantioselectivity. This 
study also found that the addition of a 1% acetic acid additive had a significant effect 
on the enantioselectivity of the column in the case of strong acidic analytes where 
retention time was shortened, however there was little or no effect for weak acidic or 
basic compounds. The influence of the acidic additive preferentially on the retention 
of strongly acidic analytes was hypothesised to be due to the masking of the cationic 
moiety on the chiral selector by the acidic additive which weakened the strong 
electrostatic interactions between the strongly acidic analyte and the stationary phase 
normally present thus reducing retention.  Interactions between the cationic 
stationary phase and the weakly acidic and basic analytes were already low so less of 
an effect was observed. Xiang et al.[100] reported the separation of 9 amide 
enantiomers on various polysaccharide based chiral stationary phases with a variety 
of mobile phases containing acetonitrile, methanol and isopropanol as modifiers. As 
is commonly the case, methanol proved to be the most successful mobile modifier 
with eight of the nine enantiomers efficiently separated on a Chiralpak IC column, 
while acetonitrile and isopropanol were capable of separating six and one of the 9 
enantiomers respectively on the same IC column. Fig. 1.3.5 shows the separation of 
amide 7 using all 3 modifiers using a Chirapak IC column. As can be seen, 
enantiomers are well resolved using all 3 mobile phases. It was noted by the authors 
that amide 7 was only separated by an IPA/CO2 mobile phase. IPA was thought to 
change the 3 dimensional structure of the stationary phase by adsorption leading to 
steric hindrance for chiral interaction. As amide 7 was the least sterically hindered, it 
was least affected by the 3 dimensional structural change. The increase in retention 
noted for an acetonitrile mobile phase(c) when compared to a methanol mobile phase 
(a) was most likely due to acetonitriles lesser capability for hydrogen bonding with 
the analytes, leading to higher retention. 
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Fig. 1.3.5: The effect of organic modifiers on the separation of amide 7. Conditions: 
Chirapak IC column, 40 ◦C, 4 mL/min, back pressure of 150 bar and 10% organic modifier 
of (a) methanol; (b) isopropanol; and (c) acetonitrile. Reproduced from Ref. [100] 
As mentioned previously additives are added to modifiers in order to improve or aid 
a separation whether it be increasing the polarity of the mobile phase or improving 
peak shape. In chiral SFC, an additive is often added in order to improve 
enantioselectivity or peak shape. De Klerck et al.[97] report the effect of combining 
both an acid additive and a base additive and their effect on enantioselectivity of four 
different polysaccharide stationary phases. While generally, depending on the nature 
of the compound, either an acid or base is added to a mobile phase, De Klerck 
showed that combining an acid and base can have unexpected positive effect. Both 
0.5% TFA and IPA was added to methanol modified mobile phase and 
the.combination of these two additives provided a wider enantioselectively than if 
the two additives were to be used separately. As mentioned previously relating to a 
similar study carried out by De Klerck and co-workers[84] the role of TFA was most 
likely to deactivate free silanol groups by forming hydrogen bonds, as well as 
lowering the pH of the mobile phase, partially protonating and charging basic 
functional groups, thus reducing retention times. The role of IPA was to suppress 
non stereospecific interactions between analytes and the silica matrix of the 
stationary phase, enhancing enantioselectivity and reducing retention.  
As shown, SFC is a technique which is typically analogous to normal phase LC due 
to the polarity of its primary mobile phase, which in most cases is sCO2. Advantages 
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of SFC include reduced viscosity and higher diffusivity of the mobile phase, which 
leads to ability to use faster flow rates than obtainable in HPLC under the same 
conditions. Lower operating pressures mean longer columns can be used without 
pressure maximums being reached; this in turn leads to more efficient separations. 
With the addition of organic modifiers, the selectivity range of SFC can be 
significantly increased to include more polar solutes. The most widely used modifier 
in SFC is methanol, due to its high polarity, low viscosity and low boiling point. 
Similar to HPLC, the use of additives also has a significant effect on 
chromatography, the addition of additives such as TFA has been found to reduce 
tailing due to masking silanol interactions of the stationary phase surface. Adjusting 
the temperature and pressure of supercritical fluid is also another important method 
of adjusting retention, however the effect of temperature is complex is not fully 
understood. SFC has found significant applicability in the area of chiral 
chromatography[90, 94, 101] and has proven to be a very effective method of 
separating enantiomers without the need for significant quantities of toxic solvent 
which is normally associated with chiral chromatography on normal phase HPLC. 
Because the main mobile phase in SFC is CO2, which is non-toxic, safe to use and 
easy to dispose of as sCO2 is just converted back to its gaseous state, there is limited 
waste generated, making SFC a much greener alternative to traditional LC. The 
literature search however does highlight gaps which include determination of the 
exact effect of temperature on selectivity in SFC and also the lack of applications in 
achiral chromatography. 
 
 
 
 
 
 
44 
 
1.4 Conclusions 
There has been significant developments in the area of LC over the last 30 years in 
terms both hardware and understanding the fundamental principles of HPLC. Over 
the years the main focus of research in the area has been on achieving the ultimate 
goal in HPLC – the most efficient separation achievable in the shortest amount of 
time. From a theoretical point of view, the key to increasing efficiency while also 
decreasing analysis time lay in reducing the particle size of columns, and this is the 
approach which many researcher have explored[102, 103]. This is evident in the ever 
decreasing particle sizes used in chromatography going from >10 µm columns in the 
early days to the present sub 2 µm columns on the market today. Another approach 
taken to addressing the need for efficient separations in the shortest possible time 
was the development of core-shell particles, which has been discussed here. 
Earlier generations of core-shell particles encountered many obstacles, including the 
sustained drive to develop smaller fully porous particle sizes, which lead to their 
ultimate demise as the newly developed fully porous particles provide faster and 
more efficient separation with greater applicability. However development of the 
new or so-called 3rd generation of core-shell particles, have been proven to provide 
increased efficiencies when compared to fully porous particles of an equal and 
indeed smaller particle size due to their narrow particle size distribution which 
resulted in a reduced A term and also improved mass transfer kinetics. This increase 
in efficiency meant that larger particle sizes could be used negating the requirement 
for higher back pressure.  Lower back pressure and high efficiency make core-shell 
particles a very attractive alternative to fully porous sub 2 µm particles.  
The majority of the research which has been carried out on core-shell particles 
relates to their fundamental properties and how these compare to their fully porous 
counter parts, however, there are limited examples in the literature of core-shell 
particles columns being used in a real chromatographic environment. This is 
highlighted by a survey carried out by Mayors for the magazine LC-GC, which 
found that over 50% of chromatographers still use particle sizes which are greater 
than 3 µm in size. The review of the literature has highlighted two areas where major 
gaps appear. The first is in area of the sample capacity of these stationary phases 
while the other is in the area of the applications which these stationary phase types 
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are used. Applications in the literature were mainly focussed on the topic of the 
separation of proteins and peptides, however like their fully porous counterparts, a 
wide range of stationary phase selectivities are becoming increasing available, 
widening the scope and applicability of these stationary phase types. 
HPLC as a technique is reaching maturity in terms of instrumentation and also 
reaching the point at which reducing particle size will no longer continue to have a 
positive effect on efficiency and speed. While the new generation core-shell 
stationary phases are being developed to address this issue, other complementary 
techniques such as SFC have seen also seen a renaissance. SFC has the advantage of 
having liquid like solvation properties which the viscosity and diffusive properties 
are more in line with GC. Supercritical fluids such as CO2 are cheap, non-toxic, with 
modest critical parameters making it an ideal solvent for SFC. As well as this, there 
is very little waste generated with SFC as the supercritical fluid can just be de-
pressurized into its gaseous state and either vented or recycled Supercritical CO2 is 
very non polar and has similar polarity to heptane and for this reason SFC is 
considered analogous to normal phase LC. With normal phase LC selectivity, SFC 
has an orthogonal selectivity compared to reversed phase LC. With the addition of 
organic modifiers to sCO2, as well as the addition of additives, polarity of the mobile 
phase can be changed and thus the selectivity of SFC can be altered making it 
applicable to a wider range of analyte polarities. As well as the addition of modifiers 
and additives, selectivity and solvation can also be altered using temperature and 
pressure, which affect the density of CO2, changing its solubility and selectivity 
capabilities.  
SFC is seen as analogous to a normal phase HPLC and thus for this reason, it finds 
most applicability in the area of chiral separations. However using a suite of 
approaches mentioned earlier, SFC holds great potential in the separation of achiral 
compounds as well due to tuneable selectivity. As well at that, its orthogonal 
selectivity to reversed phase LC also makes it an attractive complementary technique 
for a whole host of other applications. This is an area that has yet to be fully 
explored. 
Both of these topics are examined in this thesis. In Chapter 2, an existing isocratic 
impurity assay, method USP 36-NF-31, Voriconazole Monograph; for the separation 
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of Voriconazole and related impurities Compound X, Voriconazole related 
compound C (this compound shall be referred to as “compound C”) and 
Voriconazole related compound D (this compound shall be referred to as compound 
D), originally carried out on a 4 µm fully porous C18 stationary phase was transferred 
to a 2.6 µm core-shell particle column with further optimisation carried out. 
Optimisation carried out included, optimisation of the organic mobile phase 
component composition and concentration, nature of the aqueous component (both 
concentration and pH) and optimisation of the column temperature. Further gradient 
optimisation was carried out on this stationary phase also. This method was then 
further transferred to a 1.7 µm core-shell column with subsequent method 
optimisation in an effect to further reduce the run time and increase efficiency..  
In Chapter 3, the evaluation of 16 stationary phase/mobile phase combinations with 
potential orthogonal selectivity to the methods outlined in chapter 2 was carried out. 
4 stationary phases and 4 mobile phases were selected for the study. In all cased the 
supercritical fluid used was supercritical carbon dioxide (sCO2) Stationary phases 
included; silica, cyano, diol and 2-ethylpyridine chemistries. Methanol was selected 
as the primary modifier in this study. A number of additives to the mobile phase 
were also investigated, these were; triflouroacetic acid (TFA), ammonium formate 
(AA) and triethylamine (TEA). Each stationary phase was analysed using all four 
mobile phases. A cyano stationary phase with a 20% methanol mobile phase was 
found be to the most suitable stationary and mobile phase combination for the 
separation of the separation of Voriconazole and related impurities compound C and 
D. 
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2 Chapter 2: Development of ultrafast pharmaceutical inpurity 
assay using 3rd Generation core-shell stationary phase 
technologies. 
2.1 Introduction 
The goal in chromatography can be defined as “the best separation achievable in the 
shortest amount of time”. Some of the most widely used chromatographic techniques 
include HPLC and GC. HPLC is a very popular and widely used analytical technique 
and forms the basis of many analytical laboratories around the world. It is used in a 
variety of settings including research laboratories, academic laboratories and a wide 
variety of industrial settings including the pharmaceutical and petrochemical 
industry. [2] 
The demand for the best separation in the shortest time has been a key driver in 
chromatographic research[3]. One approach to this is the reduction of particle size of 
the columns used, as smaller particles produce fast run times and greater 
efficiency[5]. Whilst in the past, columns with particle sizes in the region of 5-10 µm 
were common, recently the trend has been towards smaller particle sizes in the 
region of sub 2 µm[8].  While these particle sizes produce a fast and more efficient 
separation, an increase in back pressure is associated with such columns. A typical 
sub 2 µm column produces far in excess of what a typical HPLC instrument with a 
400 bar pressure limit is capable of handling. For this reason, new instruments have 
been developed capable of coping with such pressures. Another downfall of smaller 
particle sizes is  the frictional heating associated with operating these column types 
which leads to a decrease in efficiency[11] 
An alternative to sub 2 µm columns which have seen a renaissance in recent years 
have been core – shell particle columns [23, 104]. Core shell particles in the region 
of 2.7 µm have been found to be capable of producing sub 2 µm particle 
performance without the associated increase in back pressure [12]. This is an 
attractive alternative to sub 2 µm particles as standard HPLC hardware can be used. 
While most research on core-shell particles has primarily focussed on their 
performance parameters[32, 103], significant research has not been carried out to 
explore the potentials of these core-shell particles in real chromatographic 
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applications. Some work has been carried out on the separation of proteins and 
peptides [46, 105], however there is significant scope to extend the applicability of 
these particles to a wider ranges of applications such as impurity analysis for 
pharmaceutical drug products. 
Voriconazole (Vfend) is an tri-azole anti-fungal drug used for the treatment of 
serious fungal infections such aspergillosis and esophageal candidiasis and works by 
slowing the growth of infection causing fungi[106, 107]. Voriconazole is available in 
one of three forms; a lyophilised powder used to prepare solution for intravenous 
injection, film-coated tablets or oral administrations or powder for preparation of 
oral suspensions.. The current method used for assay and impurity analysis of 
voriconazole is a reversed phase HPLC assay using a reversed phase C18 column 
(150 x 0.39 mm, 4 µm) which has a run time of 11 minutes. (USP 36-NF-31, 
Voriconazole monograph) Voriconazole has 3 known impurities compound C, 
compound D and compound X (see Fig. 2.1.1). 
 
 
                                                       
Fig. 2.1.1: Stucture of Active Pharmaceutical Ingredient (API) Voriconazole and related 
impurities compound C, compound D (Structures provided by Pfizer Process Development 
Centre (PDC), Ringaskiddy, Cork) 
Voriconazole 
pKa = ~11.5 (OH), 
2.7 (N) 0.75 (N) 
Voriconazole related 
compound C 
pKa = ~2.1 (N) 
 
 
Voriconazole related 
compound D 
pKa = ~11.75 (OH), 
2.75 (N), 1.7 (N) 
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The aim of this work was to develop an ultrafast impurity assay to separate, active 
pharmaceutical ingredient (API) Voriconazole, from its related impurities compound 
X, compound D and compound C utilising novel core-shell 2.6 and 1.7 µm columns. 
Optimisation of isocratic method parameters such as mobile phase composition and 
analysis temperature were carried out initially, ultimately leading to the development 
of a gradient separation which had a 57% reduction in retention time whilst still 
maintaining a critical resolution between peak pairs of  > 1.7. 
 
2.2 Materials and Methods 
2.2.1 Materials 
2.2.1.1 Chemicals 
 
API standard – Voriconazole, impurity standards - compound C, compound D and 
compound X were obtained from Pfizer Process Development Centre (PDC) (Cork, 
Ireland). Ammonium formate ≥99.995 trace metals basis and formic acid ≥ 96% 
were obtained from Sigma Aldrich (Dublin, Ireland), HPLC grade Methanol 
(MeOH) HPLC grade and Acetonitrile (ACN) were purchased from Fisher Scientific 
(Cheshire, UK). Ultra-pure water was obtained from a Millipore Milli-Q water 
purification system (Bedford, MA, USA) purified to resistance of ≥ 18.2 MΩ.cm 
 
2.2.1.1.1 Mobile Phases 
 
For the Pfizer HPLC method, the mobile phase consisted of 55% v/v 30 mM 
ammonium formate adjusted to pH 4 with formic acid (≥96% purity), HPLC grade 
MeOH (30% v/v) and HPLC grade ACN (15% v/v). For method development, the 
mobile phase consisted of ammonium formate adjusted to the required pH with 
formic acid (≥96%), and HPLC grade ACN. All mobile phases were vacuum filtered 
using Supelco 0.2 µm nylon 66 membrane filters. (Sigma Aldrich, Dublin, Ireland) 
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2.2.1.2 Apparatus 
2.2.1.2.1 HPLC instrumentation 
 
Chromatographic separations were carried out on an Agilent 1200 series Liquid 
Chromatograph consisting of a quaternary pump (G1311A), thermostatted 
autosampler (G1329A), column oven (G1316A) and variable wavelength detector 
(G1314A). Columns used consisted of aWaters Nova-pak C18 reversed phase column 
(150 x 3.9 mm, particle size 4 µm) (Waters, Ireland) and Phenomenex Kinetex 
reversed phase C18 column (100 x 2.1 mm, particle size 2.6 µm), (Phenomenex, 
Cheshire, England) 
2.2.1.2.2 UPLC instrumentation 
 
UPLC chromatographic separations were carried out on a 1.7 µm core-shell 
Phenomenex Kinetex reverse phase C18 column (100 x 2.1 mm, particle size 1.7 
µm), (Phenomenex, Cheshire, England) with a Shimadzu Nexera UPLC (Mason 
Technology, Dublin Ireland) consisting of 2 x Nexera LC-40AD pumps, Nexera 
SIL-30AC autosampler, Nexera CTO-30A high temperature column oven, and 
Prominence SPD-20AV UV-Vis detector. 
 
2.2.2  Methods  
2.2.2.1 Preparation of standards 
 
Standards required for running USP 36-NF-31 - Voriconazole monograph  were 
prepared every 7 days in diluent consisting of 55% 30 mM ammonium formate 
buffer (FB) (pH 4), 30% MeOH and 15% ACN.  A stock solution of the 
Voriconazole including its three known impurities, compound C, compound D and 
compound X was prepared to a concentration of 250 µg/mL. 12.5 mg of each 
standard was weighed out and dissolved in 50 mL diluent. This was diluted 10 fold 
in 50 mL diluent and further diluted 10 fold in 50 mL diluent to a concentration of 
2.5 µg/mL. Injection volume for analysis was 20 µL. This sample was known as S3. 
For HPLC method development using the Phenonenex Kinetex C18 2.6 µm reversed 
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phase core-shell column, a stock solution of 250 µg/mL was used with a 0.2 µL 
injection volume. After initial method development, new diluent was used which 
consisted of 25% ACN in 30 mM FB (pH 4). Subsequently all standards were 
prepared in this diluent. The optimisation parameters selected for method 
development is the shortest run time possible, while maintaining a critical resolution 
of above 1.7 between peak pairs. 
 
2.2.2.2 HPLC Method development 
 
All method development carried out on the Phenomenex Kinetex core-shell 2.6 µm 
column was based on an existing USP 36-NF-31 - Voriconazole monograph used for 
the determination of impurities in Voriconazole. This isocratic method used a C18 -
reversed phase column (Waters Nova-pak, C18, 150 x 3.9 mm, 4 µm particle size). 
Mobile phase consisted of 55% 30 mM FB, 30% HPLC grade MeOH and 15% 
HPLC grade ACN. As previously mentioned a 20 µL, 2.5 µg/mL sample (S3) was 
injected onto the column. The flow rate used was 1 mL/min, detector wavelength 
was 256 nm and a temperature was set to 35°C.  When optimising the method for the 
core-shell column, the isocratic conditions were first optimised. Parameters 
optimised included; optimisation of the nature of the organic component of the 
mobile phase, the percentage organic strength of the mobile phase, the nature of the 
aqueous portion of the mobile phase and finally the temperature of the separation. 
The injection volume chosen for method development was 0.2 µL as recommended 
by Phenomenex. To compensate for the use of a smaller volume of sample being 
injected on the column, the concentration of the standard injected was increased by 
the same factor – thus a 250 µg/mL standard (S3a) was injected on to the column. 
Temperature throughout the study remained at 35°C (unless otherwise stated), 
detector wavelength of 256 nm and flow rate of 0.3 mL/min also remained constant. 
A flow rate of 0.3 mL/min was chosen to compensate for the smaller particle sizes of 
the column, smaller internal diameter and also to maintain a modest back pressure of 
approximately 230 bar during method development.  
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2.2.2.3 Calculation of performance parameters. 
 
For all chromatograms obtained, retention factors, resolutions and peak symmetry 
values were calculated according to the following formulae using Agilent 
Chemstation and Waters Empower software: 
 
Retention factor:   ݇ ൌ ௧ೝష ೟೚௧బ  
 
Peak symmetry:  
௔భశೌమ
௔య ൅ ೌర
 
 
Resolution:  Rs = 
ሺଶ.ଷହ ଶ⁄ ሻሺ்ೃሺಳሻష೅ೃሺಲሻ 
ௐఱబሺ್ሻାௐఱబሺೌሻ  
 
2.3 Results and Discussion 
2.3.1  Original reversed- phase HPLC method. 
A separation of Voriconazole and its 3 related impurities; compound C, compound D 
and compound X (S3) was carried out on a Waters NovaPak C18 reversed phase 
column (150 x 3.9 mm, particle size 4 µm) using the following conditions; flow rate 
1 mL/min, temperature 35°C, mobile phase 55:30:15 FB:MeOH:ACN, injection 
volume 20 µL, detector wavelength 256 nm. The resulting separation is given below 
in Table 2.3.1 with the chromatogram shown in Fig. 2.3.1. 
Table 2.3.1: Analysis of separation of Voriconazole (peak 4) from its related impurities; 
compound C, compound D and compound X (S3).  
 
Peak
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 1.069
Compound X 2.143 1.005 0.8 0.0788 28060
Compound C 2.491 1.330 0.85 0.07744 41327 2.68
Compound D 5.46 4.108 0.87 0.1657 40080 14.53
Voriconazole 9.221 7.626 0.99 0.2422 53133 10.81
53 
 
 
Fig. 2.3.1: Chromatogram illustrating separation of Voriconazole from its related 
impurities; compound C, compound D and compound X using the original Pfizer Assay and 
Impurity method for Voriconazole. The conditions were as follows; flow rate 1 mL/min, 
temperature 35°C, mobile phase 55:30:15 FB:MeOH:ACN, injection volume 20 µL, 
detector wavelength 256 nm. 
As shown in Table 2.3.1 elution order of the above separation (Fig. 2.3.1) was as 
follows; compound X, compound C,  compound D  and Voriconazole. The run time 
of the impurity assay was 10 min with the last peak (Voriconazole) eluting at 9.221 
min. Resolution between the critical peak pair (Impurities; compound X, compound 
C) was 2.68. Efficiency of the API peak was 53133 plates/metre. 
 
2.3.2 Transfer of existing impurity analysis method to core-shell Kinetex 2.6 
µm reversed phase C18 column.  
 
The aim of this study was to reduce the run time of the existing Pfizer impurity assay 
in Section 2.3.1 which had a 10 minute. duration. Along with reducing the run time 
of the assay, it was necessary to maintain adequate resolution between the critical 
peak pairs of at least 1.7. 
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2.3.2.1 Isocratic method optimisation 
 
Initially, the separation of S3a was carried out on a 2.6 µm column using the method 
parameters for the existing USP 36-NF-31 - Voriconazole monograph (Section 
2.3.1) with the following adjustments; injection volume chosen was 0.2 µL as 
recommended by Phenomenex; the flow rate chosen was 0.3 mL/min in order to 
compensate for the increased pressure observed due to the decrease in particle size 
and internal diameter of the column compared to the column used for the Pfizer 
method. To compensate for the 100 fold decrease in injection volume, the 
concentration of the samples injected onto the column was increased by the same 
factor; therefore, 250 µg/mL mixed standard samples (S3a) were injected onto the 
column.  
 
2.3.2.1.1 Optimising the composition of the organic mobile phase component. 
 
The mobile phase used in the initial method for impurity determination was 55% 
(v/v) 30 mM FB, 30% (v/v) MeOH and 15% (v/v) ACN. This was used as a starting 
point for the optimisation of the nature of the organic mobile phase. While keeping 
the aqueous component of the mobile phase constant at 55%, the MeOH 
concentration was varied, which in turn varied the ACN concentration. Table 2.3.2 
below shows the varying concentrations of both MeOH and ACN which were 
analysed using sample S3a to obtain chromatograms for comparison. 
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Table 2.3.2: Composition of eluents examined in Isocratic mobile phase 
Eluent No. FB MeOH ACN 
1 55% 45% 0% 
2 55% 40% 5% 
3 55% 35% 10% 
4 55% 30% 15% 
5 55% 25% 20% 
6 55% 20% 25% 
7 55% 15% 30% 
 
The results of this study are shown in Fig. 2.3.3 and 2.3.4. (Raw data can also be 
found in Appredix 6.1, Fig. 6.1.1) 
 
Fig. 2.3.3: Retention factor vs. percentage of ACN present in the mobile phase for          
Voriconozole (   ), compound X (    ), compound C (    ) and compound D (    ).  Percentage 
of FB remains constant at 55% throughout the experiment. Mobile Phase B contained 
various ratios of methanol and acetonitrile as outline in Table 2.3.2.  The red box indicates 
the data which meet ideal Retention factor criteria of between 1 and 10. 
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Fig. 2.3.4: Resolution between peak pairs vs. percentage of MeOH/ACN. Peak pairs are as 
follows (1,2   ): compound X:compound C,   (2,3   ): compound C:compound D,                 
(3,4   ): (compound D:Voriconazole) Minimum resolution at Rs of 1.7 is indicated by the 
solid black line. 
ACN has a stronger eluting strength than MeOH, so as MeOH was replaced with a 
greater concentration of ACN and the mobile phase became stronger, retention of 
analytes was expected to decrease.  Retention factors of each of the four compounds 
show, as expected, that with an increasing % of ACN in the mobile phase, there was 
decreased retention. As can be seen from Fig. 2.3.4 above and Table 6.1.1 
(appendices) impurities compound X and compound C co-eluted with greater than 
15% ACN (eluent 4) present in the organic phase. Ideally, retention factors of 1 ≤ k 
≤ 10 are the most desirable, as retention factors of  <1 indicate inadequate interaction 
of the analyte with the stationary phase, while in the other extreme, retention factors 
of >10 mean lengthy analysis which do not provide greater resolution as band 
broadening cause peaks to become shorter and wider. The red box in Fig. 2.3.3 
indicated the concentration at which optimal retention factors were achieved i.e. 
above 15% ACN (eluent 4), however as was previously mentioned, co-elution 
between compound X and compound C occurred at concentrations above 15% ACN. 
Therefore mobile phases containing more than 15% ACN in a binary mixture with 
MeOH (45% total organic) were unsuitable from a retention perspective. 
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As retention decreased, resolution ultimately decreased for peak pair (2,3) and (3,4) 
when the percentage of ACN is increased in the mobile phase B.  With more than 
15% ACN (eluent 4) present in the mobile phase, compound X and compound C co-
eluted, as mentioned previously, this in turn meant resolution between this peak pair 
fell to 0. A resolution of 1.7 for the critical peak pair, in this case - compound 
X:compound C, was defined as an optimisation parameter at the start of the 
experiment. The black horizontal line in Fig. 2.3.4 defines the critical resolution limit 
and as can be seen from Fig. 2.3.4, only at 45% MeOH, 0% ACN (Eluent 1) was this 
optimisation parameter threshold achieved. 
It was therefore evident that a mixed organic composition was not suitable as an 
organic modifier, as adequate resolution between the peak pair (1,2) was not 
maintained at any point when ACN and MeOH were combined.  For this reason, it 
was decided to use a single organic modifier for future studies on the effect of the 
organic component strength on retention of S3a. The organic solvents chosen for all 
further analyses were 100% ACN and 100% MeOH. 
 
2.3.2.1.2 Optimising the organic component strength of the mobile phase 
 
As mentioned in the previous section (Section 2.3.2.1.1) the use of a mixed organic 
mobile B component proved unsuitable. As a 45% MeOH (Eluent 1) mobile phase 
provided good resolution between critical peak pairs (1.81), MeOH was chosen as a 
potential organic component. From Fig. 2.3.3 however, it was noted that retention 
factors of analytes at this concentration were outside the ideal retention factor 
window of 1 ≤ k ≤ 10. It was therefore decided to also explore ACN in this study as 
ACN is a stronger solvent based on the eluotropic series and therefore it was 
hypothesised that it would be possible to achieve a similar separation using a lower 
concentration of ACN, thus allowing greater scope for further gradient development 
if required. Also, MeOH and ACN were expected to have different effects on 
retention, as MeOH is a protic solvent and participates in hydrogen bonding while 
ACN has more dispersive effects with analytes. Table 2.3.3 below outlines the 
different eluents (8-18) which were analysed in this experiment. 
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Table 2.3.3: Percentage (%v/v) of ACN/MeOH present in the mobile phase during 
optimisation of the organic content. 
Eluent No. FB MeOH Eluent No. FB ACN 
   13 75% 25% 
8 70% 30% 14 70% 30% 
9 60% 40% 15 60% 40% 
10 50% 50% 16 50% 50% 
11 40% 60% 17 40% 60% 
12 30% 70% 18 30% 70% 
 
For comparison purposes a similar concentration range for both MeOH and ACN 
was chosen as illustrated in Table 2.3.3. The separations achieved using each of the 
mobile eluents 8 – 18 were evaluated both in terms of retention factor (Fig. 2.3.5) 
and resolution between peak pairs as shown in Fig. 2.3.6 and 2.3.7. Raw data for this 
experiment is given in Tables 5.1.2 (MeOH as MPB) and 5.1.3 (ACN as MPB) in 
appendices. 
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(a)  
(b)  
Fig. 2.3.5: Retention factor of Voriconozole (   ), compound X (    ), compound C (    ) and 
compound D (    )vs. increasing (a) MeOH* and (b) ACN concentration. All other conditions 
remain as per Section 2.3.1 Red box indicated the ideal retention factor window of between 
1 and 10,. 
* Retention factors for copound D and Voriconazole at 30% and 40% MeOH are off scale, at values 
of 52.250, 98.746 and 14.505, 26.593 respectively. 
From analysis of Table 6.1.2/6.1.3 (appendices) and Fig. 2.3.5, it was noted that the 
elution order of the first two peaks compound X and compound C switched 
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depending on whether MeOH or ACN was used as mobile phase B. This change in 
elution order can be explained by preferential hydrogen bonding interactions 
between MeOH and the carbonyl functionality of compound C when MeOH was 
used as a mobile phase B which did not occur when ACN was used. The increased 
elution strength of ACN compared to MeOH was clearly demonstrated as the total 
run time with 30% MeOH (eluent 8) was 67 min while with 30% ACN (eluent 14), 
total run time was just 6 min. This is clearly indicated in Fig. 2.3.5a where the 
retention factors of both compound D and Voriconazole are both off scale (retention 
factor cut-off of k=15) at 30% and 40% MeOH while at these concentrations of 
ACN, retention factors are less than 10. The binary nature of ACN/water mixtures 
and clustering of the ACN molecules around solute molecules with increasing ACN 
concentration lead to the significant decreases in retention for all four molecules. 
The red box in Fig. 2.3.5a and 2.3.5b indicates the ideal retention factor window (1 ≤ 
k ≤ 10) and as can be seen from Fig. 2.3.5b, only 30% ACN (eluent 14)  and 50% 
MeOH ( eluent 10) fell within this window as at higher ACN concentrations, 
retention factors for compound X and compound C fell below 1, indicating 
insufficient interaction with the stationary phase. This is also the case for higher than 
50% MeOH. At lower concentrations of MeOH, retention factors for later eluting 
peaks compound D and Voriconazole were above the k = 15 upper threshold. At 
greater than 50% ACN or MeOH, solvation properties of the organic solvent 
becomes more important as the mobile phase is now predominantly organic in nature 
and so analytes have a greater affinity for the now, less polar mobile phase. Each 
eluent (8-18) was also analysed with respect to resolution between peak pairs, this 
data is shown below in Fig. 2.3.6 and 2.3.7. 
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Fig. 2.3.6. Resolution between peak pairs vs. ratio of MeOH concentration. Peak pairs are 
as follows (1,2)(     ): compound C:compound X (2,3)(    ): compound X:compound D, (3,4 )  
(    ): compound D:Voriconazole. All other parameters remain as per Section 2.3.1. 
Minimum resolution at Rs of 1.7 is indicated by the solid black line. 
 
Fig. 2.3.7: Resolution between peak pairs vs. % ACN. Peak pairs are as follows (1,2)(    ): 
compound X:compound C, (2,3)(   ): compound C:compound D, (3,4)(   ): compound 
D:Voriconazole. All other parameters remains as per Section 2.3.1. Minimum resolution at 
Rs of 1.7 is indicated by the solid black line. 
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Resolution is affected by three main parameters: retention, efficiency and selectivity. 
As a result with decreasing retention and decreased selectivity between peaks, 
resolution between peak pairs was expected to decrease. This was evident in both 
experiments where; as the concentration of MeOH or ACN increased, there was 
decreased retention of analytes and resolution between peak pairs decreased. As 
analytes began to co-elute at 50% ACN (eluent 10), resolution between peak pair 
compound X:compound C was lost completely and had a value of 0.  Resolution 
between compound D and Voriconazole decreased from 20.36 with 30% (eluent 14) 
ACN to just 0.63 when 70% ACN was used (eluent 18). A similar trend was evident 
for MeOH where resolution between the same peak pair decreased from 13.88 at 
50% MeOH (eluent 10) to 2.84 at 70% MeOH (eluent 12). At lower concentrations 
of MeOH, resolution between peak pair compound D:Voriconazole, resolution 
remained ~17.5 when both 30% and 40% MeOH were used (eluent 8 and 9). This 
was due to the large retention factors for Voriconazole of 98.74 and 26.593 at 30% 
and 40% MeOH respectively. At retention factors of greater than 20, resolution did 
not increase[6].  
From the analysis of the separations using the various eluents (8-18) in terms of 
retention factor and the obtaining the shortest run time possible only, two possible 
eluents were highlighted as fit for purpose - eluent 10 (50% MeOH) and  eluent 14 
(30% ACN), therefore these mobile phase compositions were then investigated in 
terms of resolution. Critical resolution was  defined at the start of the experiment 
(between peak pair (1,2), which in the case of MeOH was compound C:compound X 
and compound X:compound C in the case of ACN) was found to pass in both cases 
with a value of 2.42 recorded in the case of eluent 10 and 2.22 recorded in the case 
of eluent 14. A summary of both separations are given below in Table 2.3.4. 
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Table 2.3.4: Best separation achieved using a 50% MeOH (eluent 10) and 30% ACN (eluent 
14) and 30 mM FB, pH4 as mobile phase during organic component mobile phase 
composition study.  
 
With a mobile phase containing 70% 30 mM FB, pH 4 and 30% ACN, the run time 
of the assay was 6.315 min with a resolution between critical peak pair compound 
X:compound C of 2.22. A run time of 6.14 min and a resolution between critical 
peak pair compound C: compound X of 2.42 was achieved using 50% MeOH. 
Whilst both ACN and MeOH at the above concentrations gave similar results with 
respect to run times and resolution achieved, a mobile phase containing ACN was 
deemed to be the most suitable as the retention factor of compound C with a MeOH 
mobile phase was less than 1. A retention factor of 1 ≤  k’ ≤ 10 is preferred[37], as 
retention factors of less than 1 suggests that the analyte has not properly interacted 
with the stationary phase. ACN also has a lower viscosity and thus a lower 
associated back pressure than MeOH, allowing for higher flow rates to be used and 
is also advantageous in gradient method development as changing the concentration 
of ACN would not produce such a dramatic change in back pressures. This was also 
a contributing factor in the choice of organic solvent used. Therefore for further 
method development, the organic solvent and concentration chosen was 30% ACN 
(eluent 14). When compared to the USP 36-NF-31Voriconazole monograph as 
shown in Fig. 2.3.1 in Section 2.3.1, there was a decrease in run time of 
approximately one third, while the resolution between critical peak pair compound 
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half 
height (mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.728
Compound C 1.302 0.788 0.670 0.043 62260
Compound X 1.459 1.004 0.670 0.045 83390 2.420
Compound D 3.803 4.224 0.950 0.083 124970 23.400
Voriconazole 6.140 7.434 1.030 0.122 150780 13.880
Peak
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half 
height (mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.683
Compound X 1.560 1.284 0.770 0.043 99480
Compound C 1.700 1.489 0.720 0.046 113220 2.220
Compound D 3.552 4.201 0.870 0.074 141140 20.150
Voriconazole 6.315 8.246 0.960 0.121 156270 17.150
Eluent 10: 50% Formate Buffer : 50% Methanol
Eluent 14: 70% Formate Buffer : 30% Acetonitrile
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X:compound C (critical peak pair is the same in both cases)  decreased from 2.68 to 
2.22; however the critical resolution was still maintained above 1.7 so this was 
deemed acceptable  Fig. 2.3.8 below is a representative chromatograph of the 
separation of S3a and its related impurities. In order to optimise the separation 
further, the pH and concentration of the aqueous buffer was then investigated, this 
will be discussed in Section 2.3.2.1.3. 
 
Fig. 2.3.8: Chromatogram of the best separation achieved using 70:30 FB:ACN mobile 
phase. Conditions were as follows; FB (FB): 30 mM, pH 4, flow rate: 0.3 mL/min, injection 
volume: 0.2 µL, column temp: 35°C, detector wavelength: 256 nm. 
 
 
2.3.2.1.3 Optimisation of the nature of the aqueous component of the mobile 
phase 
 
Changing the concentration of a buffer affects its buffer capacity – it’s ability to 
maintain a constant pH throughout a separation[108]. The selection of an appropriate 
buffer concentration and thus its ability to adequately resist small changes to the pH 
is often of critical importance in HPLC in order to avoid problems such as partial 
ionisation of an analyte. At 2 pH units less than their pKa, acidic analytes are mainly 
in their neutral form while basic analytes are protonated, similarly at 2 units above 
their pKa, the opposite is true, where acids are in their ionic from and bases are 
neutral. At a pH which is close to their pKa, analytes exist as an equilibrium of both 
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neutral and ionised forms affecting peak shape and retention due to unwanted strong 
interactions with surface silanols on the stationary phase.  Therefore it is important to 
select an optimum pH for the analytes to ensure that they are either fully ionised or 
fully neutral. 
In Fig. 2.1.1 the structures and pKa of Voriconazole and related impurities 
compound C, compound D are shown. Voriconazole and its related impurities are 
acidic with the highest predicted pKa being 2.75. In order for all analytes to be fully 
ionised the pH of the mobile phase should be 2 pH units above its pKA. Therefore 
based on this theory, the optimum pH should be at least 4.75. Therefore, FB was 
chosen as the buffer for this study as it has a pKa of 3.8 and therefore at pH 4.75 it 
lies within the appropriate pH range for maximum buffer capacity of ± 1 pH unit.  
Using the optimal ACN concentration of 30% (eluent 14) obtained in Section 
2.3.2.1.2, the nature of aqueous component of the mobile phase was then analysed. 
FB was optimised by first changing the concentration and then its pH, as in Table 
2.3.5, whilst maintaining the constant FB:ACN ratio of 70:30. All other parameters 
remained the same as detailed in Section 2.3.1. Table 2.3.5 details the various mobile 
phase A compositions (eluent 19-27) which were analysed for the separation of S3.  
Table 2.3.5: Conditions for experiments carried out when the pH and concentration of FB 
were systematically changed. Mobile Phase B in all cases was 30% ACN. 
 Ammonium FB 
Eluent (E) pH Concentration (mM) 
19 4.0 10 mM 
20 4.0 20 mM 
21 4.0 30 mM 
22 4.0 40 mM 
23 4.0 50 mM 
24 3.0 30 mM 
25 3.5 30 mM 
26 4.5 30 mM 
27 5.0 30 mM 
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2.3.2.1.3.1 Changing the concentration of ammonium FB 
 
Ammonium FB was prepared with concentrations ranging from 10 mM to 50 mM in 
10 mM increments (E19-23). This was then adjusted to pH 4 in all cases with formic 
acid. pH 4 was chosen as a starting point as this was the pH used in the original 
method outlined in USP 36-NF-31 –Voriconazole monograph. All other method 
parameters remained the same as detailed in Section 2.3.1. S3a standard was 
analysed for each mobile phase composition. Results of this experiment are shown 
below in Table 6.1.4 (appendix) and Fig. 2.3.9 and 2.3.10. Chromatography obtained 
was analysed in terms of peak symmetry.  
 
Fig. 2.3.9: Peak symmetry of Voriconazole (   )and related impurities compound X(   ) 
compound C(   ) and compound D(   ) vs. concentration of FB. Mobile phase: 70:30 
FB:ACN. pH: 4.00, column cemperature: 35°C, injection vol: 0.2 µL, detector wavelength: 
256 nm. *raw data for this study is given in Fig. 6.1.4 (appendices). 
Fig. 2.3.9 shows the peak symmetries for all four analytes across the concentration 
range selected (eluent 19-23). Peak symmetries remained quite constant across the 
range of FB concentrations investigated. For all analytes a deviation of ± 0.04 units 
was observed, which indicated that at all buffer concentrations, pH was adequately 
maintained. A deterioration in  peak shape would have indicated insufficient buffer 
capacity causing partial ionisation of analytes and associated variations in stationary 
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phase/analyte interactions; however no deterioration was observed. It was concluded 
therefore that the concentration of ammonium formate should remain at 30 mM 
based on the data obtained for peak symmetry, as no significant advantages were 
noted when the concentration was changed. A concentration of 30 mM FB was used 
for the remainder of the study. 
 
2.3.2.1.3.2 Optimisation of ammonium FB pH 
 
In this investigation, the buffer concentration was maintained at 30 mM while the pH 
of the mobile phase was changed in 0.5 pH unit increments from 3.0 to 5.0. All other 
parameters remained as outlined in Section 2.3.1. Again chromatography was 
analysed terms of peak symmetry. Results of the study are given below in Fig. 
2.3.10. 
 
Fig. 2.3.10: Peak symmetry of Voriconazole (   ) and related impurities compound X(    ), 
compound C(    ) and compound D(    ) vs. pH of FB. FB concentration: 30 mM. All other 
parameters remained as per Fig. 2.3.9. *Raw data is shown in Fig. 6.1.5 (appendices) 
At 2 pH units above or below its pKa an analyte is either fully ionised or non-
dissociated depending on whether the analyte is an acid or a base. The analyte in this 
study with the highest predicted pKa was compound D with a pKa of 2.75, therefore, 
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to ensure that the compound and all other analytes were fully ionised, a pH of 4.75 
should have been selected. However during the investigation the maximum pKa was 
believed to be 2.00 and therefore an optimum pH of 4.00 was chosen. This error was 
only realised after the investigation was completed. Analysis of Fig. 2.3.10 indicated 
however that the peak symmetry between pH 4 and pH 5 deviated by <5%. This was 
not unexpected given that at 1 pH unit above its pKa, 90% of the analyte was in its 
fully ionised form. A concentration of 30 mM and a pH of 4.00 were used for the 
remainder of the investigations. The final isocratic parameter which was optimised 
was temperature. 
2.3.2.1.4 Optimisation of the temperature of the run 
 
An increase in temperature was expected to in result in a decrease in retention[37]. 
Another advantage of higher temperature is a reduction in mobile phase viscosity 
and thus back pressure so higher flow rates can be used. In this research temperature 
was varied from 35°C to 55°C in 5°C increments. The mobile phase which was used 
was 70:30 FB:ACN All other parameters remained the same as outlined in Section 
2.3.1. 
Results of this study are given in Fig. 2.3.11 and 2.3.12. Similar to the organic 
component study, the chromatography was analysed in terms of retention factor (k) 
and resolution between peak pairs. 
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Fig. 2.3.11: Retention factor Voriconazole(   ) and related impurities compound X(   ) 
compound C(    ) and compound D(    )  vs. column temperature. Other chromatographic 
parameters included: Mobile phase 70:30 30mM FB, pH 4.00:ACN, detector wavelength: 
256 nm, injection vol: 0.2 µL. *Raw data for this experiment is given in Fig. 6.1.6. 
 
Fig. 2.3.12: Resolution between peak pairs vs. column temperature Peak pairs are as 
follows (1,2)(    ): compound X:compound C, (2,3)(    ): compound C:compound D, (3,4)       
(    ): (compound D:Voriconazole). Chromatographic parameters as per Fig. 2.3.11. 
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As expected increasing temperature affected the retention of Voriconazole and its 
related impurities, with retention of all four components decreasing as column 
temperature increased as seen from the plots of retention factor vs. column 
temperature (Fig. 2.3.11). Retention of compound C, compound D and Voriconazole 
were more significantly affected than the earliest eluting analyte compound X. The 
decrease in retention of compound C had the greatest impact on the overall 
separation as with increased temperature, not only did the retention factor 
continuously decrease across the temperature range 35-55°C from 1.425 to 1.244, 
the  resolution  of peak pair compound X and compound C as shown in Fig. 2.3.12 
decreased from 2.22 at 35°C, to a resolution of  0 and complete co-elution of the two 
analytes at  55°C.  At 40°C, resolution of this peak pair is just above a critical value 
of 1.7 at 1.73, however given its closeness to the lower threshold value, this was 
deemed to be unsuitable. 
While increasing temperature was demonstrated a decrease retention when a 70:30 
FB:ACN mobile phase was used as shown in Fig. 2.3.12, the loss of resolution 
between the critical peak pair (compound X:compound C) with increasing 
temperature meant that this particular mobile phase composition was deemed 
unsuitable. Table 6.1.3 (appendices) show the raw data from the optimisation of the 
organic component strength (ACN),  illustrating that whilst the total run time of the 
assay at 25% ACN (eluent 13) (12.882 min) was almost twice that at 30% ACN 
(eluent 15) 6.315 min), resolution between the critical peak pair also more than 
doubled, going from 2.22 at 30% ACN to 5.94 at 25%. This increase in resolution 
was hypothesised to afford a higher temperature to be used, shortening retention 
times, without bringing the resolution between the critical peak pair (compound 
X:compound C) close to a critical value of 1.7. Therefore the experiment was 
repeated with a 25:75 ACN:FB mobile phase (exp 4b). All other parameters 
remained the same as in Section 2.3.1.The results of this experiment are given in 
Table 6.1.7 (appendices) and  Fig. 2.3.13 and 2.3.14. 
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Fig. 2.3.13: Retention factor of Voriconazole(   ) and related impurities compound (   ), 
compound C (   ) and compound D(    ) vs. temperature of column Mobile phase is 25% 
ACN: 75% ammonium FB. All other parameters remain as per Fig. 2.3.11. 
 
Fig. 2.3.14: Resolution between peak pairs vs. column temperature. Peak pairs are as 
follows (1,2)(    ): compound X:compound C, (2,3)(    ): compound C:compound D, (3,4)(   ): 
(compound D:Voriconazole). Mobile phase is 25% ACN: 75% ammonium FB. 
Chromatographic parameters as per Fig. 2.3.11 
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Similar to the previous temperature study the same trends were observed here, with 
slightly  decreasing retention factors (Fig. 2.3.13) for each of the four components 
and decreasing resolution between peak pairs (Fig. 2.3.14). However unlike the 
temperature study using 30% ACN there was still sufficient rentention factors of 
above 1 at all temperatures when 25% MeOH is used. Resolution in all cases is 
above 2. Despite having adequate resolution between peaks 1 and 2 (compound 
X:compound C) when a column temperature of 55°C was applied (3.40 @ 50°C, 
2.59 @ 55°C) a temperature of 50°C was taken as the optimum temperature using 
this mobile phase because as well as good resolution, efficiency at this temperature, 
as seen in Table 6.1.7, was highest here. 
Fig. 2.3.15. below shows a representative chromatogram at 50°C. The run time of 
this impurity assay was now over 1 minute lower than the USP 36-NF-31 
Voriconazole monograph, resolution between the critcal peak pair compound 
X:compound C was increased from 2.68 to 2.97. Given that the run time of this 
assay was now longer than the original method and negating the goal of the 
developement of a faster assay, further method development was necessary.  
 
Fig. 2.3.16. Chromatogram of best separation obtained using 75% ammonium FB : 25% 
ACN with a column temperature of 50°C. All other parameters as described in Section 2.3.1 
and 2.3.1.2. 
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2.3.2.1.5 Increasing the flow rate of the method to obtain a faster separation 
 
Increasing the flow rate of a method decreased analysis time, however also resulted 
in an increase in the column back pressure. Since the back pressure of the system 
with the current mobile phase (70:30 FB:ACN) and temperature (55°C) was >200 
bar and the instrument and column were capable of reaching pressures of 400 bar, it 
was hypothesised that while increasing the flow rate by a factor of 2 would increase 
the back pressure by approximately 2 and theoretically half the run time, back 
pressure would still remain within the acceptable limit of 400 bar for the instrument. 
Details of the method used for this analysis are as follows. Mobile phase: 25% ACN: 
75% 30mM ammonium formate (pH 4), flow rate: 0.6 mL/min, column temp: 50°C, 
detector wavelength 256 nm, injection volume. 0.2 µL. Results of this investigation 
are tabulated below in Table 2.3.6 and a representative chromatogram is also shown 
in Fig. 2.3.17. 
Table 2.3.6: Results of investigation to increase the flow rate to 0.6 mL/min (600 µL/min) 
 
 
Peak
Retention 
time (mins)
Retention 
Factor
Symmetry
Effiency 
(plates per 
metre)
Resolution
Void 0.336
Compound X 0.929 1.765 0.79 117960
Compound C 1.084 2.226 0.9 129210 4.27
Compound D 3.295 8.807 0.95 151130 20.21
Voriconazole 6.265 17.646 1.14 141960 17.46
25% ACN, 75% Formate Buffer, 50° @ 600 µL/min
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Fig. 2.3.17. Representative chromatogram separation obtained when the flow rate is 
doubled to 0.6 mL/min. All other parameter remain the same as Fig. 2.3.15 
When compared with results from the previous method where 0.3 µL/min flow rate 
was used, (Appedices, Table 6.1.3) increasing the flow rate of the run to 0.6 µL/min 
led to a 42% decrease in retention time for the API peak from 10.916 min down to 
6.265 min. It is noted here, that should an isocratic method have be developed, a Van 
Deemter study should have been carried out in order to determine the optimum flow 
rate for maximum efficiency, however as the method development was to ultimately 
change to a gradient approach, this was deemed unnecessary. 
From the optimisation of the nature of the mobile phase and temperature, it was clear 
that the concentration of organic solvent and the temperature of the column have a 
greater impact on the chromatography obtained than the nature of the aqueous 
mobile phase A. While there was a reduction in the run time of the assay of 
approximately 41% (6.265 min) when compared to the USP method (9.221 min), it 
was felt that by applying a gradient, run times could be further reduced.  
 
2.3.2.2 Development of a gradient separation 
 
Gradient elution allows the efficient separation of compounds with widely varying 
polarities and retentions in a reasonable period of time. Development of a gradient 
separation is often favoured over an isocratic separation due to the fact that at a 
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single mobile phase B concentration, resolution of early eluting peaks may be low, 
while strongly retained compounds have excessively long retention times which 
leads to very broad peaks with small peak heights making them harder to detect 
[109]. The use of a gradient over an appropriate mobile phase B concentration range 
in this study was hypothesised to allow the maintenance of adequate resolution 
between earlier eluting peaks, while the previously more strongly retained 
compounds  are eluted faster with higher B concentrations leading to sharper taller 
more efficient peaks. Both the gradient length and % ACN at the top end of the 
gradient were optimised in this experiment. Parameters which were optimised during 
isocratic optimisation were carried through to gradient development. The optimised 
parameters for isocratic optimisation were as follows; column temperature 50°C, 
buffer concentration; 30 mM with a pH of 4, flow rate 0.6 mL/min, detector 
wavelength: 256 nm. 
 
2.3.2.2.1 Determination of the delay volume of Agilent 1200 series liquid 
Chromatograph. 
 
The ultimate goal in this HPLC method development was the transfer of the method 
developed on a 2.6 µm core-shell particle column to a smaller particle size 1.7 µm 
column. The use of this smaller particle size column required the use of a dedicated 
instrument capable of handling the high pressure generated by the column. The first 
step was to calculate the dwell volume of the instrument which was used for the 2.6 
µm method development, as dwell volumes vary from instrument to instrument and 
gradient times must be altered accordingly when methods are transferred between 
instruments. The delay volume of the Agilent 1200 series liquid chromatograph was 
determined by injecting a water blank with a mobile phase gradient which involved 
an isocratic hold for 3 min and a subsequent step from 0% mobile phase B (MP B) to 
100% MP B at 3.01 min. MP B was chosen so that at the desired wavelength, the 
MP would give a detector response. MP B used in this experiment was 1% v/v 
acetone as acetone has an absorbance at 220 nm. The time taken for a change in 
baseline absorbance after the step gradient was affected was an indicator of the delay 
volume of the system. The gradient table used for this experiment is given in Table 
2.3.7. 
76 
 
 
Table 2.3.7: Gradient profile for determination of Agilent 1200 series delay volume. 
Gradient for the determination 
of system dwell volume 
Time (mins) 
% Mobile 
Phase B (1% 
v/v Acetone) 
0.00 0
3.00 0
3.01 100
7.00 100
7.01 0
10.00 0
 
The time at which 5% of the total absorbance for acetone was observed was 
recorded. The chromatogram obtained is shown in Fig. 2.3.18. This value was then 
used to calculate the dwell volume of the system. 
 
Fig. 2.3.18: Determination of void volume of Agilent 1200 series HPLC. Conditions as 
outlined in Section 2.3.2.2.1.  
5% of the maximum absorbance recorded for a 1% acetone solution was noted at 
3.95 min. As the mobile phase composition did not change until 3.01 min, this was 
subtracted from the total time taken to give a value of 0.94 min. As the flow rate 
used was 1 mL/min, the dwell volume was calculated to be 0.94 mL. The dwell 
volume of this system was then later compared to the dwell volume of the Shimadzu 
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Nexera when transferring the newly developed method and the gradient profiles 
were adjusted accordingly. 
 
2.3.2.2.2  Gradient method development 
 
As seen in Section 2.3.2.1.5, retention factors of analytes compound D and 
Voriconazole were 8.807 and 17.646 respectively while resolution between the peak 
pairs compound C:compound D and compound D:Voriconazole were 20.21 and 
17.46 respectively.  Retention of both analytes was deemed to be excessive, as too 
was the resolution between the peak pairs. Development of a gradient method was 
therefore explored in an effort to reduce retention of these analytes and shorten run 
times.  
To maintain resolution between impurities compound X and compound C obtained 
during an isocratic run when 25% ACN was used as mobile phase B, a 25% ACN 
hold was applied for 1.2 min as compound C eluted at 1.084 min. In order to 
decrease the retention time of well retained compounds, a linear gradient with a final 
ACN concentration of 80% over 2.8 min was applied. A step from 80% to 25% ACN 
was then applied with an isocratic hold of 3.0 min in order to re-equilibrate the 
column. The gradient table and profile are presented in Table 2.3.8. Other separation 
conditions which were maintained throughout gradient development are as follows; 
injection volume; 0.2 µL, flow rate: 0.6 mL/min, column temperature: 50°C, detector 
wavelength: 256 nm. 
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Table 2.3.8 Development of an optimum separation using a gradient method on a 
Phenomenex Kinetex 2.6 µm core-shell stationary phase (2.1 x 100 mm).Gradient 
profile/conditions of Gradient 1: All other parameters remained constant. Mobile Phase A: 
30 mM FB, pH 4.00, Temperature: 50°C, Wavelength: 256 nm, Injection volume 0.2 µL 
Gradient 1 
Time (mins) % ACN 
0.00 25% 
1.20 25% 
4.00 80% 
4.01 25% 
7.00 25% 
 
The separation obtained was evaluated in terms of run time and resolution between 
peak pairs. Results of separation are given in Table 2.3.9. When compared to the 
isocratic run in Section 2.3.2.1.5, overall run time was reduced by approximately 1/3 
from 6.265 min to 4.14 min. Critical resolution between impurities compound X and 
compound C decreased to 3.78, however this was still significantly higher than the 
resolution threshold of 1.7 which was set previously. Fig. 2.3.19 shows 
representative chromatograms for this gradient, Gradient 1. 
Table 2.3.9: Result of Gradient 1; 1.2 min isocratic hold, 25-80% gradient ramp over 2.8 
min, followed by a 3 min 25% ACN isocratic hold. 
 
Peak
Retention 
time (mins)
Retention 
Factor
Resolution
Void 0.343
Compound X 0.909 1.650
Compound C 1.061 2.093 3.860
Compound D 3.244 8.458 28.440
Voriconazole 4.251 11.394 13.180
Gradient 1
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Fig. 2.3.19: Chromatograms of a separation of Voriconazole and its related impurities 
compound X, compound C and compound D using gradient profiles 1 (shown in red). 
Conditions for the separation were as follows: Mobile phase FB:ACN. Column temperature: 
50°C. Detector wavelength: 256nm. Injection vol: 0.2 µL 
Despite the decrease in overall retention time of the assay and the reduction in the 
resolution between peak pair compound D and Voriconazole from 17.46 to 13.180, 
there was no decrease in the retention of compound D which eluted at 3.244 min 
during the gradient separation – an almost identical retention time as for the isocratic 
separation shown in Fig.2.3.17. Since a linear gradient did not produce the desired 
reduction in retention time for this analyte, a step gradient was introduced in order to 
facilitate a faster transition to higher MP B concentrations and thus reduce retention. 
The following step gradient in Table 2.3.10 with a step at 1.2 min and an isocratic 
hold for 2.8 min.was chosen for analysis. As well as changing to a step gradient 
rather than a linear gradient, the final concentration of ACN was raised to 90% for 
this experiment. It was anticipated that this increase in final ACN concentration 
would further reduce the run time of the assay. 
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Table 2.3.10 Development of an optimum separation using a gradient method on a 
Phenomenex Kinetex 2.6 µm core-shell stationary phase (2.1 x 100 mm).Gradient 2 mobile 
phase conditions. All conditions remained as per Fig. 2.3.19 
Gradient 2 
Time (mins) % ACN 
0.00 25% 
1.20 25% 
1.21 90% 
4.00 90% 
4.01 25% 
7.00 25% 
 
Table 2.3.11: Results of separation of S3 using Gradient 2 profile (Table 2.3.10). 
 
Results of this experiment as given in Table 2.3.11; additionally a chromatogram of 
the separation is given in Fig. 2.3.20. The results showed that total run time was 
indeed reduced by almost 1 min. This was due to both an increase in end 
concentration of ACN and also the switch to a step gradient. It was noted that 
retention of compound D was still not significantly affected by the step gradient. 
This was most likely due to the dwell volume of the system, which had not 
previously been taken into account when developing a gradient profile. The delay 
volume of the system was 0.94 mL and as a result, with a 0.6 mL/min flow rate, the 
90% step did not reach the column until 1.5 min later than originally programmed. 
As a result, instead of 90% ACN reaching the column at 1.21 min, it instead reached 
the column at ~ 2.7 min. From the retention times of both Compound C and X,  it 
was noted that both analytes eluted quite rapidly, in ~ 0.4 min when the ACN 
concentration was raised to 90%. 
Peak
Retention 
time (mins)
Retention 
Factor
Resolution
Void 0.343
Compound X 0.906 1.641
Compound C 1.055 2.076 3.780
Compound D 3.227 8.408 28.420
Voriconazole 4.140 11.070 12.340
Gradient 2
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Fig. 2.3.20: Chromatograms of a separation of Voriconazole and its related impurities 
compound X, compound C and compound D using gradient profile 2 (shown in red). 
Conditions for the separation as per Fig. 2.3.19. 
To counteract the effect of the delay volume, the length of the isocratic hold was 
shortened systematically in an attempt to reduce the retention of compound X and 
Voriconazole further. The gradient profiles for this experiment is given in Table 
2.3.12. The isocratic hold time was reduced by 0.7 min which was half that of the 
delay time, the expected result of this was maintenance of the resolution of 
compound X and compound C, as the gradient step would still  not take effect until 
after both peaks had eluted from the column. Retention of compound D and 
Voriconazole was expected to be reduced further. 
Table 2.3.12: Development of an optimum separation using a gradient method on a 
Phenomenex Kinetex 2.6 µm core-shell stationary phase (2.1 x 100 mm).Gradient 3 gradient 
profile conditions. All other parameters remained as per Fig. 2.3.19. 
Gradient 3 
Time (mins) % ACN 
0.00 25% 
0.50 25% 
0.51 90% 
4.00 90% 
4.01 25% 
7.00 25% 
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Table 2.3.13: Results of separation of S3a using Gradient profile 3 as shown in Table 
2.3.12. 
 
As the initial hold time was shortened from 1.20 min to 0.50 min, the anticipated 
reduction in the retention of both compound D and Voriconazole due to the 90% 
gradient step reaching the column faster was observed (Table 2.3.13). As was noted 
with Gradient 2 (table 3.10), compound D and Voriconazole were eluted off the 
column almost immediately after the 90% step reached the column. Based on 
previous calculation of a 1.5 min dwell time, 90% ACN was expected to reach the 
column at 2.20 min. Retention times of compound D and Voriconazole were  2.361 
and 2.495 min respectively. Resolution above 3 continued to be maintained for the 
earlier eluting peak pair, while a resolution of 6.69 was noted for the last eluting 
peak pair compound D and Voriconazole. Fig. 2.3.21 shows the separation of 
Voriconazole and its related impurities using mobile phase gradient 3. 
 
 
Peak
Retention 
time (mins)
Retention 
Factor
Resolution
Void 0.345
Compound X 0.878 1.545
Compound C 0.993 1.878 3.060
Compound D 2.361 5.843 45.020
Voriconazole 2.495 6.232 6.690
Gradient 3
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Fig. 2.3.21: Chromatograms of a separation of Voriconazole and its related impurities 
compound X, compound C and compound D using gradient profiles 3 (shown in red). 
Conditions for the separation as per Fig. 2.3.19.  
As mentioned previously, the expected delay time of the Agilent 1200 series liquid 
chromatograph at a flow rate of 0.6mL/min was expected to be 1.5 min. While the 
isocratic hold was reduced to 0.5 min previously, it was hypothesised that this could 
further be reduced to 0.1 min without significant impact on the resolution of 
compound X and compound C. As well as this, it was felt that the isocratic hold at 
90% could be significantly reduced. The isocratic hold in the previous method was 
90% for 3.5 min, however it was felt that an isocratic hold of 0.6 min would be 
sufficient to elute the last two analytes in an adequate time frame and with sufficient 
resolution. Adjustment of the gradient in line with the dwell time meant that the 
gradient would take effect at 1.6 min and be held for 0.6 min, thus eluting compound 
D and Voriconazole within this time frame. Gradient profiles are given in Fig. 
2.3.22. 
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(a) (b)   
Fig. 2.3.22: Development of an optimum separation using a gradient method on a 
Phenomenex Kinetex 2.6 µm core-shell stationary phase (2.1 x 100 mm using “Gradient 4” 
mobile phase conditions (a) and (b) Gradient 4 profile 
The result of this final gradient optimisation is given in Table 2.3.14 and Fig. 2.3.23. 
As hypothesised, resolution was maintained between peak pair compound X and 
compound C with these analytes eluting at 0.92 and 1.076 min respectively with a 
resolution of 3.8. The chromatogram in Fig. 2.3.23 shows the separation of 
voriconazole and its related impurities, as well as the gradient profile and adjusted 
gradient profile. It can be seen from this chromatogram that when adjusted, the 
gradient chosen eluted compound X and compound C during the 25% isocratic hold, 
while analytes compound D and Voriconazole were eluted during the 90% isocratic 
hold. 
Table 2.3.14: Results of separation of S3 using the final optimised gradient, which includes 
a 0.1 min linear ramp, 0.5 minute hold and a 90% to 25% step. 
 
Time (mins) % ACN
0 25%
0.1 25%
0.11 90%
0.6 90%
0.61 25%
4.3 25%
Gradient 4
Peak
Retention 
time (mins)
Retention 
Factor
Resolution
Void 0.343
Compound X 0.920 1.682
Compound C 1.076 2.137 3.800
Compound D 1.926 4.615 25.540
Voriconazole 2.031 4.921 4.500
Gradient 4
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Fig. 2.3.23: Chromatograms of a separation of Voriconazole and its related impurities 
compound X, compound C and compound D using gradient profiles 4 (shown in red) and 
gradient 4 adjusted to match dwell volume (shown in green) Conditions for the separation 
as per Fig. 2.3.18 
The final optimised method on the Phenomenex Kinetex core-shell C18 reversed 
phase column had a run time of 4.3 min, a critical resolution of 3.80 between 
impurities compound X and compound C  and a critical resolution of 4.5 between 
impurity compound D and Voriconazole. When compared to the original Pfizer 
impurity assay for Voriconazole, the run time has been shortened by 57% and 
resolution between the original peak pair (compound X:compound C) has increased 
from 2.68 to 3.80, while resolution between compound D and Voriconazole has 
decreased from 10.81 to 4.5. The use of a core-shell stationary phase as well as 
reduced particle size provided shorter diffusion pathlengths for analytes thus 
speeding up the separation. Additionally the application of a gradient to this method 
allowed more strongly retained compounds such as Voriconazole to elute faster and 
reduced unnecessary resolution between peak pairs. This method was then 
transferred to a core-shell column with a particle size of 1.7 µm in diameter and 
further optimised in an effort to reduce run time further. 
 
CO
M
PO
U
N
D
 X
  
CO
M
PO
U
N
D
 C
 
CO
M
PO
U
N
D
 D
 
Vo
ri
co
na
zo
le
 
86 
 
2.3.2.3 Development of an optimised UPLC method on a core-shell 1.7 µm 
column 
 
The optimised method from Section 2.3.2.2.2 was then transferred to a smaller 1.7 
µm core-shell Phenomenex Kinetex column (100 x 2.1 mm, particle size 1.7 µm) 
and further optimised to provide the shortest run time possible while maintaining a 
resolution of at least 1.7 between peak pairs. Again this was carried out by changing 
the gradient time and the percentage ACN in the mobile phase. Moving to smaller 
particle size should in theory lead to a faster separation due to shorter interstitial 
diffusion pathways.  Moving to a 1.7 µm particle size column, however, brings the 
added issue of increased back pressure (>400 bar). For this reason a specialised high 
pressure instrument is required to cope with the increase in back pressure. The 
instrument used for this study was a Shimadzu Nexera UPLC Liquid 
Chromatography capable of withstanding pressures of up to 1000 bar. 
2.3.2.3.1 Determination of the dwell volume of the Shimadzu Nexera UPLC 
Liquid Chromatograph 
 
Determination of the dwell volume of the Shimadzu Nexera liquid chromatograph 
was carried as per the gradient profile method carried out in to Section 2.3.2.2.1. As 
mentioned previously (Section 2.3.2.2.1), determination of the dwell volume is 
required when transferring gradient methods from instrument to instrument as each 
gradient method is specific to the instrument on which it was developed and 
adjustments to the gradient timings are necessary to compensate for the differences 
in dwell volumes between instruments. 
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Fig. 2.3.24 Determination of void volume of Shimadzu Nexera UPLC utilising acetone. 
Conditions as outlined in Section 3.2.2.1. 
5% of the maximum absorbance recorded for a 1% acetone solution was noted at 
3.17 min. As the mobile phase composition did not change until 3.01 min, this was 
subtracted from the total time taken to give a value of 0.16 min. As the flow rate 
used was 1 mL/min, the dwell volume was calculated to be 0.160 mL. 
 
2.3.2.3.2 Transfer of the 2.6 µm core-shell column RP HPLC method to a 1.7 
µm core-shell column. 
 
The gradient method which was previously developed and optimised for a 2.6 µm 
particle size stationary phase in Section 2.3.2.2.2 (Fig. 2.3.23, Table 2.3.14) was 
transferred to the 1.7 µm column with the necessary adjustments for differences in 
delay volume of the two instruments Other parameters of the method included; 0.2 
µL injection volume, column temperature; 50°C, flow rate; 0.6 mL/min and a 
detector wavelength of 256 nm. 
The delay volume of the Agilent 1200 series liquid chromatograph and the Shimadzu 
Nexera UPLC chromatograph were experimentally determined to be 0.94 mL/0.94 
min and 0.16 mL/0.16 min respectively in Section 2.3.2.2.1 and 2.3.2.3.1. To 
compensate for the decrease in delay volume, the isocratic hold at the start of the 
gradient was increased by 0.9 min. Below is the updated gradient profile (Table 
88 
 
2.3.15) with results of the separation given in Table 2.3.16 and the corresponding 
chromatogram in Fig. 2.3.25. 
Table 2.3.15: Development of an optimum separation using a gradient method on a 
Phenomenex Kinetex 1.7 µm core-shell stationary phase (2.1 x 100 mm). Gradient 1a mobile 
phase conditions. All other parameters as per Fig. 3.18 
Gradient 1a 
Time (mins) % ACN 
0.00 25% 
1.00 25% 
1.01 90% 
1.40 90% 
1.41 25% 
4.30 25% 
 
It was expected that increasing the isocratic hold time would maintain the resolution 
between peak pair compound X and compound C. From the results presented in 
Table 2.3.16 and Fig. 2.3.25 it was noted that resolution between the peak pair was 
indeed maintained above 2, however the dramatic gradient step at 1.01 min from 
25% to 90% ACN caused resolution to be lost between peak pair impurity compound 
D and voriconazole with a resolution of just 0.9 between the two peaks.  
Table 2.3.16: Results of separation of S3 where initial hold time is increase to 1.0 minute 
(gradient 1a) 
 
Peak 
Retention 
Time
Retention 
Factor
Resolution
Void 0.380
Compound X 0.990 1.605
Compound C 1.087 1.861 2.070
compound D 1.613 3.245 4.950
Voriconazole 1.643 3.324 0.900
Gradient opt_1A
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Fig 2.3.25: Chromatograms of a separation of Voriconazole and its related impurities 
compound X, compound C and compound D using gradient profiles 1a (shown in red). 
Conditions for the separation as per Fig 2.3.19.  
In order to rectify this and restore resolution between compound D and voriconazole, 
a linear ramp was introduced from 1.01 min to 1.40 min and also a 90% isocratic 
hold from 1.40 to 2.00 min (Table 2.3.17). 
 Table 2.3.17: Development of an optimum separation using a gradient method on a 
Phenomenex Kinetex 1.7 µm core-shell stationary phase (2.1 x 100 mm).Gradient 2a mobile 
phase conditions. All other parameters as per Fig.2.3.19 
Gradient 2a 
Time (mins) % ACN 
0.00 25% 
1.00 25% 
1.40 90% 
2.00 90% 
2.01 25% 
4.30 25% 
 
Table 2.3.18 and its representative chromatogram (Fig. 2.3.26) show that, similar to 
the previous gradient, a resolution of above 2 was maintained between impurity 
peaks compound X and compound C. While as anticipated, there was an increase in 
the resolution from 0.900 to 1.760 between compound D and Voriconazole, so that 
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this now passes the optimisation specification of 1.7, there was still scope for further 
optimising the gradient profile. 
Table 2.3.18: Results of separation of S3 where initial hold time is reduced to 0.90 min, 
gradient 2a. Chromatographic conditions as per Fig 2.3.19. 
 
 
 
Fig. 2.3.26: Chromatograms of a separation of Voriconazole and its related impurities 
compound X, compound C and compound D using gradient profiles 2a (shown in red). 
Conditions for the separation as per Fig 2.3.19  
It was hoped that a shallower gradient, despite resulting in a longer retention time 
would increase the resolution between impurity compound D and Voriconazole. By 
decreasing the initial gradient hold by 0.4 min to 0.6 min, the slope of the linear 
gradient was lessened. The new gradient profile is given below in Table 2.3.19 
(gradient 3a). 
 
Peak 
Retention 
Time
Retention 
Factor
Resolution
Void 0.380
Compound X 0.990 1.605
Compound C 1.088 1.863 2.090
compound D 1.797 3.729 17.950
Voriconazole 1.852 3.874 1.760
Gradient 2A
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Table 2.3.19: Development of an optimum separation using a gradient method on a 
Phenomenex Kinetex 1.7 µm core-shell stationary phase (2.1 x 100 mm).Gradient 3a mobile 
phase conditions. All other parameters as per Fig. 2.3.18 
Gradient 3a 
Time (mins) % ACN 
0.00 25% 
0.60 25% 
1.40 90% 
2.00 90% 
2.01 25% 
4.30 25% 
 
Shortening the isocratic hold time at the beginning of the gradient, thus decreasing 
the slope of the gradient had the desired effect and the resolution between impurity 
compound D and Voriconazole peak increased from 1.76 to 2.66 with Voriconazole 
now eluting at 1.642 min as shown below in Table 2.3.20 and Fig. 2.3.27. 
Table 2.3.20 Results of separation of S3 where initial hold time is reduced to 0.6 min, as 
gradient 3a (Table 2.3.19) All other parameters remain as per Fig. 2.3.19 
 
 
Peak 
Retention 
Time
Retention 
Factor Resolution
Void 0.380
Compound X 0.994 1.616
Compound C 1.095 1.882 2.160
compound D 1.554 3.089 11.290
Voriconazole 1.642 3.321 2.660
Gradient 3A
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Fig. 2.3.27: Chromatograms of a separation of Voriconazole and its related impurities 
compound X, compound C and compound D using gradient profiles 3a (shown in red). 
Conditions for the separation as per Fig.2.3.19.  
 Due to the presence of an artefact eluting close to the Voriconazole peak it was 
decided to decrease the concentration of the ACN 80%. This gradient profile is 
shown in Fig 2.3.28. By decreasing %ACN, it was hoped to increase the resolution 
between the API and artefact on the column, while also maintaining the resolution 
between all peak pairs.  
Table 2.3.27: Development of an optimum separation using a gradient method on a 
Phenomenex Kinetex 1.7 µm core-shell stationary phase (2.1 x 100 mm). Gradient 4a mobile 
phase conditions. All other parameters remain as per Fig. 2.3.19. 
Gradient 4a 
Time (mins) % ACN 
0.00 25% 
0.60 25% 
1.40 80% 
2.00 80% 
2.01 25% 
4.30 25% 
 
Table 2.3.28 and its related chromatogram Fig. 2.3.27 show that resolution increased 
from 2.160 to 3.310. The resolution between impurity compound D and 
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Voriconazole decreased from 2.660 to 2.430, however this was within optimisation 
parameters that were set and was deemed acceptable. There was a resolution of 3.73 
between the API peak and the artefact. A high resolution between these peak pairs 
was necessary to ensure that it did not impact on the separation. Compared to the 
original Pfizer impurity method there was a decrease in run time of 57 % - the same 
as the reduction seen for the newly developed impurity assay developed on a 2.6 µm 
core-shell column (Fig. 2.3.23, Table 2.3.14). While there was a decrease in 
retention of the latest eluting peak –Voriconazole of ~ 0.4 minutes from 2.031 min to 
1.750 min, this decrease was negated by the time necessary to equilibrate the column 
after each run due to the gradient. Resolution between the critical peak pair of 
compound X and compound C was decreased slightly compared to the 2.6 µm 
column impurity assay from 3.800 to 3.310. Resolution between this peak pair was 
also compared to the original USP-36-NF-31 Voriconazole monograph (Section 
2.3.1) whose resolution was 2.68 between the same peak pair.  
Table 2.3.28: Results of separation of S3a where the final concentration of ACN lowered to 
80%  (gradient 4a) 
 
 
Peak 
Retention 
Time
Retention 
Factor Resolution
Void 0.380
Compound X 1.293 2.403
Compound C 1.433 2.771 3.310
compound D 1.669 3.392 6.820
Voriconazole 1.749 3.603 2.430
Artefact 1.936 4.095 3.730
Gradient 4A
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Fig. 2.3.27: Chromatograms of a separation of Voriconazole and its related impurities 
compound X, compound C and compound D using gradient profiles 4a. Conditions for the 
separation as per Fig 2.3.18. 
2.4 Conclusions 
Methods were successfully developed and optimised for use on Phenomenex Kinetex 
core-shell reversed phase C18 columns (100 x 2.1 mm) of particle sizes 2.6 µm and 
1.7 µm. Optimisation parameters were successfully meet with resolution between 
peak pairs above 2.0 for all compounds. A 57% reduction in the total run time of the 
impurity assay was recorded when transferred to both 2.6 µm and 1.7 µm column. 
Moving to smaller particles sizes has some distinct advantages such as; a decrease in 
retention time of analytes and an increase in efficiency. All three columns which 
were investigated were reversed phase C18 columns and so as expected the elution 
order across the 3 columns remained the same, which is as follows compound X 
Æcompound C Æ compound D Æ Voriconazole. Changes in retention behaviour 
between columns of different manufacturer can be attributed to the differences in 
carbon loading between manufacturers. 
The new optimised methods on both the core-shell 2.6 µm column and the 1.7 µm 
column were compared to the existing impurity assay in terms of retention factor and 
resolution. Table. 2.3.29 compares each of these parameters across all 3 columns.  
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Table. 2.3.29: Comparison of the 3 optimised methods in terms of their retention factor (left) 
resolution (right).  
 
As expected there was a decrease in overall retention time for newly optimised core-
shell methods of 57%. This was due to smaller particle sizes having shorter flow 
pathlengths leading to faster separations. When moving from a 2.6 µm core-shell 
column to a 1.7 µm core-shell column there was a slight decrease in retention time 
from 2.031 min to 1.749 min, however this decrease in run was negated due to the 
time necessary to re-equilibrate the column before the next injection. While the 2.6 
µm core-shell column could be operated on a standard HPLC with pressure 
capabilities of 400 bar, it was necessary to use a specialised instrument capable of 
withholding pressures of up to 1000 bar when operating the 1.7 µm core-shell 
column. From the point of view of total run time, no time saving benefit was found 
in transferring to the 1.7 µm core-shell column; it was therefore concluded that the 
use of 1.7 µm core-shell columns and state of the art high pressure instruments for 
gradient analysis are unnecessary for this application as they provide no additional 
benefit.  
 
 
 
 
Analyte
USP       
36-NF-31
DCU 2.6 
µm 
Method
DCU 1.7 
µm 
Method
Analyte
USP       
36-NF-31
DCU 2.6 
µm 
Method
DCU 1.7 
µm 
Method
Void 0.000 0.000 0.000 Void
Compound X 1.005 1.682 2.403 Compound X
Compound C 1.330 2.137 2.771 Compound C 2.680 3.800 3.310
Compound D 4.108 4.615 3.392 Compound D 14.530 25.540 6.820
Voriconazole 7.626 4.921 3.603 Voriconazole 10.830 4.500 2.430
ResolutionRetention Factor
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3 Chapter 3: The evaluation of stationary phase/mobile phase 
combinations for the development of an pharmaceutical 
impurity assay using Supercritical Fluid Chromatography 
3.1 Introduction 
While faster and more efficient chromatography is a constant driver within 
chromatographic research, another driver is the desire for greener chromatography 
and reduced solvent consumption [110]. Supercritical Fluid Chromatography (SFC) 
has the potential to deliver greener chromatography, as it uses non-toxic carbon 
dioxide as its mobile phase. This technique sits between HPLC and GC and 
possesses qualities of both [48], for example, supercritical fluids have density and 
solvation power which is close to liquids whist maintaining more gas like viscosity 
and diffusivity [48, 50]. As a result of its increased diffusion capabilities and the low 
viscosity of supercritical fluids compared to solvents used in HPLC, much higher 
linear velocities can be used, allowing faster separations and higher throughput [51]. 
An area where SFC has found great success and applicability has been preparative 
chromatography and chiral chromatography [63]. SFC is typically known as a 
technique which is analogous to normal phase HPLC due to the polarity of its 
primary mobile phase, which in most cases is supercritical carbon dioxide (sCO2), 
however with the addition of polar additives, its scope can be extended to encompass 
more reverse phase HPLC applications. As SFC offers complementary selectivity to 
HPLC, its potential for enhancing resolution in problematic HPLC separations is 
being explored for multiple applications. 
In Chapter 2, an existing reversed phase HPLC pharmaceutical impurity assay, 
previously carried out on a 5 µm C18 column, was transferred to a core-shell reversed 
phase C18 stationary phase. The aim of the study was to reduce the run time of the 
assay while maintaining adequate resolution between critical peak pairs. The run 
time of the assay was reduced by 57% from ~10 min to 4.3 min with the reduction in 
particle size from 5 µm fully porous to a 2.6 µm core-shell particle column. 
However, there was no subsequent decrease in run time when the 2.6 µm method 
was transferred to a 1.7 µm core-shell with the same particle morphology, due to re-
method constraints. 
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The aim of this study was  to develop a  SFC pharmaceutical impurity assay to 
separate Voriconazole and related impurities, compound C, compound D and 
compound X which had orthogonal selectivity to the reversed phase HPLC assay 
optimised in Chapter 2. A range of stationary phase and mobile phase modifiers and 
additives were investigated to determine the most suitable stationary phase and 
mobile phase modifier for this assay. Across all 16 mobile phase/stationary phase 
combinations evaluated, orthogonal selectivity was demonstrated. Selectivity 
differences were also demonstrated on a cyano column depending on whether acidic 
or basic additives were used. In general the stationary phase and mobile phase 
combinations selected proved to be unsuitable for further method development as 
compound X, due to its very non-polar nature was not retained on the very polar 
stationary phase and mobile phase combinations. As regards retention of 
Voriconazole and its other impurities, compound C and D, the use of additives on a 
silica stationary phase lead to significant loss of retention and also resolution. This 
was mostly due to competition between the analytes and additives for hydrogen 
bonding with surface silanols necessary for retention. The use of TFA on a cyano 
stationary phase lead to an increase in retention for all compounds compared to 
MeOH alone. Both the diol and 2-ethylpyridine column performed poorly across all 
mobile phase combinations analysed. 
3.2 Materials and Methods 
3.2.1 Materials 
3.2.1.1 Chemicals 
 
API standard – Voriconazole, impurity standards - compound C, compound D and 
compound X and Voriconazole test material were obtained from Pfizer Process 
Development Centre (PDC) (Cork, Ireland). HPLC grade Methanol (MeOH) was 
purchased from Fisher Scientific (Cheshire, UK). Trifluoroacetic acid Reagent plus 
99% (TFA), triethylamine ≥99% (TEA) and ammonium acetate ≥99.99% trace 
metals basis (AA) were purchased from Sigma Aldrich (Dublin, Ireland). All 
chemicals were used without further purification. Carbon dioxide (CO2), food fresh 
grade was obtained from BOC Gases Ltd (Dublin, Ireland)  
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3.2.1.2 Mobile Phases 
 
Mobile phases for SFC method development consisted of supercritical carbon 
dioxide (sCO2) (mobile phase A) containing a MeOH modifier and, if indicated, a 
TFA, TEA or AA modifier (mobile phase B). Total modifier concentration ranged in 
concentration from 2% to 20% v/v. Mobile phases containing 0.1% TFA, 0.1% TEA 
and 20 mM AA were prepared in 100% MeOH. All mobile phases were vacuum 
filtered using Supelco 0.2 µm nylon 66 membrane filters. (Sigma Aldrich, Dublin, 
Ireland). 
 
3.2.2  Apparatus 
 
3.2.2.1 SFC Instrumentation. 
 
The Agilent 1260 Infinity Analytical SFC system consisted of an Aurora SFC Fusion 
A5 module, Agilent 1260 Infinity SFC binary pump (G4303A), Agilent 1260 
Infinity standard degasser (G1332A), Agilent 1260 Infinity standard autosampler 
(G4303A) and Agilent 1260 Infinity diode array detector with high pressure SFC 
flow cell (G1315C). The Aurora SFC Fusion A5 module provided the Agilent 
HPLC-SFC pump with predistilled and preconditioned CO2, negating any 
compression requirements needed by the HPLC pump[111]. Mobile phase was 
redirected to the Aurora SFC Fusion A5 downstream of the detector to an integrated 
back pressure regulator which maintained back pressure across the system. A back 
pressure regulator kept the CO2 mobile phase under subcritical conditions at all 
times. Columns used included the Agilent Zorbax silica column (150 x 4.6 mm, 
particle size 5 µm), (Agilent, Ireland) Waters Spherisorb Cyano column (250 x 4.6 
mm, particle size 5 µm), (Waters, Ireland), Princeton SFC Diol column (150 x 4.6 
mm, particle size 5 µm) and Princeton SFC 2 –ethyl pyridine (150 x 4.6 mm, particle 
size 5 µm). Both the diol and 2-ethylpyridine columns were kindly donated by Pfizer 
Process Development Centre (PDC), Cork, Ireland 
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3.2.3  Methods 
3.2.3.1 Preparation of Standards 
 
Standards for SFC method development were prepared every 14 days in 100% 
MeOH diluent. A 250 µg/mL Voriconazole stock solution including its three known 
impurities, compound C, compound D and compound X was prepared. 12.5 mg of 
each standard was weighed out and dissolved in 50 mL diluent. This was further 
diluted 10 fold in 50 mL diluent. A 5 µL aliquot was injected for SFC analysis, 
known at S3b. The optimisation parameters selected for method development were 
the shortest run time possible, while maintaining a critical resolution of above 1.7 
between peak pairs. 
 
3.2.4 SFC Method Development 
 
SFC method development was carried out on a variety of stationary phases and 
mobile phases as outlined in Section 3.2.1.2 and 3.2.2.1. Results were compared to a 
pre-existing reversed phase HPLC method. This method is detailed in Chapter 2, 
Section 3. Flow rate was 3 mL/min, detector wavelength selected was 256 nm while 
column temperature was set to 37.5°C on the inlet side and 40°C on the outlet side as 
recommended by Agilent engineers. An injection volume of 5 µL of sample S3b was 
used. It was necessary for the solvent path to be pressurized at all times during 
analysis to avoid expansion of supercritical fluid, therefore a fixed 5 µL sample loop 
injector was employed [111]. These conditions remained the same throughout 
method development. 
3.2.4.1  Stationary Phase Selection 
 
Stationary phase and mobile phase selection for a particular set of analytes can be 
challenging due to the wide range of both stationary phase and mobile phases which 
are available[112]. Any stationary phase which can be used in HPLC can also be 
used in SFC; this is also the case for mobile phases, as CO2 is miscible with most 
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solvents used in HPLC.  SFC is known to be a typically analogous to normal phase 
liquid chromatography. CO2 is generally considered very non-polar with a polarity 
similar to pentane[50]. Commonly used polar stationary phases utilised in normal 
phase HPLC were chosen, namely bare silica, cyano and diol stationary phases, and 
a 2-ethylpyridine stationary phase specially designed for SFC.   
 
3.2.4.1.1 Stationary phase chemistry and mobile phase screening studies. 
 
Stationary phase and mobile phases screening studies were carried out 
simultaneously. A total of 16 different experiments were carried out. Each 
experiment involved varying the % organic modifier in CO2 over a range of 8% to 
20%, , unless otherwise stated. The four stationary phases bare silica, cyano, diol and 
ethyl pyridine were utilised with each of the modifier compositions MeOH only, 
MeOH with 0.1% TFA, MeOH with 0.1% TEA and MeOH with 20 mM AA. Other 
method parameters remained constant throughout the study; as detailed in Section 
3.3. Results were analysed in terms of retention factor, and resolution achieved with 
varying modifier concentrations, modifier types and different stationary phase 
chemistries. Results were also compared to the existing USP 36-NF-31 reverse phase 
HPLC method and newly developed UPLC methods achieved on 2.6 µm and 1.7 µm 
C18 reversed phased method discussed in Chapter 2. 
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3.3 Results and Discussion 
3.3.1  Selection of the optimal stationary phase/mobile phase modifier 
combination for the separation of API Voriconazole and its related 
impurities, compound X, compound C and compound D. 
As detailed in Section 3.2.4.1.1, the parameters which were varied in this study were 
stationary phase chemistry and modifier composition. The effect of both stationary 
phase and mobile phase on the retention of Voriconazole and related impurities, 
compound X, compound C and compound D were investigated simultaneously.  
Injections of individual standards of Voriconazole and its related impurities 
compound X, compound C and compound D were carried out on each of the four 
stationary phases under all mobile phase conditions. It was found that impurity 
compound X was not retained under any of the stationary phases analysed. For 
example, retention times and retention factors for compound X analysed on a bare 
silica stationary phase using MeOH only as a modifier are shown in Table 3.3.1. 
Table 3.3.1: The effect of modifier concentration on retention of impurity compound X. 
Modifier: MeOH only. Stationary phase: Agilent Zorbax Silica (150 x 4.6 mm, 5 µm) 
 
As can be seen from Table 3.3.1, compound X is not retained on a silica stationary 
using MeOH as a modifier. Poor retention is likely due to the hydrophobic nature of 
the analyte, which has a greater affinity for the less polar CO2 mobile phase over the 
polar silica stationary phase. Similar results were found for each of the other mobile 
phase/stationary phase combinations as all stationary phases which were chosen are 
polar in nature. An increase in void time was also noted with decreasing modifier 
concentration, a phenomenon that is not seen in reverse phase HPLC. 
Since compound X was not found to be retained within any of the parameters of this 
investigation it was decided to omit this impurity from the mixed standard used in 
Concentration of 
Modifier
Retention time of 
void (mins)
Retention time 
Compound X (mins)
Retention factor 
Compound X
20% 0.498 0.606 0.217
16% 0.51 0.615 0.206
12% 0.527 0.627 0.190
8% 0.567 0.632 0.115
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the subsequent study. S3b used in this study contained, Voriconazole, compound C 
and compound D. 
 
3.3.1.1 Optimisation of mobile phase for separation of Voriconazole and 
related impurities compound C and compound D. 
 
The parameters for optimal separation of Voriconazole, compound C and compound 
D were a minimum resolution between all peak pairs of 1.7 with the shortest possible 
runtime. Addition of a mobile phase modifier such as MeOH in SFC is expected to 
have a number of different effects such as favouring compound solubility, inducing 
selectivity changes by specific interactions such as hydrogen bonding and dipole-
dipole interactions[113]. Organic solvents are also known to change the density of 
the mobile phase as well as adsorbing onto the stationary phase surface, changing the 
polarity, volume and three dimensional structure of the stationary phase[114]. It was 
expected that with an increase in MeOH concentration there would be a decrease in 
retention of the analytes.  
To enhance the improvements in separation observed with modifiers, modifier 
additives are also used in SFC for a number of reasons, including; coverage of 
stationary phase active sites and suppression of ionisation or ion pairing[62]. 
Another role is to promote elution of very polar analytes and also to improve peak 
shape[82]. 
A series of investigations were carried out to investigate the effect of mobile phase 
modifiers and additives on the separation in question. In the first series, the effect of 
the modifier MeOH in the sCO2 mobile phase was examined. In the next three series, 
the effect of augmenting the MeOH modifier with additives with different properties 
were investigated. An acid – Trifluoroacetic acid (TFA), a base – Triethylamine 
(TEA) and a volatile salt – Ammonium Acetate (AA) were chosen for these studies. 
 
3.3.1.1.1 Investigation of the effect of a MeOH mobile phase modifier on 
retention of Voriconazole and related impurities Compound C and 
Compound D on stationary phases of varying polarities. 
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The effect of MeOH modifiers of different concentrations in the sCO2 mobile phase  
was investigated  for the four stationary phases chemistries chosen for this study, 
namely; bare silica, cyano, diol and ethyl pyridine. A modifier concentration range 
of 6-20% was chosen. The upper limit of 20% was chosen to prevent a two phase 
(liquid vapour) system developing, as would happen if the solubility of the MeOH in 
the sCO2 was exceeded[115].  Method conditions are given in Section 3.2.  
The results were analysed in terms of retention factors and resolution between peak 
pairs. Retention factors for each of the four columns across the MeOH range 
analysed as shown in Fig. 3.3.1 – 3.3.4. 
 
Fig. 3.3.1: Retention factor of Voriconazole(     ) and related impurities compound C(    ) 
and compound D(    ) vs. concentration of MeOH in mobile phase on a bare silica stationary 
phase (Agilent Zorbax silica dimensions: 150 x 4.6 mm, 5 µm particle size) (Raw Data, 
Appendix 6.2, Table 6.2.1) 
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Fig. 3.3.2: Retention factor of Voriconazole (    ) and related impurities compound C(     ) 
and  Compound D(    ) vs. concentration of MeOH in mobile phase on a cyano stationary 
phase (Phenomenex Spherisorb CN dimensions: 250 x 4.6 mm, 5 µm particle size) (Raw 
Data, Appendix 6.2, Table 6.2.2)  
 
Fig. 3.3.3: Retention factor of Voriconazole(    ) and related impurities compound C (    ) 
and compound D (     ) vs. concentration of MeOH in mobile phase on a diol stationary 
phase (Princeton Diol dimensions: 150 x 4.6 mm, 5 µm particle size) (Raw Data, Appendix 
6.2, Table 6.2.3) 
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Fig. 3.3.4: Retention factor of Voriconazole (     ) and related impurities UK-51-060 (    ) 
and compound D(   ) vs. concentration of MeOH in mobile phase on a ethyl pyridine 
stationary phase (Princeton 2-ethyl pyridine dimensions: 150 x 4.6 mm, 5 µm particle size) 
(Raw Data, Appendix 6.2, Table 6.2.4) 
As expected, across all four stationary phases analysed there was a consistent trend 
of decreased retention with increased MeOH concentration. This was also seen by 
Patil et al.[116] for the separation of acetaminophen and other analgesics using a 
phenyl column where retention decreased across the MeOH concentration 4.8 to 
16.7%. The decrease in retention shown in Fig. 3.3.1 – 3.3.4 appears to be more 
significant at lower concentrations of MeOH than at higher concentrations of MeOH. 
This trend is similar to that observed in normal phase HPLC where at higher 
concentrations of polar mobile phase, retention is not significantly affected[6]. For 
this reason, just as with normal phase HPLC, the dominant retention mechanism was 
hypothesised to be adsorption over partition on the stationary phases selected for this 
study. Again, this agrees with published literature, where polar stationary phases in 
SFC induce normal phase retention behaviour [113].  
The cyano stationary phase was shown to result in longest retention, while the 
pyridine stationary phase retained least, with silica and diol stationary phases 
exhibiting intermediate retention. On a silica stationary phase Voriconazole had a 
retention factor of 2.894 at 8% MeOH while retention factor was reduced to 1.014 at 
20% MeOH (raw data for this experiment is given in Fig. 6.2.1 and 6.2.2 in 
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Appendices). This was a reduction in retention factor of approximately 3. Retention 
factors for Voriconazole on the cyano stationary phase were almost twice that of a 
silica column with retention factors of 2.19 at 20% and 4.97 at 8% MeOH. Retention 
on the cyano column was hypothesised to be due both to hydrogen bonding between 
the cyano group and the analytes but also interaction between the hydrophobic 
carbon chain of the cyano column increasing retention, while retention on the silica 
stationary phase was hypothesised to be due to hydrogen bonding only. With 
increasing MeOH concentration, interactions between the mobile phase and analytes 
were increased through hydrogen bonding interactions. 
 There was significantly less retention on both an ethyl pyridine stationary phase 
with a maximum retention factor obtained of 1.06 with 6% MeOH. The poor 
retention of the analytes on a pyridine stationary phase was hypothesised to be due 
absence of significant hydrogen bonding capacity of the pyridine stationary phase. 
Zheng et al.[117] suggest that internal hydrogen bonding between surface silanols 
and the nitrogen moiety of the pyridine ring reduced active sites available for solute 
interaction. Similar retentions and retention factors were achieved on the diol 
stationary phase and the silica stationary phase across the range of MeOH 
concentrations analysed. Retention on both the silica and diol columns is thought to 
be due to hydrogen bonding with the surface silanols on the silica column and the 
hydroxyl groups of the diol stationary phase. 
On all stationary phases, compound D was the latest eluting compound. 
Voriconazole and compound C switched elution order on the diol and pyridine 
column compared to the silica and cyano column. Compound D and Voriconazole 
are very similar in structure, however compound D was thought to be more retained 
due to the absence of the extra fluorine Voriconazole possesses. The presence of 
halogens reduces retention in normal phase HPLC; since it was anticipated that the 
columns would produce normal phase retention behaviour due to their polar nature, 
the decreased retention of Voriconazole was expected. The change in elution order 
between the silica and cyano and diol and pyridine column was also anticipated; due 
to increased steric hindrance between the analytes and the diol and pyridine 
stationary phase. While both analytes were thought to interact with the hydroxyl 
groups of the diol column and surface silanols, it thought that steric hindrance and 
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thus reduced capability for hydrogen bonding caused the larger Voriconazole analyte 
to be eluted first.  
As in HPLC a good separation is defined as having a retention factor (k) of between 
1 and 10[118]. A retention factor of less than 1 indicates compounds do not interact 
sufficiently with the stationary phase and therefore are not adequately retained, while 
retention factors of greater than 10 indicate excessive retention. It was noted that the 
pyridine column for concentrations of MeOH above 8% a retention factor of less 
than 1 achieved and therefore compounds were inadequately retained. It was 
therefore concluded that a pyridine column with a MeOH stationary phase was 
unsuitable for the separation of Voriconazole and its related impurities.  
The silica, cyano and diol columns were analysed in terms of the resolution between 
critical peak pairs. A resolution of greater than 1.7 was selected as a critical 
performance parameter between all peak pairs. Resolutions values for peak pairs for 
each of the three columns are given below in Fig 3.3.5 – 3.3.7. 
 
Fig. 3.3.5: Retention of peak pairs vs. concentration of MeOH in mobile phase. Peak pairs 
are as follows: (1,2)(     ): compound C:Voriconazole, (2,3)(     )Voriconazole:compound D 
on a bare silica stationary phase (Agilent Zorbax Silica dimensions: 150 x 4.6 mm , 5 µm 
particle size) minimum resolution is shown by the green line(Raw Data, Appendix 6.2, Table 
6.2.1) 
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Fig. 3.3.6: Retention of peak pairs vs. concentration of MeOH in mobile phase. Peak pairs 
are as follows: (1,2 )(     ): compound C:Voriconazole, (2,3)(     ): Voriconazole:compound 
D on a cyano stationary phase (Phenomenex Spherisorb CN dimensions: 250 x 4.6 mm, 5 
µm particle size) minimum resolution is shown by the green line. (Raw Data, Appendix 6.2, 
Table 6.2.2) 
 
Fig. 3.3.7: Retention of peak pairs vs. concentration of MeOH in mobile phase. Peak pairs 
are as follows: (1,2(     ): compound C:Voriconazole, (2,3)(     ): Voriconazole:compound D 
on a diol stationary phase (Princeton Diol, dimensions: 150 x 4.6 mm, 5 µm particle 
size)Minimum resolution is indicated by the green line. (Raw Data, Appendix 6.2, Table 
6.2.3) 
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On a silica stationary phase, shown in Fig. 3.3.5, resolution between Voriconazole 
and compound D is above 1.7 at all MeOH concentrations selected for this study. At 
8% MeOH resolution was 9.99 (see raw data, Appendix 6.2.1) with increasing 
MeOH concentration and resultant decreasing retention there was also a decrease in 
resolution between peaks with a final resolution of 5.89 at the highest concentration 
of MeOH of 20%. The critical peak pair on a silica stationary phase was compound 
C and Voriconazole. The green line in Fig 3.3.5 – resolution between peak pairs on a 
silica column, indicates the resolution threshold of 1.7. It can be seen that sufficient 
resolution was only achieved on a silica stationary phase with a modifier 
concentration of less than 12% with the greatest resolution achieved at 8% MeOH, of 
2.61. It was found that resolution between the critical peak pair, 
Voriconazole:compound D on a cyano column (Fig. 3.3.6) increased with increasing 
MeOH concentration, the opposite effect than on a bare silica column. Critical 
resolution was achieved at a MeOH concentration above 12%, with the best 
resolution achieved at 20% of 1.92 ( raw data; appendix 6.2, table 6.2.2). While on a 
diol column (Fig 3.3.7, raw data; appendix 6.2, table 6.2.3), using MeOH as a mobile 
phase modifier at no concentration investigated in this study was critical resolution 
achieved, rendering this stationary phase/mobile phase combination unsuitable.  
 
3.3.1.1.2 Optimal MeOH modified mobile phases 
 
It was concluded that stationary phase/MeOH combinations which provided the best 
resolution and suitable retention were a bare silica and cyano columns at 10% and 
20% respectively. Chromatograms below in Fig. 3.3.8 and Fig. 3.3.9 show the 
optimal separations achieved on a bare silica column. In each case, all 3 components 
were shown to be resolved. The runtime for the bare silica stationary phase was 
slightly shorter than for the optimal cyano separation, at 3.5 minutes relative to 4.5 
minutes. 
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Fig 3.3.8: Chromatogram of the optimal separation of S3b achieved on a bare silica 
stationary phase using a 10% MeOH, 90% sCO2 mobile phase. Conditions: Injection 
Volume: 5µL, Column Temp: 37.5°C (in) 40.0°C(out), Detector wavelength: 256 nm, 
booster pressure: 130 bar. 
 
 
Fig 3.3.9: Chromatogram of the optimal separation of S3b achieved on a cyano stationary 
phase using a 20% MeOH, 80% sCO2 mobile phase. Conditions: Injection Volume: 5µL, 
Column Temp: 37.5°C (in) 40.0°C(out), Detector wavelength: 256 nm, booster pressure: 
130 bar  
COMPOUND C 
Voriconazole 
COMPOUND D 
COMPOUND C 
Voriconazole 
COMPOUND D 
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3.3.1.1.3 Investigation of the effect of a MeOH mobile phase modifier with 
0.1% TFA additive on retention of Voriconazole and related 
impurities compound C and compound D on stationary phases of 
varying polarities. 
 
3.3.1.1.3.1 Bare silica stationary phase 
 
The addition of TFA in SFC was reported to have a number of effects. De Klerck 
[97] reported a reduction in retention when TFA was added to a methanol modifier 
for the separation of a range of enantiomers. Reduced retention was thought to be 
due to de-activation of surface silanols and also the partial protonation of basic 
functional groups. Brunelli et al.[74] found that the addition of TFA to a methanol 
mobile phase reduced peak tailing for acidic pharmaceutical compounds on a 
cyanopropyl stationary phase, while Dispas et al.[119] found that TFA acted as an 
ion pairing reagent which interacted with the amine functionalities of 
pharmaceuticals and neurotransmitters analysed. It was expected that TFA would 
perform similarly on the stationary phases chosen. The first stationary phase chosen 
was a bare silica column. The results are given below in Fig. 3.3.10 
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Fig. 3.3.10a: Retention factor of Voriconazole (     )  and related impurities compound C (   ) 
and compound D(      ) vs. concentration of MeOH w/0.1% TFA in mobile phase on a bare 
silica stationary phase (Agilent Zorbax silica dimensions: 150 x 4.6 mm, 5 µm particle size.) 
(Raw Data, Appendix 6.2, Table 6.2.5) 
 
Fig. 3.3.10b: Resolution of peak pairs vs. concentration of MeOH w/0.1% TFA in the mobile 
phase. Peak pairs are as follows: (1,2(   ): compound C:Voriconazole, (2,3)(    ): 
Voriconazole:compound D on a bare silica stationary phase. (Agilent Zorbax Silica 
dimensions: 150 x 4.6 mm , 5 µm particle size) minimum resolution is shown by the green 
line. (Raw Data, Appendix 6.2, Table 6.2.5) 
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With the addition of TFA to the mobile phase, at a concentration of modifier above 
8% Voriconazole and compound C co-elute (Fig. 3.3.10a). An overall decrease in 
retention of Voriconazole and its impurities was noted using TFA compared to a 
MeOH only mobile phase as seen in Fig. 3.3.1. It was hypothesised that coverage of 
surface silanols on the surface of the silica by TFA, causing less active sites being 
available for bonding by the analytes, led to the reduced retention noted on this 
stationary phase. This behaviour to similar to trends reported by DeKlerck where the 
addition of TFA to the mobile phase led to a reduction in retention for 
enantiomers[84] As can be seen due to co-elution of compound C and Voriconazole 
resolution between this peak pair is 0 above 8% modifier. At 6% resolution is below 
the critical resolution value of 1.7 as denoted by the green line in Fig 3.3.10b (raw 
data; appendix 6.2, Table 6.2.5) It was therefore concluded that the addition of TFA 
to the MeoH modified mobile phase was unsuitable at any concentration used in this 
study.  
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3.3.1.1.3.2 Cyano stationary phase 
 
This study was repeated on a cyano stationary phase using identical parameters. 
Results of this study are given in Fig 3.3.11. 
 
Fig. 3.3.11a: Retention factor of Voriconazole (     ) and related impurities compound C (    ) 
and compound D (     ), with ideal retention window illustrated by the area within the red 
box vs. concentration of MeOH w/0.1% TFA in mobile phase on a cyano stationary phase 
(Phenomenex Spherisorb CN dimensions: 250 x 4.6 mm , 5 µm particle size). (Raw Data, 
Appendix 6.2, Table 6.2.6) 
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Fig. 3.3.11b: Resolution of peak pairs vs. concentration of MeOH w/0.1% TFA in mobile 
phase on a cyano stationary phase (Phenomenex Spherisorb CN dimensions: 250 x 4.6 mm , 
5 µm particle size. Peak pairs are as follows: (1,2)(    ): compound C:Voriconazole, (2,3)(   ) 
Voriconazole:compound D. Minimum resolution illustrated by the green line(Raw Data, 
Appendix 6.2, Table 6.2.6) 
 
When compared to a MeOH only mobile phase (Fig 3.3.2), the addition of TFA has 
increased retention of all 3 components of S3b. This increase in retention was 
hypothesised to be due to protonation of the cyano group on the stationary phase by 
TFA and deprotonation of the hydroxyl groups on both Voriconazole and compound 
D resulting in ion pairing increasing retention. Ideally a retention factor window of 
between 1 and 5 (as indicated by the red box in Fig. 3.3.11a) is optimum and as can  
be seen in Fig. 3.11a, 16% and 20% MeOH w/0.1% TFA provided retention factors 
for Voriconazole and compound C within this window. Resolution across the entire 
modifier concentration (Fig. 3.3.11b) is above 1.7 for both peak pairs. 20% MeOH 
w/0.1% TFA was deemed to be the most suitable with a complete run time of 6.542 
min (appendix 6.2, table 6.2.6) 
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3.3.1.1.3.3 Diol stationary phase 
 
This study was continued on a diol stationary phase using identical parameters. 
Results of this study are given in Fig 3.3.12. 
(a
 
Fig. 3.3.12a: Retention factor of Voriconazole (     ) and related impurities compound C (    ) 
and compound D (   ) vs. concentration of MeOH w/0.1% TFA in mobile phase on a diol 
stationary phase (Princeton Diol dimensions: 150 x 4.6 mm, 5 µm particle size) (Raw Data, 
Appendix 6.2, Table 6.2.7) 
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Fig 3.3.12b: Retention of peak pairs vs. concentration of MeOH w/0.1% TFA in mobile 
phase on a diol stationary phase (Princeton Diol dimensions: 150 x 4.6 mm , 5 µm particle 
size) Peak pairs are as follows: (1,2) (   ): compound C:Voriconazole, (2,3) (   ): 
Voriconazole:compound D. (Raw Data, Appendix 6.2, Table 6.2.7) 
 
Retention behaviour on a diol stationary phase when TFA was added to the MeOH 
was similar to that observed when a MeOH only mobile phase was used. While the 
addition of TFA has a major effect on retention on a silica column ( Fig 3.3.10a), it 
was not expected to have as major as effect as the TFA does not have as strong of an 
interaction with the diol functionality as with surface silanols. Retention factors 
across the range of modifier and additive concentrations as expected decreased with 
modifier concentration (appendix 6.2, Table 6.2.7). As with a MeOH only mobile 
phase (Fig. 3.3.7), there was inadequate resolution between analytes compound C 
and Voriconazole over the entire range of MeOH w/0.1% TFA concentrations as 
shown in Fig 3.3.12b. Elution order also remained the same as with a MeOH only 
mobile phase.  
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3.3.1.1.3.4 ethyl-pyridine stationary phase 
 
An identical experiment was then carried out on an ethyl-pyridine stationary phase 
using identical parameters. Results of this study are given in Fig 3.3.13. 
 
 
Fig. 3.3.13a: Retention factor of Voriconazole(     ) and related impurities compound C (    ) 
and compound D(    ) with retention factor threshold (≥1) indicated by the red line vs. 
concentration of MeOH w/0.1% TFA in mobile phase on an ethyl pyridine  stationary phase 
(Princeton Ethylpyridine dimensions: 150 x 4.6 mm , 5 µm particle size) (Raw Data, 
Appendix 6.2, Table 6.2.8) 
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Fig. 3.3.13b: Retention of peak pairs vs. concentration of MeOH w/0.1% TFA in mobile 
phase on a ethyl pyridine stationary phase (Princeton Ethylpyridine dimensions: 150 x 4.6 
mm , 5 µm particle size) Peak pairs are as follows: (1,2)(    ): compound C:Voriconazole, 
(2,3)(   ): Voriconazole:compound D. Minimum resolution threshold is indicated by the 
green line. (Raw Data, Appendix 6.2, Table 6.2.8) 
 
To allow sufficient interaction with the stationary phase, retention factors of analytes 
should be greater than one. The red line in Fig 3.3.13a indicates that Retention 
factors of greater than 1 are only achieved on an ethyl pyridine column using a 
MeOH w/ 0.1% TFA modifier at a concentration of 6%. However resolution at this 
concentration of modifier is inadequate for both peak pairs. This stationary phase 
mobile phase combination is entirely unsuitable. 
 
3.3.1.1.3.5 Optimal MeOH modified mobile phases with TFA additive 
 
The addition of TFA to a MeOH modifier was only suitable on a cyano stationary 
phase. On all other stationary phases, i.e. bare silica, diol and pyridine columns, 
analytes were either not sufficiently retained,such as in the case of a pyridine 
column, or the threshold set out for resolution for critical peak pairs was not met as 
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occurred for both the bare silica and diol stationary phases. Fig.3.3.14 below 
illustrates the separation of S3b using 20% MeOH, 0.1 % TFA on a cyano stationary 
phase. All the optimisation parameters are met, as the resolution exceeds 1.7 for all 
pairs. However, the runtime, at almost 7 minutes is significantly greater than the 4.5 
minutes recorded when MeOH was added as a mobile phase modifier without any 
additive. 
 
 
Fig 3.3.14: Chromatogram of the best separation of S3b achieved on a cyano stationary 
phase using a 20% MeOH, 0.1% TFA, 80% sCO2 mobile phase. Conditions: Injection 
Volume: 5µL, Column Temp: 37.5°C (in) 40.0°C(out), Detector wavelength: 256 nm, 
booster pressure: 130 bar 
 
3.3.1.1.4 Investigation of the effect of MeOH mobile phase modifier with 0.1% 
TEA on retention of Voriconazole and related impurities compound C 
and compound D 
 
Triethylamine (TEA) is a base which is commonly used as an additive in both HPLC 
and SFC. Phinney et al.[120] hypothesised that TEA had a number of different 
effects on retention including ion suppression of analytes and/or stationary phase 
leading to a change in retention as well as reducing solute interactions with surface 
silanols which gave rise to unwanted retention. 
Voriconazole
COMPOUND C
COMPOUND D
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3.3.1.1.4.1 Bare silica stationary phase 
 
Results of the separation of S3b on the bare silica stationary phases is given below in 
Fig. 3.3.15. 
 
 
Fig. 3.3.15a: Retention factor of Voriconazole(      )and related impurities compound C (     ) 
and compound D(     ) vs. concentration of MeOH in mobile phase w/0.1% TEA in mobile 
phase on a bare silica stationary phase (Agilent Zorbax silica dimensions: 150 x 4.6 mm , 5 
µm particle size) (Raw Data, Appendix 6.2, Table 6.2.9) 
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Fig. 3.3.15b: Retention of peak pairs vs. concentration of MeOH in mobile phase w/0.1% 
TEA in mobile phase on a bare silica stationary phase (Agilent Zorbax silica dimensions: 
150 x 4.6 mm , 5 µm particle size). Peak pairs are as follows: (1,2)(   ): compound 
C:Voriconazole, (2,3)(    ): Voriconazole:compound D. Minimum resolution threshold is 
indicated by the green line.(Raw data; Appendix 6.2, Table 6.2.9) 
 
As was the case when TFA was added to the MeOH modifier peaks 2 and 3, 
Voriconazole and compound D, co-elute with a concentration of greater than 8% 
modifier. As was the case with TFA, it was hypothesised that TEA played the same 
role in retention in covering surface silanols on the silica stationary phase rendering 
them unavailable for interaction with the solute, decreasing retention. Retention 
factors and retention times were similar for both TEA and TFA. It is hypothesised 
that decreasing the modifier concentration below 6% would not provide a significant 
increase in resolution between critical peaks to satisfy the experimental critical 
parameters set out at the start of the experiment. 
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3.3.1.1.4.2 cyano stationary phase 
 
Results of the separation of S3b on the cyano stationary phases is given below in 
Fig. 3.3.16. 
 
 
Fig. 3.3.16a: Retention factor of Voriconazole (     ) and related impurities compound C (    ) 
and compound D (      ), with retention factor threshold (≥1) indicated by the red line vs. 
concentration of MeOH w/0.1% TEA in mobile phase on a cyano stationary phase 
(Phenomenex Spherisorb CN dimensions: 250 x 4.6 mm , 5 µm particle size). (Raw Data, 
Appendix 6.2, Table 6.2.10) 
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Fig. 3.3.16b: Resolution of peak pairs vs. concentration of MeOH w/0.1% TEA in mobile 
phase on a cyano stationary phase (Phenomenex Spherisorb CN dimensions: 250 x 4.6 mm , 
5 µm particle size). Peak pairs are as follows: (1,2)(    ): Voriconazole:compound C (2,3)       
(     ) compound C:compound D. Minimum resolution threshold is illustrated by the green 
line. (Raw Data, Appendix 6.2, Table 6.2.10) 
Firstly, when compared to a MeOH only modifier (Fig. 3.3.2) and a MeOH with 
0.1% TFA additive (Fig. 3.3.11), the elution order of compound C and Voriconazole 
has switched with Voriconazole now eluting first (Fig. 3.3.15). TEA was 
hypothesised to cause the analytes to become ionised, while the stationary remained 
neutral leading to a reduction in retention. The switch in elution order was 
hypothesised to be due to the combination of the repulsion of the now ionised 
Voriconazole molecule with the neutral stationary phase as well as fact that 
Voriconazole is a bulkier molecule and so will be less retained, compared to the 
smaller molecule compound C. 
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3.3.1.1.4.3 Diol stationary phase 
 
The results of the study carried out on diol stationary phase are given below in Fig. 
3.3.17. 
 
Fig. 3.3.17a: Retention factor of Voriconazole (    ) and related impurities compound C (    ) 
and compound D(     )  vs. concentration of MeOH w/0.1% TEA in mobile phase on a diol 
stationary phase (Princeton Diol dimensions: 150 x 4.6 mm, 5 µm particle size)(Raw Data, 
Appendix 6.2, Table 6.2.11) 
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Fig. 3.3.17b: Resolution of peak pairs vs. concentration of MeOH w/0.1% TEA in mobile 
phase on a diol stationary phase (Princeton Diol dimensions: 150 x 4.6 mm, 5 µm particle 
size) Peak pairs are as follows: (1,2)(  ): compound C:Voriconazole, (2,3)(  ): 
Voriconazole:compound D. Minimum resolution threshold is illustrated by the green line. 
The increase in retention noted with the addition of TEA to the MeOH modified 
mobile phase compared to a MeOH only modified mobile phase (Fig. 3.3.3) and a 
MeOH modifier with 0.1% TFA aditive (Fig. 3.3.12) may be attributed 
deprotonation of the diol stationary phase and the ionisation of the solute in a now 
basic mobile phase causing ion pairing to occur between the stationary and solutes 
increasing retention. Resolution of the critical peak pair Voriconazole and compound 
C remained below the threshold set for resolution for all concentrations of modifier, 
apart from 8%. 
3.3.1.1.4.4 Ethyl pyridine stationary phase 
 
It was noted throughout this experiment on each of the four stationary phases that 
with the use of TEA an extra peak appeared in each chromatogram. After ruling out 
contamination of the TEA, it was concluded that peak was due to the TEA additive 
itself. On a diol, bare silica and cyano stationary phase, the system peak eluted after 
the analytes of interest with reasonable resolution between the last eluting peak and 
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the system peak, however when an ethyl pyridine column was used, this peak co-
eluted with analytes of interest and thus this experiment was discontinued. 
3.3.1.1.4.5 Optimal TEA additive mobile phases 
 
While 8% MeOH modified mobile phase with 0.1% TEA additive provided a good 
separation of S3b on a diol stationary phase (Fig. 3.3.17) it was decided to reject this 
mobile phase, stationary phase combination as a viable option due to the presence of 
the system peak. TEA has a detrimental effect on retention on both the cyano and 
silica stationary phases, due to interaction with surface silanols on the silica 
stationary phase and ionisation of analytes on the cyano stationary phase, therefore 
were not suitable. The final additive which was investigated in this study was 
Ammonium Acetate (AA). 
 
3.3.1.1.5 Investigation of the effect of MeOH modified mobile phase with 20 
mM AA additive on retention of Voriconazole and related impurities 
compound C and compound D 
 
Aside from the use of acids and bases as mobile additives in SFC, volatile organic 
salts are also used. The advantage of the use of such salts over acids and bases is due 
to their compatibility with mass spectrometric detection as they do not cause ion 
suppression[82]. As was the case for all previous studies of modifiers and additives,a 
MeOH modified mobile phase was used with 20 mM AA additive over the range 6% 
to 20% was analysed on all four stationary phases. The first stationary phase 
investigated was a bare silica column. 
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3.3.1.1.5.1 Silica stationary phase 
 
 
Fig. 3.3.18: Retention factor of Voriconazole(    ) and related impurities compound C (   ) 
and compound D (    )vs. concentration of MeOH w/20 mM AA in mobile phase on a bare 
silica  stationary phase (Agilent Zorbax Silica, dimensions: 150 x 4.6 mm , 5 µm particle 
size. (Raw Data, Appendix 6.2, Table 6.2.12) 
The reduced retention which was seen with a MeOH plus additives TFA and TEA 
stationary phase was also seen with the addition of an AA additive to the MeOH 
modified mobile phase (Fig. 3.3.18). This reduced retention was hypothesised to be 
due to coverage of surface silanols which were then unavailable for hydrogen 
bonding interaction with solute molecules, the same retention mechanism as was the 
dominant throughout this study.  The next stationary phase investigated was cyano 
stationary phase. 
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3.3.1.1.5.2 Cyano and Diol stationary phases. 
 
 
Fig. 3.3.19a: Retention factor of Voriconazole (    ) and related impurities compound C (   ) 
and compound D (   ) with retention factor threshold (≥1) indicated by the red line 
vs.concentration of MeOH w/ 20 mM AA in mobile phase on a cyano stationary phase 
(Phenomenex Spherisorb CN dimensions: 250 x 4.6 mm , 5 µm particle size. (Raw Data, 
Appendix 6.2, Table 6.2.13) 
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Fig. 3.3.19b:  Resolution of peak pairs vs. concentration of MeOH w/ 20 mM AA in mobile 
phase on a cyano stationary phase (Phenomenex Spherisorb CN dimensions: 250 x 4.6 mm , 
5 µm particle size. Peak pairs are as follows: (1,2)(    )Voriconazole:compound C (2,3)(    ) 
compound C:compound D. Minimum resolution threshold indicated by the green line. (Raw 
Data, Appendix 6.2, Table 6.2.11) 
As can be seen in Fig 3.3.19, with the addition of AA to the MeOH modified mobile 
phase there is a significant reduction in retention and thus resolution compared to the 
when no additive was used (Fig 3.3.2) and when TFA was added (Fig. 3.3.11). It is 
hypothesised that AA has the same effect on retention as TEA (Fig 3.3.17), that is; 
ionisation of the analytes in the basic mobile phase causing retention to decrease due 
to decreased interaction with the stationary phase. Finally, a concentration study of 
MeOH modified mobile phase with 20 mM AA additive was carried out on a diol 
stationary phase (Fig 3.3.20). As retention was poor for all other mobile phases on an 
ethyl pyridine column, this column was disregarded from this study. 
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Fig. 3.3.20a:Retention factor of Voriconazole (    ) and related impurities compound C (    ) 
and compound D (    ) with ideal retention window illustrated by the area within the red box 
vs. concentration of MeOH w/ 20 mM AA in mobile phase on a diol stationary phase 
(Princeton Diol dimensions: 150 x 4.6 mm , 5 µm particle size) (Raw Data, Appendix 6.2, 
Table 6.2.14) 
 
Fig. 3.3.20b: Resolution of peak pairs vs. concentration of MeOH w/ 20 mM AA in mobile 
phase on a diol stationary phase (Princeton Diol dimensions: 150 x 4.6 mm , 5 µm particle 
size Peak pairs are as follows: (1,2)(  ): compound C:Voriconazole, (2,3)(  ): 
Voriconazole:compound D. Minimum resolution threshold is illustrated by the green line. 
(Raw Data, Appendix 6.2, Table 6.2.14) 
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As was also the case for a cyano column, TEA and AA were hypothesised to have a 
similar effect on retention on diol column. With the addition of AA to the MeOH 
overall retention of all analytes were increased. It was hypothesised that the increase 
in retention compared to a methanol only modifier on this stationary phase was due 
to ion pairing of the ionised solutes and the deprotonated diolic stationary phase.  
3.3.1.1.5.3 Optimal AA additive mobile phases 
 
The addition of AA to a MeOH modifier was found to be advantageous on a diol and 
a cyano stationary phase but not a silica stationary phase as was previously 
discussed. Fig.3.3.21 below illustrates the separation of S3b using 8% MeOH 
modified mobile phase with 20 mM AA additive on a cyano stationary phase. Run 
time for this separation was 2.263 minutes with a critical resolution of 1.81 between 
compound C and D. Fig.3.3.22 illustrates the separation of S3b using 10% MeOH 
modified mobile phase with 20 mM AA additive on a diol column, the run time of 
this assay was 2.272 minutes with a critical resolution between compound 
Voriconazole and compound C of 1.82.  
 
Fig 3.3.21: Chromatogram of the best separation of S3b achieved on a cyano stationary 
phase using a 8% MeOH,20 mM AA, 92% sCO2 mobile phase. Conditions: Injection 
Volume: 5µL, Column Temp: 37.5°C (in) 40.0°C(out), Detector wavelength: 256 nm, 
booster pressure: 130 bar 
COMPOUND C
Voriconazole
COMPOUND D
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Fig 3.3.22: Chromatogram of the best separation of S3b achieved on a diol stationary phase 
using a 10% MeOH,20mM AA, 90% sCO2 mobile phase. Conditions: Injection Volume: 
5µL, Column Temp: 37.5°C (in) 40.0°C(out), Detector wavelength: 256 nm, booster 
pressure: 130 bar 
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3.4   Conclusions 
The first conclusion which can be drawn from this study was that polar stationary 
phases such as the ones selected for this study, with MeOH based modifiers are 
unsuitable for the retention of some impurities associated with Voriconazole such as 
compound X. It was hypothesised that this compound was not retained due to the 
higher polar nature of each of the stationary phases shown. Compound X is a non 
polar molecule and thus none of the stationary phases chosen were suitable. It is 
hypothesised that on a more non-polar stationary phase such as a C8 or C18 column, 
retention of this compound may be achieved.  
An advantage of SFC to chromatographers is its orthogonality compared to reversed 
phase HPLC. For this reason, SFC is a very attractive alternative or complementary 
technique to HPLC. Orthogonality compared to the existing reversed phase USP-36-
NF-31 method as shown in Fig 2.3.1 was demonstrated. The original elution order of 
the HPLC method was compound X , compound C, compound D and Voriconazole. 
Two other elution orders were demonstrated in this study. The first elution order 
was; compound C, Voriconazole, and compound D which was demonstrated in Figs. 
3.3.1, 3.3.2, 3.3.8, 3.3.9, 3.3.10, 3.3.11, 3.3.15 and 3.3.18. The second retention 
order was Voriconazole compound C, and compound D which was demonstrated in 
Figs. 3.3.3, 3.3.4, 3.3.12, 3.3.13, 3.3.14, 3.3.16, 3.3.17, 3.3.19, and 3.3.20 
A general trend of decreasing retention with increasing modifier concentration was 
seen across the entire mobile phase/stationary phase study including when various 
additives were added to the mobile phase. It is therefore concluded that the 
concentration of modifier in the mobile phase played a significant role in the overall 
retention of S3b, while the addition of additives had a more specific effect on 
retention of particular analytes. This can be seen on a cyano stationary phase where a 
methanol only modifier showed intermediate retention between that seen when an 
acidic or basic additive was included in the mobile phase. On a cyano stationary 
phase, the addition of TFA to the mobile phase was hypothesised to cause ion 
pairing between the solute and the stationary phase increasing retention while the 
addition of a basic additive such as TEA or a salt such as AA were found to decrease 
retention which was hypothesised to be due to ionisation of analytes causing 
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retention to decrease. Voriconazole and compound D were most affected by basic 
analytes due to the easy protonation of their alcohol functionality. 
On a silica stationary phase the addition of additives were found to have a 
detrimental effect on retention of S3b and a loss of resolution and co-elution was 
noted across all 3 modifiers across all modifier concentrations. It was hypothesised 
that the reduction of retention was due to coverage of surface silanols on the silica 
stationary phase by the additive molecules which provided valuable retention when a 
methanol only mobile phase was used. 
It was found that a pyridine column was entirely unsuitable for the separation of this 
API and related impurities. Pyridine columns were designed especially for use with 
highly polar analytes, however as the analytes in question are more hydrophobic in 
nature they were not well retained at all. MeOH with a TEA or AA additive included 
in the MeOH modifier provided reasonable retention and resolution of Voriconazole 
and two of the related impurities, however the presence of a system peak due to TEA 
lead to this mobile phase being disregarded. 
Following the study it was concluded that a cyano stationary phase with a 20% 
MeOH modified mobile phase with 0.1% TFA additive or diol stationary phase with 
a  8% MeOH modified mobile phase with 0.1% AA additive were the most suitable 
for the separation of Voriconazole and related impurities compound C and 
compound D. These stationary phase combinations had a complete run time of 6.54 
minutes and 2.272 minutes respectively. Runtime on a cyano stationary phase was 
almost three times that of the diol stationary stationary phase using AA as a 
modifier, however, resolution is significantly higher at 4.32 for peak pair compound 
C:Voriconazole and 12.28 for peak pair Voriconazole:Compound D, compared to 
1.82 for peak pair Voriconazole:compound C and 4.3 for compound C:compound D. 
It is also worth mentioning here the switch in elution order of Voriconazole and 
compound C between the two columns. Both columns used in conjunction with each 
other, could provide valuable complementary information in confirming the identity 
and quantity of an unknown impurity should it elute in this region as both columns 
would provide a different elution order and could be used to confirm whether the 
impurity existed in a test sample or was caused by some other source. When 
compared to the original USP 36-NF-31 method (section 2.3.1) run times have been 
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reduced by more than 30% in the case of the cyano column from ~ 10 min to 6.5 min 
and more than 75% in the case of the diol column from ~10 min to 2.3 minutes. 
When compared to the newly developed DCU 2.6 µm (section 2.3.2.2) and 1.7 µm 
(section 2.3.2.4.2) methods, run time on the diol stationary phase with a AA additive 
is 50% less. Compound X, however was not retained on any of the stationary phases 
chosen. As a result further stationary phase investigation would be necessary in order 
to develop a comprehensive impurity assay for analysis of Voriconazole which is 
capable of separating all related impurities. 
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4 Final conclusions and future work 
 
The aim of this thesis was to investigate if improvements could be made to the 
method USP 36-NF-31, given recent advances both in chromatographic column 
stationary phases such as core-shell phases, and in emerging chromatographic 
technologies such as supercritical fluid chromatography. Separations developed were 
compared primarily using runtime, once a minimum resolution between critical 
eluting analyte pairs of at least 1.7 was maintained. 
In Chapter 2, the USP 36-NF 31 method was successfully replicated and 
subsequently transferred to a stationary phase consisting of new 3rd generation, core-
shell technology of 2.6 µm particle size. The method was further optimised in line 
with the project objectives, namely the development of a fast pharmaceutical 
impurity assay while maintaining a resolution between critical peak pair of above 
1.7. There was a reduction of the run time of the assay by 56% while resolution 
between peak pairs was maintained above 2.0. This method was further optimised on 
a smaller 1.7 µm core-shell column, albeit with no decrease in runtime demonstrated, 
resolution of above 2 however was still maintained. It was therefore noted that for 
the method developed, the reduction in particle size did not provide any additional 
benefit in terms of reducing run times The absence of a runtime reduction was 
attributed to the equilibration time necessary for the gradient elution. Additionally, 
the use of a 1.7 µm column necessitated the use of specialised UPLC instrumentation 
capable of withstanding pressures of up to 1000 bar as the very small particle size 
produced back pressures of in excess of 550 bar, therefore it was also concluded that 
from a cost saving perspective – an increasingly important driver of research and 
innovation across all industries, the use of 1.7 µm core-shell stationary phase lead to 
unnecessary extra expenditure, as the method developed on a 2.6 µm core-shell 
particle stationary phase on a standard HPLC demonstrated equal performance based 
on the optimisation parameters set out, without the need for specialised high pressure 
instrumentation.  
It is however anticipated that should an isocratic method have been developed 
instead, there would have been a reduction in run time, due to shorter diffusion 
pathways[5]. The 1.7 µm core-shell stationary phase used in this study was capable 
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of withstanding pressures of up to 1000 bar, typical back pressures observed 
throughout the study were in the region of 550 bar.  In order to take advantage of the 
pressure capabilities of both the instruments used in this study and the columns, 
gradient and isocratic Poppe plots[43] could be used to determine optimum 
conditions to achieve the best possible run time and efficiency on both particle sizes 
using maximum pressure. This study could then be used as a measure of the value – 
if any, of using 1.7 µm particles as opposed to 2.6 µm for the development of 
chromatographic methods in the long term. 
In Chapter 3, a total of 16 stationary phase and mobile phase combinations were 
evaluated for the development of a new SFC pharmaceutical impurity assay. The 
general trend which was observed was that SFC did indeed provide orthogonal 
separation when compared to reversed phase HPLC, as a change in elution order of 
the compounds was observed. However, all 16 combinations were unsuitable to fully 
develop an SFC method for the assay and impurity determination of Voriconazole as 
compound X was very weakly retained, if at all, for all combinations chosen, due to 
its very non polar nature. Further work should include the evaluation of non polar 
stationary phase chemistries such as C8, C18 or a phenyl based column. Since SFC 
tends to give normal phase behaviour with polar stationary phases and reversed 
phase behaviour with non-polar stationary phases it is anticipated that the use of non 
polar stationary phases will provide better retention for the compound X and will 
improve resolution between peak pairs while providing the added advantages of 
higher resolution, efficiency and speed compared to  reversed phase 
chromatography[113]. A major area of interest in SFC in terms of its application is 
in the area of chiral separations [77, 78]. Since Voriconazole is a chiral compound, 
future work could also focus on the development of a chiral SFC method.  
In summary, USP 36-NF 31 has been significantly improved in terms of runtime by 
transfer to 2.6 µm core-shell stationary phase technology. There is scope to further 
enhance this improvement by exploration of isocratic elutions, as outlined above. 
SFC has also been demonstrated to provide orthogonal separation capabilities, which 
can be further investigated by broadening the types of stationary phase utilised, as 
described earlier in this section. Future work should also include a complete 
validation of the core-shell method, investigating for example the ruggedness and 
repeatability. 
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The work carried out in this thesis improving USP 36-NF 31 demonstrates the 
potential advantages in terms of runtime, and therefore analysis cost, in applying 
new separation technologies to existing methods in use by the pharmaceutical 
industry. There is therefore huge scope for expanding this research to a broad range 
of methods which use traditional packed chromatographic stationary phases. 
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6.1 Chapter 2: 
Table 6.1.1: Results of varying the ratio of MeOH:ACN in mobile phase B whilst keeping 
Mobile A (FB) constant at 55% on the separation of S3a (Section 2.3.2.1.1) 
 
 
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.680
Compound X 1.548 1.276 0.740 0.046 76460
Compound C 1.677 1.466 0.770 0.491 86380 1.810
Compound D 5.938 7.732 0.920 0.121 141030 31.260
Voriconazole 10.121 13.884 1.140 0.123 156400 15.950
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.682
Compound X 1.537 1.254 0.820 0.043 78470
Compound C 1.612 1.364 0.730 0.046 84620 1.050
Compound D 5.310 6.786 1.100 0.108 143450 29.830
Voriconazole 8.984 12.173 1.130 0.174 154960 15.740
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.686
Compound X 1.497 1.182 1.430 0.032 104650
Compound C 1.534 1.236 0.640 0.461 72270 1.020
Compound D 4.585 5.684 0.940 0.091 144490 26.520
Voriconazole 7.683 10.200 1.140 0.144 162280 15.710
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Effiency (plates 
per metre)
Resolution
Void 0.683
Compound X 1.448 1.120 0.830 0.056 40720
Compound C 1.448 1.120 0.830 0.056 40720 0.000
Compound D 3.876 4.675 1.000 0.855 122290 21.000
Voriconazole 6.431 8.416 1.130 0.128 151580 14.610
Peak
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.763
Compound X 1.368 0.793 0.750 0.046 68810
Compound C 1.368 0.793 0.750 0.046 68810 0.000
Compound D 3.157 3.138 0.950 0.058 136080 20.500
Voriconazole 5.132 5.726 1.080 0.083 158810 14.540
Peak
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.756
Compound X 1.301 0.721 0.760 0.043 55080
Compound C 1.301 0.721 0.760 0.433 55080 0.000
Compound D 2.610 2.452 0.870 0.673 129440 16.150
Voriconazole 4.148 4.487 1.030 0.099 155640 13.870
Peak
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.694
Compound X 1.214 0.749 0.720 0.059 29710
Compound C 1.214 0.749 0.720 0.059 29710 0.000
Compound D 2.132 2.072 0.860 0.061 72460 9.720
Voriconazole 3.272 3.715 0.990 0.075 118110 10.470
Eluent 6: 25% Acetonitrile : 20% Methanol
Eluent 7: 30% Acetonitrile : 15% Methanol
Eluent 1: 0% Acetonitrile : 45% Methanol
Eluent 5: 20% Acetonitrile : 25% Methanol
Eluent 4: 15% Acetonitrile : 30% Methanol
Eluent 3: 10% Acetonitrile : 35% Methanol
Eluent 2: 5% Acetonitrile : 40% Methanol
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Table 6.1.2: Results of optimising the concentration of the organic mobile phase (MeOH) on 
the retention of S3a  (Section 2.3.2.1.2.) 
 
 
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.672
Compound C 3.135 3.665 0.800 131690
Compound X 3.551 4.284 0.740 136350 3.600
Compound D 35.784 52.250 1.040 139370 48.250
Voriconazole 67.029 98.746 0.910 136240 17.780
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.675
Compound C 1.963 1.908 1.030 83100
Compound X 2.005 1.970 0.360 118540 0.540
Compound D 10.466 14.505 0.950 151400 40.820
Voriconazole 18.625 26.593 0.980 157380 17.440
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.728
Compound C 1.302 0.788 0.670 0.043 62260
Compound X 1.459 1.004 0.670 0.045 83390 2.420
Compound D 3.803 4.224 0.950 0.083 124970 23.400
Voriconazole 6.140 7.434 1.030 0.122 150780 13.880
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Effiency 
(plates per 
metre)
Resolution
Void 0.622
Compound C 0.922 0.482 0.680 0.040 38950
Compound X 1.065 0.712 0.630 0.040 54450 2.440
Compound D 1.445 1.323 0.720 0.048 65020 5.990
Voriconazole 1.923 2.092 0.820 0.054 91460 6.120
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.671
Compound C 0.827 0.232 0.640 0.036 34700
Compound X 0.944 0.407 0.590 0.035 48700 2.110
Compound D 1.045 0.557 0.720 0.045 44160 1.710
Voriconazole 1.224 0.824 0.680 0.043 60640 2.840
Eluent 8: 70% Formate Buffer : 30% Methanol
Eluent 9: 60% Formate Buffer : 40% Methanol
Eluent 12: 30% Formate Buffer : 70% Methanol
Eluent 10: 50% Formate Buffer : 50% Methanol
Eluent 11: 40% Formate Buffer : 60% Methanol
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Table 6.1.3: Results of optimising the concentration of the organic mobile phase (ACN) on 
the retention of S3a. (Section 2.3.2.1.2) 
 
Peak
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.685
Compound X 1.864 1.402 0.750 0.045 0
Compound C 2.287 1.947 0.870 0.053 143830 5.940
Compound D 6.616 7.526 0.950 0.139 164730 30.600
Voriconazole 12.882 15.601 0.970 0.267 159290 20.360
Peak
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.683
Compound X 1.560 1.284 0.770 0.043 99480
Compound C 1.700 1.489 0.720 0.046 113220 2.220
Compound D 3.552 4.201 0.870 0.074 141140 20.150
Voriconazole 6.315 8.246 0.960 0.121 156270 17.150
Peak
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.660
Compound X 1.159 0.756 0.820 0.034 70730
Compound C 1.211 0.835 0.710 0.040 70390 0.920
Compound D 1.643 1.489 0.750 0.047 96180 6.920
Voriconazole 2.403 2.641 0.890 0.058 132510 10.090
Peak
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.629
Compound X 0.944 0.501 0.670 0.034 56990
Compound C 1.041 0.655 0.650 0.035 68480 1.940
Compound D 1.134 0.803 0.680 0.040 58930 1.710
Voriconazole 1.432 1.277 0.760 0.041 91760 5.000
Peak
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Effiency 
(plates per 
metre)
Resolution
Void 0.620
Compound X 0.828 0.335 0.610 0.030 48790
Compound C 0.828 0.335 0.610 0.030 48790 0.000
Compound D 0.931 0.502 0.700 0.032 55430 2.100
Voriconazole 1.052 0.697 0.640 0.035 64070 2.370
Peak
Retention time 
(mins)
Retention 
Factor
Symmetry
Peak Width @ 
half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.776
Compound X 0.776 0.000 0.690 0.030 0
Compound C 0.835 0.076 1.710 0.023 77930 1.410
Compound D 0.873 0.125 0.760 0.030 33530 0.770
Voriconazole 0.909 0.171 0.450 0.033 46050 0.630
Eluent 14: 70% Formate Buffer : 30% Acetonitrile
Eluent 15: 60% Formate Buffer : 40% Acetonitrile
Eluent 16: 50% Formate Buffer : 50% Acetonitrile
Eluent 17: 40% Formate Buffer : 60% Acetonitrile
Eluent 13: 75% Formate Buffer : 25% Acetonitrile
Eluent 18: 30% Formate Buffer : 70% Acetonitrile
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Table 6.1.4: Results of optimising the concentration of Mobile Phase A Buffer (FB) (on 
retention characteristics of S3a. Buffer pH: 4.00 (Section 2.3.2.1.3.1) 
 
 
Peak
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.642
Compound X 1.501 1.338 0.790 0.419 96360
Compound C 1.654 1.576 0.760 0.046 107130 2.440
Compound D 3.509 4.466 0.840 0.074 142640 20.420
Voriconazole 6.301 8.815 1.070 0.122 158810 17.560
Peak
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.679
Compound X 1.551 1.284 0.750 0.041 105180
Compound C 1.697 1.499 0.730 0.042 112730 2.340
Compound D 3.535 4.206 0.800 0.073 149990 20.470
Voriconazole 6.289 8.262 0.970 0.120 161510 17.550
Peak
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.683
Compound X 1.560 1.284 0.770 0.043 99480
Compound C 1.700 1.489 0.720 0.046 113220 2.220
Compound D 3.552 4.201 0.870 0.074 141140 20.150
Voriconazole 6.315 8.246 0.960 0.121 156270 17.150
Peak
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Effiency 
(plates per 
metre)
Resolution
Void 0.678
Compound X 1.553 1.291 0.740 0.042 103190
Compound C 1.698 1.504 0.730 0.046 112940 2.310
Compound D 3.535 4.214 0.880 0.074 144730 20.210
Voriconazole 6.294 8.283 1.020 0.122 161760 17.460
Peak
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.679
Compound X 1.551 1.284 0.770 0.042 102280
Compound C 1.695 1.496 0.730 0.459 105620 2.260
Compound D 3.506 4.163 0.810 0.074 142410 19.710
Voriconazole 6.267 8.230 0.970 0.120 157060 17.360
Eluent 19: 10 mM FB
Eluent 20: 20 mM FB
Eluent 21: 30 mM FB
Eluent 22: 40 mM FB
Eluent 23: 50 mM FB
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Table 6.1.5:: Results of optimising pH of Mobile Phase A Buffer (FB) on the retention 
characteristics of S3a. Buffer concentration: 30 mM (Section 2.3.2.1.3.2) 
 
 
 
Peak
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.681
Compound X 1.582 1.323 0.720 0.425 107030
Compound C 1.750 1.570 0.800 0.464 109090 2.610
Compound D 3.860 4.668 0.920 0.785 150670 21.850
Voriconazole 6.949 9.204 1.030 0.137 155780 17.700
Peak
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.676
Compound X 1.546 1.287 0.760 0.038 106960
Compound C 1.694 1.506 0.740 0.042 119940 2.420
Compound D 3.539 4.235 0.870 0.731 145060 20.540
Voriconazole 6.307 8.330 1.070 0.121 155850 17.290
Peak
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.683
Compound X 1.560 1.291 0.770 0.043 99480
Compound C 1.700 1.496 0.720 0.046 113220 2.220
Compound D 3.552 4.216 0.870 0.074 141140 20.150
Voriconazole 6.315 8.273 0.960 0.121 156270 17.150
Peak
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Effiency 
(plates per 
metre)
Resolution
Void 0.678
Compound X 1.554 1.292 0.720 0.042 0
Compound C 1.804 1.661 0.730 0.453 113680 2.400
Compound D 3.571 4.267 0.800 0.743 147730 20.550
Voriconazole 6.371 8.397 1.030 0.123 155830 17.380
Peak
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.678
Compound X 1.552 1.289 0.740 0.041 105410
Compound C 1.703 1.512 0.720 0.045 113510 2.410
Compound D 3.556 4.245 0.830 0.074 151750 20.630
Voriconazole 6.341 8.353 1.040 0.123 160830 17.630
Eluent 24: pH 3.00
Eluent 25: pH 3.50
Eluent 21: pH 4.00
Eluent 26: pH 4.50
Eluent 27: pH 5.00
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Table 6.1.6: Results of temperature study using 30% ACN:70% FB as mobile phase on the 
retention characteristics of S3a. (Section 2.3.2.1.4) 
 
Retention 
time (mins)
Retention 
Factor
Symmetry
Efficiency 
(plates per 
column)
Efficiency 
(plates per 
metre)
Resolution
Void 0.683
Compound X 1.560 0.770 9948 99480
Compound C 1.700 1.489 0.720 11322 113220 2.220
Compound D 3.552 4.201 0.870 14114 141140 20.150
Voriconazole 6.315 8.246 0.960 15627 156270 17.150
Retention 
time (mins)
Retention 
Factor
Symmetry
Efficiency 
(plates per 
column)
Efficiency 
(plates per 
metre)
Resolution
Void 0.683
Compound X 1.548 1.266 0.750 10249 102490
Compound C 1.656 1.425 0.730 10744 107440 1.730
Compound D 3.457 4.061 0.880 14864 148640 20.270
Voriconazole 6.068 7.884 1.040 15454 154540 16.980
Retention 
time (mins)
Retention 
Factor
Symmetry
Efficiency 
(plates per 
column)
Efficiency 
(plates per 
metre)
Resolution
Void 0.679
Compound X 1.545 1.275 0.820 9980 99800
Compound C 1.619 1.384 0.950 9628 96280 1.160
Compound D 3.397 4.003 0.920 14353 143530 19.780
Voriconazole 5.912 7.707 1.080 15208 152080 16.460
Retention 
time (mins)
Retention 
Factor
Symmetry
Efficiency 
(plates per 
column)
Effiency 
(plates per 
metre)
Resolution
Void 0.683
Compound X 1.537 1.250 1.100 10499 104990
Compound C 1.576 1.307 0.600 7819 78190 0.590
Compound D 3.300 3.832 0.890 14589 145890 19.070
Voriconazole 5.676 7.310 1.060 14968 149680 16.090
Retention 
time (mins)
Retention 
Factor
Symmetry
Efficiency 
(plates per 
column)
Efficiency 
(plates per 
metre)
Resolution
Void 0.682
Compound X 1.531 1.245 0.710 8616 86160
Compound C 1.531 1.245 0.710 8616 86160 0.000
Compound D 3.201 3.694 0.920 14287 142870 19.290
Voriconazole 5.438 6.974 1.090 15048 150480 15.680
30% ACN - 35°C
30% ACN - 40°C
30% ACN - 45°C
30% ACN - 50°C
30% ACN - 55°C
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Table 6.1.7: Exp 4b: Results of temperature study using 25% ACN:75% FB as mobile phase 
on the retention characteristics of S3a. (Section 2.3.2.1.4) 
 
 
 
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.685
Compound X 1.864 1.721 0.750 0.045 127750
Compound C 2.287 2.339 0.870 0.053 143850 5.940
Compound D 6.616 8.658 0.950 0.139 164730 30.600
Voriconazole 12.882 17.806 0.970 0.027 159290 20.360
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.686
Compound X 1.856 1.706 0.850 0.043 129230
Compound C 2.209 2.220 0.820 0.051 141720 5.060
Compound D 6.340 8.242 0.920 0.119 167630 30.540
Voriconazole 12.214 16.805 1.030 0.220 160530 20.170
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.688
Compound X 1.845 1.682 0.840 0.044 127700
Compound C 2.132 2.099 0.770 0.050 139580 4.170
Compound D 6.051 7.795 0.870 0.012 166400 30.130
Voriconazole 11.604 15.866 0.970 0.021 155420 19.560
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Effiency 
(plates per 
metre)
Resolution
Void 0.687
Compound X 1.832 1.667 0.940 0.044 131460
Compound C 2.062 2.001 0.800 0.049 134440 3.400
Compound D 5.822 7.475 0.920 0.109 164730 29.730
Voriconazole 10.916 14.889 1.020 0.205 155150 19.120
Retention 
time (mins)
Retention 
Factor
Symmetry
Peak Width 
@ half height 
(mins)
Efficiency 
(plates per 
metre)
Resolution
Void 0.687
Compound X 1.819 1.648 0.750 0.043 121550
Compound C 1.992 1.900 0.750 0.048 137150 2.590
Compound D 5.560 7.093 0.990 0.105 160990 29.280
Voriconazole 10.277 13.959 1.060 0.194 151140 18.490
25% ACN - 35°C
25% ACN - 40°C
25% ACN - 45°C
25% ACN - 50°C
25% ACN - 55°C
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6.2 Chapter 3  
Table 6.2.1: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH only. Stationary phase: 
Agilent Zorbax bare silica. (150 mm X 4.6 mm, 5µm) 
 
 
 
 
 
 
 
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.500
Compound C 0.946 0.892 0.960
Voriconazole 1.007 1.014 0.820 1.080 1.137
Compound D 1.424 1.848 0.730 5.890 1.822
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.510
Compound C 1.086 1.129 0.960
Voriconazole 1.172 1.298 0.840 1.360 1.149
Compound D 1.772 2.475 0.730 7.030 1.906
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.527
Compound C 1.334 1.531 0.850
Voriconazole 1.479 1.806 0.790 1.780 1.180
Compound D 2.460 3.668 0.700 8.410 2.030
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.530
Compound C 1.505 1.840 0.900
Voriconazole 1.703 2.213 0.760 2.070 1.203
Compound D 3.019 4.696 0.760 9.400 2.122
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.567
Compound C 1.875 2.307 0.830
Voriconazole 2.208 2.894 0.710 2.610 1.255
Compound D 4.196 6.400 0.550 9.990 2.211
@20% Methanol
@8% Methanol
@10% Methanol
@12% Methanol
@16% Methanol
Agilient Zorbax Silica (5um, 150mm*4.6mm)
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Table 6.2.2: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH only. Stationary phase: 
Waters Spherisorb CN (250 mm X 4.6 mm, 5µm) 
 
 
  
 
Retention 
time (mins) Retention Factor Symmetry Resolution Selectivity
Void 0.882
Compound C 2.610 1.959 0.860
Voriconazole 2.810 2.186 0.810 1.920 1.116
Compound D 4.058 3.601 0.740 8.500 1.647
Retention 
time (mins) Retention Factor Symmetry Resolution Selectivity
Void 0.897
Compound C 3.056 2.407 0.810
Voriconazole 3.268 2.643 0.750 1.700 1.098
Compound D 4.990 4.563 0.690 9.560 1.726
Retention 
time (mins) Retention Factor Symmetry Resolution Selectivity
Void 0.943
Compound C 4.004 3.246 0.740
Voriconazole 4.301 3.561 0.680 1.780 1.097
Compound D 7.135 6.566 0.620 10.540 1.844
Retention 
time (mins) Retention Factor Symmetry Resolution Selectivity
Void 0.978
Compound C 4.598 3.701 0.710
Voriconazole 4.916 4.027 0.660 1.600 1.088
Compound D 8.505 7.696 0.710 10.310 1.911
Retention 
time (mins) Retention Factor Symmetry Resolution Selectivity
Void 1.028
Compound C 5.696 4.541 0.690
Voriconazole 6.133 4.966 0.680 1.650 1.094
Compound D 11.226 9.920 0.670 11.660 1.998
@8% Methanol
@10% Methanol
@12% Methanol
@16% Methanol
@20% Methanol
Waters Spherisorb CN (5um, 250mm*4.6mm)
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Table 6.2.3: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH only. Stationary phase: 
Princeton Diol (150 mm X 4.6 mm, 5µm) 
 
 
 
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.534 0.000 0.930
Voriconazole 1.140 1.135 1.030
Compound C 1.179 1.208 0.940 0.810 1.064
Compound D 1.460 1.734 0.950 3.960 1.436
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.550 0.000 0.860
Voriconazole 1.306 1.375 0.980
Compound C 1.376 1.502 0.950 0.880 1.093
Compound D 1.790 2.255 0.960 5.160 1.501
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.590 0.000 0..94
Voriconazole 1.622 1.749 0.980
Compound C 1.709 1.897 0.950 1.010 1.084
Compound D 2.389 3.049 0.980 7.000 1.608
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.630 0.000 0.800
Voriconazole 1.887 1.995 1.000
Compound C 1.974 2.133 0.970 0.960 1.069
Compound D 2.893 3.592 0.910 7.660 1.684
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.693 0.890
Voriconazole 2.288 2.302 1.160
Compound C 2.383 2.439 0.970 0.770 1.060
Compound D 3.746 4.405 0.970 8.960 1.807
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.796 0.920
Voriconazole 3.072 3.433 1.330
Compound C 3.072 3.433 1.330 1.000
Compound D 5.325 6.684 0.890 9.890 1.947
@20% methanol
Princeton Diol SFC (5um, 150mm*4.6mm)
@6% methanol
@8% methanol
@10% methanol
@12% methanol
@16% methanol
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Table 6.2.4: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH only. Stationary phase: 
Princeton ethyl-pyridine (150 mm X 4.6 mm, 5µm) 
 
 
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.510 0.000 0.840
Voriconazole 0.775 0.520 1.720
Compound C 0.816 0.600 0.816 0.670 1.155
Compound D 0.816 0.600 0.816 0.670 1.000
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.527 0.000 0.860
Voriconazole 0.848 0.609 1.130
Compound C 0.903 0.713 0.690 0.720 1.171
Compound D 0.903 0.713 0.690 0.720 1.000
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.553 0.000
Voriconazole 0.955 0.727 1.100
Compound C 1.026 0.855 0.940 0.920 1.177
Compound D 1.082 0.957 0.500 0.750 1.118
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.581 0.000
Voriconazole 1.041 0.792 1.113
Compound C 1.125 0.936 0.990 1.020 1.183
Compound D 1.206 1.076 0.990 0.890 1.149
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.631
Voriconazole 1.152 0.826 1.220
Compound C 1.255 0.989 1.030 1.110 1.198
Compound D 1.374 1.177 1.150 1.180 1.191
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.687
Voriconazole 1.302 1.063 1.320
Compound C 1.434 1.273 1.020 1.150 1.197
Compound D 1.613 1.556 1.170 1.450 1.223
@20% Methanol
Princeton Pyridine SFC (5um, 150mm*4.6mm)
@6% Methanol
@8% Methanol
@10% Methanol
@12% Methanol
@16% Methanol
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Table 6.2.5: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH w/0.1% TFA. Stationary 
phase: Agilent Zorbax bare silica. (150 mm X 4.6 mm, 5µm) 
 
 
 
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.510 0.850
Compound C 0.835 0.637 0.970
Voriconazole 0.835 0.637 0.970 0.000 1.000
Compound D 1.028 1.016 0.830 3.460 1.594
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.520 0.940
Compound C 0.934 0.796 0.910
Voriconazole 0.934 0.796 0.910 0.000 1.000
Compound D 1.212 1.331 0.830 4.460 1.671
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.537 0.890
Compound C 1.088 1.026 0.650
Voriconazole 1.088 1.026 0.650 0.000 1.000
Compound D 1.537 1.862 0.750 5.370 1.815
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.553 0.900
Compound C 1.217 1.201 0.710
Voriconazole 1.217 1.201 0.710 0.000 1.000
Compound D 1.815 2.282 0.780 5.290 1.901
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.577 0.910
Compound C 1.419 1.459 0.640
Voriconazole 1.419 1.459 0.640 0.000 1.000
Compound D 2.296 2.979 0.820 5.670 2.042
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.611 0.000 0.880
Compound C 1.737 1.843 0.880 0.000
Voriconazole 1.859 2.043 0.740 0.780 1.108
Compound D 3.120 4.106 0.790 6.330 2.010
@20% Methanol w/0.1% TFA
@16% Methanol w/0.1% TFA
@6% Methanol w/0.1% TFA
@10% Methanol w/0.1% TFA
@12% Methanol w/0.1% TFA
@8% Methanol w/0.1% TFA
Agilient Zorbax Silica (5um, 150mm*4.6mm)
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Table 6.2.6: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH w/0.1% TFA. Stationary 
phase: Waters Spherisorb CN (250 mm X 4.6 mm, 5µm) 
 
 
 
 
 
 
 
Retention time 
(mins)
Retention 
Factor Symmetry Resolution Selectivity
Void 0.847 0.740
Compound C 3.698 3.366 0.680
Voriconazole 4.283 4.057 0.760 4.320 1.205
Compound D 6.542 6.724 0.690 12.280 1.657
Retention time 
(mins)
Retention 
Factor Symmetry Resolution Selectivity
Void 0.865 0.760
Compound C 4.223 3.882 0.810
Voriconazole 4.872 4.632 0.750 4.040 1.193
Compound D 7.872 8.101 0.690 12.860 1.749
Retention time 
(mins)
Retention 
Factor Symmetry Resolution Selectivity
Void 0.908 0.850
Compound C 5.452 5.004 0.660
Voriconazole 6.345 5.988 0.810 4.190 1.197
Compound D 10.932 11.040 0.610 14.190 1.844
Retention time 
(mins)
Retention 
Factor Symmetry Resolution Selectivity
Void 0.917
Compound C 8.251 7.998 0.630
Voriconazole 9.801 9.688 0.650 4.390 1.211
Compound D 18.591 19.274 0.480 14.150 1.989
@8% Methanol w/0.1% TFA
@12% Methanol w/0.1% TFA
@16% Methanol w/0.1% TFA
@20% Methanol w/0.1% TFA
Waters Spherisorb CN (5um, 250mm*4.6mm)
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Table 6.2.7: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH w/0.1% TFA. Stationary 
phase: Princeton Diol CN (150 mm X 4.6 mm, 5µm) 
 
 
 
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.528 0.000 0.940
Voriconazole 1.102 1.087 0.970
Compound C 1.162 1.201 0.940 0.860 1.105
Compound D 1.419 1.688 0.880 3.700 1.405
.
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.550 0.000 0.950
Voriconazole 1.289 1.344 0.950
Compound C 1.363 1.478 0.930 1.040 1.100
Compound D 1.742 2.167 0.930 4.800 1.466
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.593 0.000 0.910
Voriconazole 1.600 1.698 0.980
Compound C 1.695 1.858 0.940 1.120 1.094
Compound D 2.318 2.909 0.960 6.510 1.565
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.637 0.000 1.080
Voriconazole 1.847 1.900 0.960
Compound C 1.953 2.066 0.970 1.080 1.088
Compound D 2.791 3.381 0.840 6.850 1.637
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.694 1.080
Voriconazole 2.238 2.225 0.960
Compound C 2.348 2.383 0.970 0.860 1.071
Compound D 3.595 4.180 0.840 8.280 1.754
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.796
Voriconazole 3.018 3.349 1.320
Compound C 3.018 3.349 1.320 0.000 1.000
Compound D 5.077 6.316 1.020 8.630 1.886
@6% Methanol w/0.1% TFA
@8% Methanol w/0.1% TFA
@10% Methanol w/0.1% TFA
@12% Methanol w/0.1% TFA
@16% Methanol w/0.1% TFA
@20% Methanol w/0.1% TFA
Princeton Diol SFC (5um, 150mm*4.6mm)
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Table 6.2.8: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH w/0.1% TFA. Stationary 
phase: Princeton ethyl-pyridine (150 mm X 4.6 mm, 5µm) 
 
 
 
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.507 0.000 0.780
Voriconazole 0.797 0.572 1.500
Compound C 0.797 0.572 1.500 0.000 1.000
Compound D 0.797 0.572 1.500 0.000 1.000
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.524 0.000 0.900
Voriconazole 0.833 0.590 1.130
Compound C 0.890 0.698 0.860 0.820 1.184
Compound D 0.890 0.698 0.860 0.000 1.000
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.557 0.000 0.870
Voriconazole 0.943 0.693 1.100
Compound C 1.019 0.829 0.680 0.910 1.197
Compound D 1.019 0.829 0.680 0.000 1.000
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.581 0.000 0.950
Voriconazole 1.013 0.744 1.130
Compound C 1.100 0.893 0.980 1.030 1.201
Compound D 1.139 0.960 0.680 0.510 1.075
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.630 0.880
Voriconazole 1.120 0.778 1.200
Compound C 1.226 0.946 1.000 1.130 1.216
Compound D 1.304 1.070 0.650 0.800 1.131
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.698 0.970
Voriconazole 1.266 1.010 1.280
Compound C 1.400 1.222 1.050 1.190 1.211
Compound D 1.521 1.414 1.040 0.920 1.157
@6% Methanol w/0.1% TFA
@8% Methanol w/0.1% TFA
@10% Methanol w/0.1% TFA
@12% Methanol w/0.1% TFA
@16% Methanol w/0.1% TFA
@20% Methanol w/0.1% TFA
Princeton Pyridine SFC (5um, 150mm*4.6mm)
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Table 6.2.9: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH w/0.1% TEA. Stationary 
phase: Agilent Zorbax bare silica. (150 mm X 4.6 mm, 5µm) 
 
 
Retention time 
(mins)
Retention Factor Symmetry Resolution Selectivity
Void 0.510 0.000 0.740
Compound C 0.821 0.610 1.040
Voriconazole 0.821 0.610 1.040 0.000 1.000
Compound D 0.991 0.943 0.910 3.070 1.207
System Peak 2.116 3.149 7.060 2.135
Retention time 
(mins)
Retention Factor Symmetry Resolution Selectivity
Void 0.517 0.000 0.940
Compound C 0.909 0.758 0.910
Voriconazole 0.909 0.758 0.910 0.000 1.000
Compound D 1.153 1.230 0.830 3.910 1.268
System Peak 2.694 4.211 8.290 2.337
Retention time 
(mins)
Retention Factor Symmetry Resolution Selectivity
Void 0.540 0.000 0.960
Compound C 1.073 0.987 1.050
Voriconazole 1.073 0.987 1.050 0.000 1.000
Compound D 1.443 1.672 0.900 5.150 1.345
System Peak 3.736 5.919 0.000 8.360 2.589
Retention time 
(mins)
Retention Factor Symmetry Resolution Selectivity
Void 0.577 0.000 0.920
Compound C 1.179 1.043 1.000
Voriconazole 1.179 1.043 1.000 0.000 1.000
Compound D 1.687 1.924 0.920 5.840 1.431
System Peak 4.599 6.971 0.000 8.440 2.726
Retention time 
(mins)
Retention Factor Symmetry Resolution Selectivity
Void 0.580 0.000 0.850
Compound C 1.357 1.340 0.870
Voriconazole 1.357 1.340 0.870 0.000 1.000
Compound D 2.074 2.576 0.830 6.200 1.528
System Peak 5.890 9.155 0.000 7.990 2.840
Retention time 
(mins)
Retention Factor Symmetry Resolution Selectivity
Void 0.610 0.000 0.790
Compound C 1.653 1.710 1.000
Voriconazole 1.705 1.795 0.000 0.430 1.031
Compound D 2.789 3.572 0.940 7.920 1.636
System Peak 7.988 12.095 0.000 7.940 2.864
@10% Methanol w/0.1% TEA
@8% Methanol w/0.1% TEA
@6% Methanol w/0.1% TEA
@20% Methanol w/0.1% TEA
@16% Methanol w/0.1% TEA
@12% Methanol w/0.1% TEA
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Table 6.2.10: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH w/0.1% TEA. Stationary 
phase: Waters Spherisorb CN (250 mm X 4.6 mm, 5µm) 
 
 
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.851 0.000 1.030
Voriconazole 1.317 0.548 0.890
Compound C 1.434 0.685 0.820 1.580 1.251
Compound D 1.434 0.685 0.820 1.580 1.000
System Peak 2.689 2.160 0.000 6.380 3.153
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.875 0.000 0.870
Voriconazole 1.440 0.646 0.840
Compound C 1.591 0.818 0.650 1.870 1.267
Compound D 1.591 0.818 0.650 1.870 1.000
System Peak 3.303 2.775 0.000 6.410 3.391
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.927 0.000 0.880
Voriconazole 1.646 0.776 0.810
Compound C 1.858 1.004 0.960 2.540 1.295
Compound D 1.932 1.084 0.420 0.810 1.079
System Peak 4.402 3.749 0.000 7.810 3.458
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.963 0.000 0.900
Voriconazole 1.804 0.873 0.770
Compound C 2.064 1.143 1.060 2.850 1.309
Compound D 2.172 1.255 0.590 0.990 1.098
System Peak 5.270 4.472 0.000 7.930 3.562
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 1.020 0.000 0.730
Voriconazole 2.022 0.982 0.850
Compound C 2.358 1.312 1.020 3.210 1.335
Compound D 2.519 1.470 0.560 1.260 1.120
System Peak 6.634 5.504 0.000 8.220 3.745
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 1.080 0.000 0.860
Voriconazole 2.379 1.203 0.740
Compound C 2.843 1.632 1.090 3.550 1.357
Compound D 3.097 1.868 0.530 1.460 1.144
System Peak 8.863 7.206 4.490 7.680 3.859
Waters Spherisorb Cyano (5um, 150mm*4.6mm)
@8% Methanol w/0.1% TEA
@6% Methanol w/0.1% TEA
@20% Methanol w/0.1% TEA
@16% Methanol w/0.1% TEA
@12% Methanol w/0.1% TEA
@10% Methanol w/0.1% TEA
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Table 6.2.11: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH w/0.1% TEA. Stationary 
phase: Princeton Diol  (150 mm X 4.6 mm, 5µm) 
 
 
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.547 0.000 0.950
Voriconazole 1.105 1.020 0.940
UK-51,060 1.173 1.144 0.910 1.050 1.122
UK-83,610 1.390 1.541 0.830 3.130 1.347
System Peak 4.028 1.898 0.000 10.390 1.231
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.561 0.000 0.810
Voriconazole 1.279 1.280 0.950
UK-51,060 1.368 1.439 0.930 1.240 1.124
UK-83,610 1.684 2.002 0.960 3.990 1.392
System Peak 5.222 8.308 0.000 11.110 4.150
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.600 0.000 0.900
Voriconazole 1.565 1.608 0.970
UK-51,060 1.684 1.807 0.940 1.410 1.123
UK-83,610 2.193 2.655 0.940 5.290 1.470
System Peak 7.353 11.255 0.000 12.050 4.239
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.647 0.000 0.770
Voriconazole 1.791 1.768 1.000
UK-51,060 1.932 1.986 0.970 1.450 1.123
UK-83,610 2.613 3.039 1.010 6.030 1.530
System Peak 9.074 13.025 0.000 11.890 4.286
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.701 0.000 0.910
Voriconazole 2.026 1.890 0.970
UK-51,060 2.237 2.191 0.910 1.790 1.159
UK-83,610 2.929 3.178 0.890 4.780 1.451
System Peak 7.200 9.271 0.000 7.860 2.917
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.804 0.000 0.890
Voriconazole 2.565 2.190 0.960
UK-51,060 2.822 2.510 0.870 1.590 1.146
UK-83,610 3.915 3.869 0.850 5.940 1.542
System Peak 9.565 10.897 0.000 8.150 2.816
@10% Methanol w/0.1% TEA
@8% Methanol w/0.1% TEA
@6% Methanol w/0.1% TEA
@20% Methanol w/0.1% TEA
@16% Methanol w/0.1% TEA
@12% Methanol w/0.1% TEA
Princeton Diol SFC (5um, 150mm*4.6mm)
163 
 
Table 6.2.12: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH w/ 20 mM AA. 
Stationary phase: Agilent Zorbax bare silica. (150 mm X 4.6 mm, 5µm) 
 
 
 
 
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.500 0.790
Compound C 0.865 0.730 0.970
Voriconazole 0.865 0.730 0.970 0.000 1.000
Compound D 1.124 1.248 0.950 4.450 1.710
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.511 0.860
Compound C 0.966 0.890 0.980
Voriconazole 0.966 0.890 0.980 0.000 1.000
Compound D 1.310 1.564 0.890 5.250 1.756
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.537 0.920
Compound C 1.143 1.128 0.970
Voriconazole 1.143 1.128 0.970 0.000 1.000
Compound D 1.662 2.095 0.930 6.200 1.856
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.557 0.800
Compound C 1.270 1.280 0.970
Voriconazole 1.270 1.280 0.970 0.000 1.000
Compound D 1.931 2.467 0.950 6.800 1.927
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.580 0.800
Compound C 1.451 1.502 0.970
Voriconazole 1.451 1.502 0.970 0.000 1.000
Compound D 2.376 3.097 0.930 7.070 2.062
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.613 0.000 0.860
Compound C 1.786 1.914 0.930
Voriconazole 1.896 2.093 0.760 0.740 1.094
Compound D 3.219 4.251 0.880 7.210 2.031
@10% Methanol, 20 mM AA
@8% Methanol, 20 mM AA
@6% Methanol, 20 mM AA
Agilient Zorbax Silica (5um, 150mm*4.6mm)
@20% Methanol, 20 mM AA
@16% Methanol, 20 mM AA
@12% Methanol, 20 mM AA
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Table 6.2.13: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH w/20 mM AA. 
Stationary phase: Phenomenex Spherisorb CN (250 mm X 4.6 mm, 5µm) 
 
 
 
 
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.844 0.000 0.950
Voriconazole 1.338 0.585 0.900
Compound C 1.452 0.720 0.000 1.660 1.085
Compound D 1.452 0.720 0.000 0.000 1.000
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.875 0.960
Voriconazole 1.478 0.689 0.880
Compound C 1.627 0.859 1.080 2.420 1.101
Compound D 1.696 0.938 0.590 0.870 1.042
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.927 0.960
Voriconazole 1.692 0.825 0.880
Compound C 1.901 1.051 1.080 2.640 1.124
Compound D 2.021 1.180 0.590 1.340 1.063
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 0.967 0.540
Voriconazole 1.850 0.913 0.890
Compound C 2.105 1.177 1.190 2.930 1.138
Compound D 2.263 1.340 0.670 1.560 1.075
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 1.020 0.940
Voriconazole 2.076 1.035 0.900
Compound C 2.404 1.357 1.210 3.260 1.158
Compound D 2.623 1.572 0.670 1.810 1.091
Retention time 
(mins) Retention Factor Symmetry Resolution Selectivity
Void 1.081 0.930
Voriconazole 2.450 1.402 0.850
Compound C 2.903 1.846 1.210 3.590 1.185
Compound D 3.238 2.175 0.670 1.180 1.115
@10% Methanol, 20 mM AA
@8% Methanol, 20 mM AA
@6% Methanol, 20 mM AA
@20% Methanol, 20 mM AA
@16% Methanol, 20 mM AA
@12% Methanol, 20 mM AA
Waters Spherisorb CN (5um, 250mm*4.6mm)
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Table 6.2.14: The effect of modifier concentration on retention of API, Voriconazole and 
related impurities; compound C and compound D. Modifier: MeOH w/ 20 mM AA. 
Stationary phase: Princeton Diol  (150 mm X 4.6 mm, 5µm) 
 
 
Retention time 
(mins)
Retention Factor Symmetry Resolution Selectivity
Void 0.550 0.000 0.940
Voriconazole 1.058 0.924 1.000
Compound C 1.137 1.067 0.910 1.260 1.156
Compound D 1.280 1.327 0.950 2.160 1.244
Retention time 
(mins)
Retention Factor Symmetry Resolution Selectivity
Void 0.577 0.000 0.880
Voriconazole 1.216 1.107 0.960
Compound C 1.319 1.286 0.940 1.470 1.161
Compound D 1.524 1.641 0.780 2.680 1.276
Retention time 
(mins)
Retention Factor Symmetry Resolution Selectivity
Void 0.610 0.000 0.920
Voriconazole 1.465 1.402 0.970
Compound C 1.607 1.634 1.000 1.730 1.166
Compound D 1.944 2.187 1.010 3.710 1.338
Retention time 
(mins)
Retention Factor Symmetry Resolution Selectivity
Void 0.660 0.000 1.080
Voriconazole 1.668 1.527 0.960
Compound C 1.835 1.780 0.970 1.820 1.166
Compound D 2.272 2.442 0.840 4.300 1.372
Retention time 
(mins)
Retention Factor Symmetry Resolution Selectivity
Void 0.725 0.950
Voriconazole 1.959 1.702 1.050
Compound C 2.161 1.981 0.930 1.840 1.164
Compound D 2.791 2.850 0.990 5.070 1.439
Retention time 
(mins)
Retention Factor Symmetry Resolution Selectivity
Void 0.831 0.950
Voriconazole 2.448 2.377 1.070
Compound C 2.689 2.709 1.030 1.720 1.140
Compound D 3.685 4.083 1.060 6.040 1.507
@6% Methanol, 20 mM AA
@20% Methanol, 20 mM AA
@16% Methanol, 20 mM AA
@12% Methanol, 20 mM AA
@10% Methanol, 20 mM AA
@8% Methanol, 20 mM AA
Princeton Diol SFC (5um, 150mm*4.6mm)
